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Abstract  
The koala (Phascolarctos cinereus) is an iconic arboreal marsupial and the only surviving 
member of the Family Phascolarctidae. Chlamydiosis in koalas causes significant morbidity 
and mortality and adds to the detrimental effects of anthropological changes such as 
deforestation, bush fire, motor vehicle trauma and dog attacks. Mathematical modelling 
suggests that by reducing the negative effects of chlamydiosis, koala population in decline 
could well be saved. Chlamydia is an obligate intracellular pathogen of both humans and 
animals and C.pecorum is the most common and serious species affecting koalas. Ocular 
infections in koalas cause kerato-conjunctivitis leading to blindness, whereas uro-genital 
infections cause thickening of the bladder wall, incontinence and fibrosis in the uterine tract. 
While antibiotics are the current leading curative measures, these are ineffective for severe 
chlamydiosis and can also affect the intestinal micro flora and the overall health of the 
animals.  The asymptomatic nature of the chlamydial infection and the variable effects of the 
long term antibiotic treatment heighten the importance of developing a suitable anti-
chlamydial vaccine.  
 
The overall goal of developing an effective koala -Chlamydia vaccine requires a focus on 
exploring suitable vaccine antigens with immune stimulating adjuvants, to produce a long 
lasting cellular and humoral immune response. Our group has been developing a koala-
Chlamydia vaccine over the past 6 years using the recombinant major outer membrane 
protein (MOMP). While the koala-Chlamydia vaccine looks promising, it still needs to 
address some critical aspects. The present study aimed to extend the previous work by (a) 
evaluating a simpler vaccine to administer, preferably single dose vaccination, utilising a 
novel adjuvant formulation, (b) understanding the detailed mechanism that underpin humoral 
immunity in both naturally infected and vaccinated koalas, (c) determining the therapeutic 
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and protective effects of the rMOMP vaccine strategy against the course of the infection in 
free-ranging koalas, and (d) understanding the role of the adjuvant on eliciting cellular and 
humoral responses in wild koalas.  
 
In koala, the current vaccine regime utilized recombinant C. pecorum specific major outer 
membrane protein (MOMP) as the vaccine antigen. This protein represents 60% of the 
chlamydial membrane structure and consists of T and B cell epitopes. While MOMP is the 
subunit component of the chlamydial outer membrane protein, a suitable adjuvant 
formulation could further enhance its immunogenicity. Several immunisation studies have 
used ISC (Immune stimulating complex) adjuvant and this has provided the best immune 
protection to date. One disadvantage of ISC is it requires multiple immunisations to be 
efficient. This requirement for several immunisations is not ideal as it could cause additional 
stress to the koala through repeated capture and handling processes. Therefore, to overcome, 
the limitations of multiple vaccination schedules, we evaluated a combination adjuvant 
containing polyphosphazine based poly I: C and host defense peptides, which has previously 
been shown to be effective in other species after a single dose injection. In this current study, 
we demonstrated that this novel adjuvant elicited systemic and mucosal humoral immune 
responses against MOMP antigen. 
 
Although Th1 immune response is critical in chlamydial infection, the role of antibodies has 
been described in a considerable number of research articles in mouse and guinea pig models, 
which supports the immune-protective role of antibodies. In this thesis, we have characterised 
the role of antibody mediated immune response in koalas with ongoing chlamydial infection 
either with vaccination or without vaccination. Particularly, our study in koalas has shown 
that antibodies induced through vaccination had neutralising ability and have unique epitopes 
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specificity apart from the natural infection. Interestingly, the vaccine induced epitopes are 
located in the conserved domains, suggesting their role in cross recognition against 
diversified MOMP genotypes. In broader perspective, we first examined the effect of 
chlamydial infection load against our prototype vaccine in free ranging koala. It has shown 
that the current vaccine was able to reduce the Chlamydia shedding in infected animals. The 
vaccine induced a significant immune response which might prevent new C. pecorum 
infection. This study strongly suggests the therapeutic effect of this vaccine through distinct 
epitopes specificity. Overall, the vaccine induced immunity prevents infection burden and 
increased the longevity of the animals.  
 
The ideal vaccine against Chlamydia should elicit IFN-γ secreting CD4+ T cells and 
neutralizing antibodies at the infection site. In addition, the Th2 or antibody response 
prevents reinfection and a balance of these two mechanisms coordinates the key immune 
protective role. In the final study, we measured the cytokine gene expression of the PBMCs 
following vaccination with the two different adjuvants each combined with the same rMOMP 
protein antigen.  Overall, both adjuvants produced a strong Chlamydia-specific cellular 
response in circulating PBMCs (peripheral blood mononuclear cells) as well as MOMP and 
functional antibodies. Whilst the immune responses were similar, there were differences 
between the adjuvants, particularly in relation to the specificity of the antibody responses. 
Together, these data suggest that a single dose vaccine (referred as Tri-adjuvant vaccine) 
regime appears as effective in triggering an anti-Chlamydia immune response in koalas.  
 
Key words: 
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immune response 
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1.1 A description of the scientific problem investigated 
Chlamydial infection is widespread in koalas and causes significant morbidity and mortality 
across the koala population in Australia [1]. Chlamydia infection directly threatens the 
survival of the koala and has been associated with ocular and reproductive illness. This 
infection is transmitted through sexual behaviour as well as vertical transmission from mother 
to joey during pap feeding. This disease can significantly reduce the reproductive health of 
the population and when combined with other anthropological pressures, can result in serious 
decline of the population. This infection is unfortunately the second most common reason for 
the admission of koalas to koala rehabilitation centres after car accidents. Disease modelling 
suggests that checking the chlamydial infection would be a significant management strategy 
that could help reverse the population decline [2]. While there are different grades of 
chlamydial infections, the chronic active chlamydiosis results in the shedding of the highest 
number of infectious particles, posing a serious impact for future transmission. However, the 
asymptomatic nature of the infection makes it difficult to deal with systemic antimicrobials. 
Therefore a vaccine would be an ideal option to control this infection.  
 
The current vaccine utilising the recombinant major outer membrane protein (rMOMP) with 
multiple immunisations, elicited strong cellular and humoral immunity in koalas in several 
vaccine trials [3-6]. This multi-dose vaccine regime is problematic both logistically and 
financially to deploy in the wildlife settings. Therefore, to overcome the limitations of 
multiple vaccination schedules, a single dose vaccine with appropriate adjuvant would be an 
ideal option. Whilst MOMP is an immunogenic antigen accounting for 60% of the membrane 
structure [7] that constitutes B and T cell epitopes [8], it has been reported that there are some 
limitations of using rMOMP protein for vaccine development.  Indeed, MOMP is (a) unable 
to elicit cross-serovar-protection and (b) requires adequate 3-D structure to restore the 
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required level of immunogenicity [9]. While MOMP is the leading subunit vaccine antigen 
and has shown good promise, the adjuvant component is equally important and further effort 
is still needed. Adjuvants are an important component of vaccine formulations and have 
major functions for enhancement of antigen uptake and presentation to the secondary 
lymphoid tissues. These immunomodulatory substances have multiple activities, including 
antigen delivery, recruitment of the specific immune cells to the site of immunisation and 
maturation of antigen presenting cells [10].  
 
The ideal anti- Chlamydia vaccine should induce Th1 directed immune –protection with IFNγ 
secreting CD4+ T cells and neutralising antibodies at the infection site, given the evidence 
available from animal [11, 12] and human studies [13, 14]. The antibodies neutralise the 
infection at their entry as well as in FcR mediated phagocytosis and complement activation 
linked with T cell response [15-18]. There is still limited data available on antibody mediated 
immune response in koalas following either vaccination or infection. While the lack of a 
koala-Chlamydia infection model, the vaccine response in naturally infected animals could be 
an alternative option. Nevertheless, for the management of the wild animal’s disease, it is 
significantly important to minimise the infection burden at population level and warrant the 
therapeutic and prophylactic vaccine as a practical solution. Animal model against  
chlamydial infection have shown the important role of Th1 directed cytokines, specially IFN-
γ [13]. In the mouse model having strong IgA response without IFN-γ secretions fails to 
mount immune-protection. This pro-inflammatory cytokine inhibits the growth of Chlamydia 
through several ways [19, 20].  
 
Taken together this several aspects of chlamydial immunity and vaccine research in koala, we 
aimed to investigate the following key aspects in this thesis. 
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1.2 The specific aims of the current study 
The overall aim of the study described in this thesis is to contribute to the development of a 
C. pecorum vaccine for koalas. In our research we aimed: 
1. Investigate the immune response of a novel Tri-adjuvant component polyphosphazine 
based poly I: C and host defense peptides combined with rMOMP C. pecorum antigen 
in koalas with single vaccination. 
2. Characterise the antibody mediated immune response in koalas following either 
natural infection or vaccination. 
3. Compare the immune response following MOMP vaccine and adjuvanted with either 
ISC or Tri-adjuvant. 
 
1.3 Progress of research linking the scientific papers 
 
This thesis consists of four papers, which have been published (4) in peer reviewed journals. 
The scientific work presented in these papers directly addresses the specific aims of this 
research project.  
 
The first paper (Chapter 3) entitled “Vaccination of koalas (Phascolarctos cinereus) with a 
recombinant chlamydial major outer membrane protein adjuvanted with Poly I:C, a host 
defense peptide and polyphosphazine, elicits strong and long lasting cellular and humoral 
immune responses” has been published in the “Vaccine” journal, Volume 32  on September 
4, 2014. This paper describes that single dose rMOMP vaccine combined with a poly I:C, 
host defense peptide and polyphosphazine adjuvant is able to stimulate both cellular and 
humoral immune response in koalas. This is the first study in koalas that utilised these novel 
adjuvant components. The immune responses that we observed in koalas to rMOMP 
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incorporated with the Tri-adjuvant were similar to the previously described study. Although 
the Th1 immune response is critical in chlamydial infection, the role of antibodies has been 
described in a considerable number of published articles in laboratory animal models, though 
there was no detailed analysis of the humoral immune response to vaccine in koalas. This 
leads us to the next article describing the role of antibody against chlamydial infection and 
vaccination. 
 
The second paper (Chapter 4) entitled “Humoral immune responses in koalas (Phascolarctos 
cinereus) either naturally infected with Chlamydia pecorum or following administration of a 
recombinant chlamydial major outer membrane protein vaccine” has been published in the 
“Vaccine” journal, Volume 34 on December 30, 2015. As part of the thesis work, we utilised 
a wild koala population to study (a) the immune response of naturally infected koala and (b) 
the immune response following vaccination. One of the important findings in this study was 
that a different and unique set of antibodies were induced by vaccination, compared to those 
from natural infections. All these epitopes were in the conserved domain and these would be 
conserved across the multiple ranges of MOMP genotypes. As koala chlamydial infection is 
wide spread and often asymptomatic in free ranging koalas, a therapeutic vaccine is 
significantly important. This leads us to the next paper describing the prophylactic and 
therapeutic effect of chlamydial vaccine.  
The third paper entitled “A prototype recombinant-protein based Chlamydia pecorum vaccine 
results in reduced chlamydial burden and less clinical disease in free-ranging koalas 
(Phascolarctos cinereus)” has been published in the “PLoS One” journal, Volume 11, 
January 12, 2016.  In the broader aspect of the larger koala vaccine project, this study 
confirms the effectiveness and protective immune response of C. pecorum positive koalas 
following vaccination. The vaccine induced very high antibody titers in koalas even for those 
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with current infections. Notably, the percent of neutralisation was significantly higher in the 
vaccinated group, compared to natural infections.  
The final aspect of the thesis was to evaluate the adjuvant effects on the immune response of 
koalas and is depicted in the final article. This paper entitled “Antibody and cytokine 
responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial major 
outer membrane protein (MOMP) with two different adjuvants” has recently been published 
in the “PLoS One” journal. In this study we first measured the T cell response through IFN-γ 
gene response in koalas. The animals showed comparatively similar immune response 
regardless of the two different adjuvant regimes. Both ISC and single dose Tri-adjuvant 
immunisation resulted in high antibody titers with good in vitro neutralisation levels.  
Taken together, the results presented in chapters 3, 4, 5 and 6 clearly improve our 
understanding of chlamydial immune response in koalas in response to vaccine. These results 
will help us in targeting vaccine antigens along with appropriate adjuvant for future vaccine 
design in koalas against chlamydiosis. 
 
1.4 Thesis outline 
This thesis has been written according to Queensland University of Technology’s (QUT) 
“PhD thesis by publications” guidelines. Chapter 2 describes the literature relevant to the 
field of this particular study. Then Chapter 3, 4, 5 and 6 describe published and submitted 
work in the peer reviewed journals as part of the thesis. Chapter 7 describes the significant 
findings of this research project along with a few outlines for future scientific work. 
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Chlamydia is a gram negative, coccoid intracellular bacterium that is pathogenic for humans 
and animals and causes a wide spectrum of diseases in the respiratory and uro-genital tracts 
as well as in the eyes. The Greek word Chlamydia means “cloak” or “a mantle” and describes 
the bacterial inclusions morphology around the host nucleus [1]. 
2.1 Chlamydia 
Chlamydia is an obligate intracellular bacterium with a unique biphasic developmental cycle 
that exists inside a range of eukaryotic host cells [2]. This bacterium infects a wide range of 
animals as well as humans causing a wide spectrum of diseases in the eyes, respiratory and 
urogenital tracts [3, 4]. Currently, the genus Chlamydia has 11 recognised species: C. 
abortus, C. avium, C.caviae, C. felis, C. gallinacea, C. muridarum, C. pecorum, C. psittaci, 
C. suis, C. pneumoniae and C. trachomatis. The host range of these species varies. For 
example,  C. trachomatis infects humans, swine and mice; C. psittaci infects mammals, birds, 
cats and guinea pigs; C. pecorum infects a wide range of animals including mammals (sheep, 
cattle, goats), marsupials (koalas) and swine; C. pneumoniae infects humans and other 
animals [5, 6]. 
 
 
2.2 Developmental cycle 
Chlamydia has two morphologically and physiologically distinct developmental forms; the 
non-dividing, infectious elementary bodies (EB) and replicative, non-infectious reticulate 
bodies (RB) [7]. Another developmental phenotype characterised by an atypical aberrant 
body is associated with persistent infections of this pathogen. The infectious EB is small in 
size compared to RBs with highly condensed chlamydial DNA and histone-like proteins hctA 
and hctB [8]. While EBs are thought to be metabolically inactive, studies have shown that 
EBs exhibit a low-level of metabolic activity by utilising glucose-6 phosphate [9]. 
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Initial attachment of Chlamydia EBs is thought to be a two stage process involving the 
electrostatic interactions of the bacteria with heparin sulphate proteoglycans [10], followed 
by high affinity irreversible binding which is mediated by an, as yet, unidentified secondary 
receptor [11]. However, mannose, mannose 6-phosphate as well as the estrogen receptor have 
all been suggested to play a role in Chlamydia entry in the host cell [12, 13]. Both infectious 
EBs and the host proteins function synergistically to promote the invasion process [14]. EBs 
have a unique cysteine-rich disulphide cross-linked outer membrane surface structure [15], 
which is osmotically stable and resistant to extracellular stresses [16]. 
 
Following entry, the EB is internalised into a membrane bound compartment termed an 
inclusion. The inclusion contains various biosynthetic precursors, amino acids and lipid 
substances from the host cells [17, 18]. The inclusion avoids fusion with lysosomes and 
subsequently moves to the peri-golgi region [19]. Additionally, the inclusion interacts with a 
number of cellular organelles including multivesicular bodies [20], lipid droplets [21], 
mitochondria [22] and lysosomes [23] to acquire the nutrients for replication and as well as 
for membrane stability. Chlamydia differentiates from the EB form into actively replicating 
RBs, predominantly by multiplying through binary fission within the inclusion [24]. 
Persistence can be induced during this stage through nutrient starvation, interferon-gamma 
stimulation, and induction of nitric oxide synthase or antibiotic treatment [25-27]. After 
completing the developmental cycle, RBs transform back to EBs through an asynchronous 
process with repackaging bacterial chromosomes, nutrients and type 3 secretions (T3S) [24, 
28, 29]. Release of EBs  can occur in two ways either via disruption of the host cell 
membrane through the lytic pathway or extrusion of the EBs from the host cell without 
disturbance of the cell membrane [30]. 
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Fig 1.  Diagrammatic presentation of the chlamydial developmental cycle in a typical host 
cell. It depicts the key events that occur inside the host cell as part of their developmental 
cycle. EB: Elementary body; RB: Reticulate body; CPAF: Chlamydial protease like activity 
factor; TARP: Translocated actin recruiting phospho-protein; MEP: Methylerythritol 
phosphate; TTSS: Type three secretion systems (Taken from: AbdelRahman and Belland, 
[31]). 
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2.3 Chlamydia Taxonomy 
The taxonomy of Chlamydia is a debatable issue, which can be divided into two eras. 
According to the pre-1999 era, Chlamydia consisted only in one Family Chlamydiaceae and 
one genus Chlamydia. In this taxonomy, the genus Chlamydia contained four species: 
Chlamydia trachomatis, Chlamydia psittaci, Chlamydia pneumoniae and Chlamydia 
pecorum. Following the publication of Everett et al., in 1999, the genus Chlamydia was split 
into two genera namely Chlamydia and Chlamydophila, consisting of a total of nine species. 
C.pneumoniae, C. psittaci, C. pecorum, C. abortus, C. felis and C. caviae were under 
Chlamydophila and C. trachomatis, C. suis and C. muridarum were within the genus 
Chlamydia. In the twenty-first century, Stephens et al. rearranged and proposed a single 
genus, Chlamydia. In this nomenclature, nine species exist within the genus Chlamydia as 
such C. trachomatis, C.pneumoniae, C. psittaci, C. pecorum, C. abortus, C. suis, C. felis, C. 
caviae and C. muridarum [32].  Two new species have been recently added to the 
Chlamydiaceae – C. avium and C. gallinacea. C. avium has been isolated from a number of 
avian species including pigeons and parrots while C. gallinacea was isolated from chickens 
[33]. 
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Table 1. Taxonomy of chlamydial organisms (Taken from Schautteet and Vanrompay, [34]) 
 
Chlamydial taxonomy before 1999 Chlamydial taxonomy since 1999 (Everett et al., 1999) Chlamydial taxonomy used in the 
twenty-first century (Stephens et al., 
2009) 
Order Chlamydiales Chlamydiales Chlamydiales 
Family Chlamydiaceae Chlamydiaceae, Simkaniaceae, Parachlamydiaceae, 
waddliaceae 
Chlamydiaceae, Simkaniaceae, 
Parachlamydiaceae, waddliaceae 
Genus Chlamydia Chlamydia Chlamydophila Chlamydia 
Species C. 
trachomatis 
Trachoma 
biovar 
C. trachomatis Trachoma 
biovar 
 C. trachomatis Trachoma 
biovar 
LGV biovar LGV 
biovar 
LGV biovar 
Murine biovar C. muridarum  C. muridarum  
Porcine biovar C. suis  C. suis  
C. 
pneumoniae 
Human biovar Cp. 
pneumoniae 
TWAR 
biovar 
C. pneumoniae TWAR 
biovar 
Koala biovar Koala biovar Koala biovar 
Equine biovar Equine 
biovar 
Equine 
biovar 
C. psittaci Avian subtype Cp. psittaci  C. psittaci  
Abortion 
subtype 
Cp. abortus  C. abortus  
Feline subtype Cp. felis  C. felis  
Guinea-pig 
subtype 
Cp. caviae   C. caviae  
C. pecorum  Cp. pecorum  C. pecorum  
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2.4 Diseases caused by Chlamydia 
Chlamydia causes a wide spectrum of diseases in different hosts [4]. Trachoma caused by C. 
trachomatis was one of the earliest ocular disease in both male and females, recorded by 
Hippocrates as far back as 420 B.C. Diseases associated with C. trachomatis can be separated 
by serovars based on the epitope recognition of  the 4 variable regions, the MOMP protein 
and nucleic acid sequence of ompA. The genital serovars (D-K) of C. trachomatis are the 
leading pathogens for the sexually transmitted diseases (STDs) in humans, with over 100 
million cases reported annually worldwide [35]. The ocular strains of the C. trachomatis 
(serovars A-D) are associated with blindness in developing countries [36]. The genital form 
of infection in women, causes cervicitis, urethritis, endometritis, pelvic inflammatory disease 
(PID), infertility with tubal occlusion [37, 38]. In men, it has been associated with urethritis, 
epididymitis and prostatitis [39-41]. Whilst, the majority of the C. trachomatis infections are 
asymptomatic, severe complications resulting from chronic infection have been seen in both 
men and women. The Lymphogranuloma serovars (L1, L2 and 3) are invasive in nature and 
predominantly restricted to the mucosal epithelium  and submucosa of the affected 
individual, thereby causing lymphadenopathies, proctitis and ulcerative lesions in the 
intestinal mucosa [42]. 
 
The mouse species of C. muridarum was initially isolated from the respiratory tracts of mice 
but the pathogen can be transmitted through an oral route. It infects both the respiratory and 
genital tract in mice, similar to C. trachomatis genital infection in humans [43], paving the 
way for utilising the mouse and C. muridarum as laboratory animal infection model for the 
study of human respiratory and sexually transmitted chlamydial infections [44]. 
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C. suis, has only been isolated from pigs, in which it may be endemic. This species of 
Chlamydia is associated with conjunctivitis, pneumonia and enteritis in both farmed and wild 
pig populations [45]. While the zoonotic potential of C. suis has not been exclusively 
examined, there is some indication that this pathogen can cause conjunctivitis in pig abattoir 
employees [46]. 
 
Psittacosis is a systemic infection caused by C.psittaci in domesticated and feral birds 
including chickens, pigeons and turkeys. This pathogen causes systemic infection in birds and 
the symptoms include conjunctivitis, difficulty breathing and watery droppings [47]. All 
avian species are likely to be the natural hosts and the infection is transmissible to humans 
with nonspecific clinical symptoms [48]. The first documented human psittacosis or 
popularly “parrot fever” was described in the early 1900s [49].  
 
C. pneumoniae causes bronchitis and pneumonia in humans [50], but it has also been 
associated with a number of other diseases such as coronary heart diseases [51], Alzheimer’s 
[52], reactive arthritis [53] and asthma [54]. This pathogen also infects a wide range of 
animals including koalas [55], horses, frogs and turtles [56]. Unlike other human species, C. 
pneumoniae exhibits a highly conserved ompA sequence, with little difference between 
human and animals strains [57]. Though animal to human transmission has been suggested on 
at least in two occasions [58], no evidence for human to animal transmission has been 
reported. 
 
C. felis is a natural pathogen of domestic cats and causes hyperaemia of nictitating 
membrane, blepharospasm, ocular discomfort and conjunctivitis [59].  It causes conjunctivitis 
in humans and the prevalence of human infection is 1.7% [60].  
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C. abortus causes abortion and mastitis in cattle and ovine enzootic abortion in lambs [61]. 
The pathogen was first identified in sheep with abortions and thus causes serious economic 
problems worldwide. This pathogen has been documented in other livestock species as well 
as rodents [62].  
 
C. caviae causes infections in its natural host, guinea pigs, and is mainly associated with 
guinea pig inclusion conjunctivitis. This pathogen is highly host-specific and the reproductive 
infection in guinea pig has been used as an experimental animal model to evaluate the 
pathogenesis of C. trachomatis genital infection [63].  
 
C. pecorum was first isolated from a calf with encephalomyelitis [64] and later on has been 
found in a number of livestock and marsupial hosts. This pathogen causes a wide spectrum of 
diseases such as conjunctivitis, pneumonia, poly-arthritis, intestinal infection, 
encephalomyelitis in a broad range of animals including koalas, bandicoots, ruminants, pigs 
and horses [3, 65, 66]. C. pecorum is well studied in koala, where it has showed genetic 
diversity due to cross-species transmission within the wild population [67].  
 
Two new species have been added to the Chlamydiaceae: C. avium and C. gallinacea. These 
two species were isolated from avian species including chickens, pigeons and parrots. These 
pathogens cause respiratory illness, enteritis and hepatic enlargement in their host animals 
[33]. 
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Table 2.  Epidemiology of chlamydiosis at the interface of the human-animal niche (Taken from Rodolakis and Yousef , [68]) 
-b not reported 
  
Chlamydia 
species 
Host Pathology in animals Route for 
human 
transmission 
Pathology in humans 
Principal host Occasional 
host 
Clinical signs Severe 
disease 
Usual disease Severe disease 
C. psitt
aci 
Bird Dog, horse, 
pig 
Hyperthermia, 
anorexia, 
lethargy, 
diarrhoea 
Conjunctiviti
s, pneumonia, 
pericarditis, 
death 
Inhalation Influenza like illness Endocarditis 
Encephalitis, pneumonia, death 
C. abor
tus 
Sheep, goat, 
cattle 
Pig, deer, 
horse 
Abortion, 
stillbirth, 
epididymitis 
Metritis Inhalation Influenza like illness Pneumonia, abortion, renal 
failure, respiratory distress, 
death 
C. felis Cat -b Conjunctivitis Pneumonia, 
chronic 
sulphingitis 
Contact Conjunctivitis Endocarditis, severe liver break 
down 
C. cavi
ae 
Guineapig - Genital tract 
infection 
- Contact Conjunctivitis - 
C. pneu
moni
ae 
Human, koala, 
horse 
Reptiles, 
amphibians 
Respiratory 
disease 
- Inhalation Pneumonia, 
bronchitis, asthma 
Atherosclerosis 
C. peco
rum 
Ruminant, 
swine, koala 
Wild 
animals 
Intestinal 
infection, 
conjunctivitis, 
urinary tract 
infection 
Encephalomy
elitis, 
pneumonia, 
arthritis 
Contact - - 
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2.5 Koala Chlamydia taxonomy 
Initially, chlamydial species in koalas were known as C. psittaci based on cell culture 
observations. Restriction enzyme and gene probe analysis subsequently revealed two distinct 
types of C. psittaci, isolated from the conjunctiva and urogenital tract and rectum in koalas 
[69]. However, based on nucleotide sequencing of the ompA gene, these were further 
reclassified into C. pneumoniae and C. pecorum respectively [70-72]. In 1999, a revised 
taxonomic division temporarily moved these two species, with seven other known species, 
into a new genus Chlamydophila [73]. This amendment was not widely established and 
revisions merged all nine species into a single genus, Chlamydia [32]. The species infecting 
koalas are now referred to as Chlamydia pecorum and Chlamydia pneumoniae. 
 
2.6 Epidemiology of koala Chlamydia 
Chlamydia infection is widespread in wild koalas across their habitat in the northern region of 
Australia, including Queensland and New South Wales [74]. A variety of approaches have 
been used to measure the infections in koalas over the last 20 years. While serological assays 
were used  in the early studies, recently, molecular techniques such as specific PCR methods 
have provided accurate data on the prevalence of chlamydiosis in koalas [75].  White et al. 
[76] conducted a molecular study to understand the epidemiology of chlamydiosis in koalas. 
This study demonstrated a high prevalence of Chlamydia in both male and female koalas at 
both anatomical sites (ocular and urogenital). Later on, Jackson et al. [77] utilised molecular 
methods to identify the epizootiology of the two chlamydial species within two different 
geographic wild populations. This study demonstrated infections caused by the C. 
pneumoniae were usually of lower intensity in comparison with C. pecorum infections. The 
study further revealed the vertical transmission pattern of the chlamydial infections within 
wild koala population. The increasing use of species-specific PCR and sequencing data has 
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revealed certain koala populations in the North-Eastern region of Australia have infection 
levels as high as 72-100% [75]. Chlamydiosis was unfortunately also the second most 
frequent reason for koala admission to a koala hospital or a koala care centre in New South 
Wales over a 30 year period [78].  
 
 
 
Fig 2. The map illustrating the prevalence of Chlamydia pecorum across the eastern half of 
Australia indicating the known geographic range of koala; Grey shading representing the 
koalas distribution (Taken from Polkinghorne et al. [75]). 
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2.7 Types of koala-Chlamydia infection  
Koalas exhibit four types of clinical presentation of disease syndrome associated with 
chlamydial infection. In ocular infections, the inflammation is confined in the mucosal 
epithelium and is characterised by serous ocular discharge, blepharospasm and purulent 
discharge with conjunctivitis, fibrosis and blindness. In severe and chronic cases, corneal 
opacity can occur. Urinary tract infection manifests by brown urinary discharge, involuntary 
urination resulting in wet bottom or dirty tail around the rump region, popularly known as 
wet bottom syndrome [79]. Rhinitis with complex respiratory disorders has been seen in 
respiratory illness. The reproductive symptoms are the significant devastating aspect of this 
disease, affecting both male and female koalas. In male koalas, infections are typically 
associated with conjunctivitis and genital infection can cause orchitis, epididymitis and 
prostatis [80]. Acute reproductive tract disease associated with severe inflammation in the 
mucosal epithelium reversibly (infertility) or irreversibly (sterility), in female koala, results in 
reproductive loss [81]. 
 
 
 
Fig 3. Clinical signs of chlamydiosis in koalas (a) the classical bilateral kerato-conjunctivitis 
and (b) wet bottom or dirty tail (Taken from Polkinghorne et al.[75]) 
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2.8 Pathological lesions 
The majority of the histopathological findings are confined to the lower genital tract of the 
reproductive tract in female genital chlamydiosis. In male koalas, mild inflammation has been 
seen within sertoli cells and interstitial spaces with intact seminiferous and epididymal 
tubules [80]. The gross pathological changes are characterised by marked and irregular 
thickening of the bladder wall; reduced diameter of the lumen has been noted [82]. Chronic 
disease is associated with cystic changes in the oviduct and ovarian bursae and in some cases 
thickening of the uterine wall. Prostatic abscess formation is the prominent pathological 
finding for male koalas [83, 84]. Ocular infections result in inflammation, characterised by 
conjuctival hyperplasia and progressing to fibrosis. In severe cases, corneal opacity develops 
and progresses to the rupture and collapse of the globe [75]. 
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Fig 4. Clinico- pathological manifestation of chlamydial infection at ocular (A-C) and 
urogenital (D-F) sites. A) Acute kerato-conjunctivities with inflamed conjunctiva with 
minimal hyperplasia; B) Chronic-inactive kerato-conjunctivitis with extensive hyperplasia; 
C) Chronic active kerato-conjunctivitis with marked hyperplasia and exudation; D) Chronic , 
inactive urogenital infection with ovarian bursal cysts; E) chronic cystitis and F) severe 
urogenital tract pathology with ruptured uterine abscess ( a. bursal cyst; b. uterine abscess; c. 
caecum; d. suppuratives exudates) [85]. 
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2.9 Immunity against Chlamydia 
The principal requirement for the immunological response of chlamydial pathogenesis is the 
T cell response in host defense against chlamydial infection. CD4+ T cells as well as CD8+ T 
cells are found at the infection site against C. trachomatis infection in human and mouse 
models [86, 87]. Antigen presenting cells (APC) are able to phagocytose chlamydial EBs, 
degrade chlamydial components into peptides and present them in conjunction with MHC 
class II to the CD4+ T cells. These T cell subsets can recognise C. trachomatis antigens, such 
as MOMP, polymorphic outer membrane protein as well as heat shock protein 60 (hsp60) 
[88, 89]. However, natural immunity against C. muridarum genital infection is mediated 
through CD4+ T cells, Th1 cytokines and antibodies. Whilst Th1 mediated response has been 
associated with protection, a Th2 mediated response is linked to immuno-pathology. The Th1 
response is characterised by the production of IL-12 and IFN-γ and Th1- associated 
antibodies like IgG2a and IgG3 in the mouse model [90]. It is also evident that all chlamydial 
infection does not exclusively result in pathological damage and disease sequelae. 
Nonetheless, microbiological as well as host factors play a critical role in chlamydial disease 
pathogenesis. Indeed, the polymorphic characteristics of TNF-α and IL-10 promoter genes 
are able to affect the immune response against C. trachomatis human infection [91, 92]. 
 
2.9.1 Innate immune response 
The first line of defense against chlamydial infection is polymorphonuclear cell activation 
through the Toll like receptor (TLR) pathway. This host innate immune response elicits 
chemokines and cytokine production in animal models within 24 h of infection [93, 94]. This 
early stage of the immune response is critical in controlling the primary infection until the 
initiation of an adaptive response [95]. In addition, natural killer (NK) cells contribute to 
enhance the innate immune response through the production of IFN-γ against C. muridarum 
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genital tract infection [96]. Human NK cells are able to lyse the C. trachomatis infected cells 
at the genital mucosa site [97]. Whilst the genital epithelial cells in response to C.trachomatis 
infection produce IL-18, the dendritic cells (DCs) generate IL-12 [98].  Both these cytokines 
are able to induce IFN-γ production from NK cells. The production of IFN-γ further initiates 
the differentiation of Th1 cells as well as increasing the degradation of tryptophan,  in 
combination with TNF-α, IL-1 and lipopolysaccharide (LPS) [99]. 
 
2.9.2 Role of antibody 
Different animal studies have addressed the role antibodies in immune protection [94]. In the 
guinea pig model, a strong antibody response was demonstrated following genital chlamydial 
infection [100]. Furthermore, this study confirmed that the role of antibody is essential for 
both controlling and eliminating the infection. In addition, the guinea pig model revealed that 
the animals are unable to resolve the primary infection, even though cellular immunity is 
activated [94, 101]. In murine models, B cells promote the protective T cell responses in the 
genital mucosa following chlamydial infection [102]. There is reported evidence that the anti-
chlamydial antibodies are able to covert Th1 activation of T cells through FcR mediation 
[103]. Mucosal immunity is very crucial as chlamydial infection localizes in the reproductive 
and conjunctival mucosal layers and its replication, excretion and subsequent dissemination 
of the infection occurs through these natural orifices [104]. IgG is the most powerful 
immunoglobulin subclass that provides antibody mediated immunity at genital mucosa, as 
reported from several animal models [101,104, 105]. 
 
2.9.3 Cellular immunity 
Several animal studies clearly indicate that a cell mediated immune response is required for 
both resolution of infection and immune protection [94,106, 107]. B cell deficient mice were 
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able to display immune protection against reinfection, which indicates the important role of T 
cells in eliciting protective immunity [108]. The Th1 cellular responses, specifically CD4+ T 
cells, are responsible for resolving genital chlamydial infection. The protective immune 
response is mediated through the induction of IFN-γ, either by CD4+ or CD8+ T cells [109, 
110]. DC cells play a central role for T cell priming and subsequent induction of chlamydial 
immunity. This cellular response might be affected by hormonal changes as such oestradiol 
and progesterone, at the time of infection [111]. In addition to IFN-γ, IL-17A has been 
suggested to be a critical cytokine for protection against chlamydial infection, both for 
protection as well as in disease pathology [112, 113]. Nonetheless, an elevated IL-17A has 
been demonstrated against chlamydiosis in the mouse model [114]. 
 
2.10 Vaccine-induced immune response 
Chlamydial vaccine research in animal models indicates the importance of both cellular and 
humoral immune responses for effective vaccine production [104]. As an intracellular 
pathogen, chlamydial infection induces antigen specific cell mediated immune response, 
mediated by T-helper cell types 1 (Th1) [115]. Indeed, the antibody action is significantly 
dependent upon T cell mediated adaptive changes at the infection site. However, Chlamydia 
specific antibodies play a critical role in protective immunity [116, 117] through 
neutralisation [118]. While the surface-acting antigen predominantly neutralizes through 
antigen-specific antibodies [119], a recent study suggests the role of hidden or unexposed 
epitopes in the neutralisation process through FcRn mediation [116, 117]. Similarly, 
antibody-deficient guinea pigs were unable to clear the infection, although the cellular 
immunity was intact [120]. Nevertheless, these animals were even more susceptible to 
reinfection following antibiotic treatment. Nonetheless, a recent study demonstrated that a 
peptide-based vaccine is feasible against chlamydial infection. This study was targeting 
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specific epitope recognition site at the rMOMP to enhance the production of neutralising 
antibodies [121].  
 
2.11 Overview of chlamydial vaccine development 
Current challenges in the vaccine design and development process attributes the selection of 
immune dominant antigen capable to elicit immune-protection [122]. In chlamydial vaccine 
development, a range of antigens has been evaluated in different animal models for their 
ability to induce an immune response.  
 
2.11.1 Whole organism vaccine/1st generation vaccine 
The initial animal and human vaccine studies against chlamydial infection were primarily 
based on either inactivated or live whole organisms [123]. The two animal pathogens C. 
abortus and C. felis have been successfully incorporated as whole organism killed or 
attenuated vaccines previously. These two vaccines are commercially available in the market 
and have been utilised against ovine enzootic abortion (OEA) and feline chlamydiosis [124, 
125]. Unfortunately, similar vaccine approaches have proved unsuccessful against human 
chlamydiosis. In humans, initial partial immunity was developed against conjunctival 
infection but subsequent re-infection exacerbated disease pathology for certain individuals 
and this lead to the termination of this vaccine approach [126]. Recent study showed that 
there was no convincing evidence that vaccination led to more severe disease in humans 
[127]. 
 
2.11.2 Subunit /2nd generation vaccine 
To overcome the adverse effects of the whole organism vaccine formulations, development 
of subunit vaccines has become the dominant strategy, with some good success. This 
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approach to vaccine development has the advantage of being safer and able to screen out the 
undesirable antigenic response related to adverse immune pathology [128]. MOMP is the 
leading subunit vaccine candidate in early vaccine trials and has been significantly used 
throughout the years in various animal models (Table 3 and Table 4)[111]. MOMP was used 
either as extracted outer membrane complex, as purified native or recombinant protein in the 
form of peptide, or as plasmid and as DNA (Table 4). 
 
2.12 The vaccine antigen 
The most promising antigen for developing an efficient chlamydial vaccine is MOMP (major 
outer membrane protein) (nMOMP, rMOMP, peptide or DNA MOMP). MOMP accounts for 
60% of Chlamydia surface proteins and has a molecular mass of ~ 40 kDa [129].  DNA 
sequencing analyses revealed five constant (CD) and four variable (VD) domains across the 
full length of the MOMP protein [130-132]. This variable nature of sequence helps to evade 
the immune system of the host.  Diversified VDs play a  key immunodominant role in all 
chlamydial strains, except C. pneumoniae [133, 134]. Vaccination with recombinant MOMP 
antigens has shown promising results (see summary in table 3). Immunisation of mice and 
monkeys with the native form of MOMP (nMOMP) produced significant levels of immune-
protection against genital and ocular challenge infections [135]. Murine and monkey models 
have shown strong protection against respiratory and intrabursal challenges by utilising the 
native form of MOMP (nMOMP) with oligodeoxynucleotide (ODN) as an adjuvant [136]. 
MOMP based-DNA vaccination had shown protection against an experimental respiratory 
infection in turkeys and budgerigars [137, 138].  
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Table 3. MOMP based vaccines in animal model against chlamydial infection 
Vaccine 
antigen 
Adjuvant/delivery 
system 
Model  Route of 
administ
ration 
Genus No. of 
immunisat
ions 
Immune status/protection Reference 
nMOMP, 
rMOMP 
CpG-Montanide ISA 
720 
Mice I/m and 
s.c 
Chlamydia trachomatis 
mouse pneumonitis 
Two times Increased Chlamydia specific antibodies [139] 
DNA MOMP Cathionic polymers Turkey I/m and 
I/n 
Chlamydia psittaci One time Moderate immunoglobulin’s in plasma [137] 
Plasmid DNA 
MOMP 
GM-CSF, LTA, B 
and CpG 
Pig Intravagi
nal 
Chlamydia trachomatis 
E 
One time Reduced macroscopic pathological lesions 
Reduced vaginal shedding of Chlamydia 
[140] 
Bacteriophage-
MOMP 
Commercial vaccine 
strain 1B (Enzovax) 
Mice I/m Chlamydia abortus Two times Moderate antibody response 
Production of high level of IFN-γ and IL-2 
[141] 
 
Ct-F-MOMP 
CpG-2395 and 
Montanide ISA 720 
VG 
Monkey I/m  and 
s.c 
Chlamydia trachomatis 
F 
Two times High level of Chlamydia specific IgG and IgA in plasma 
and natural secretions 
Detected cell mediated immune response in the peripheral 
blood mononuclear cells 
[142] 
nMOMP CpG-CTB Mice I/m and 
s.c 
Chlamydia trachomatis Two times High level of Chlamydia specific IgG in serum 
Significant T cell mediated Chlamydia specific immune 
responses 
[143] 
MOMP Vibrio cholera ghost 
(rVCG)-CTA2B –
nontoxic derivative of 
cholera toxin 
Mice I/m; I/v 
and 
transcuta
neous 
Chlamydia trachomatis 
D and Chlamydia 
muridarum 
Two times Trends of Th1 biased immune response 
Increased specific mucosal and systemic antibody 
Cross protection against heterologous chlamydial serovars 
[144] 
Multi epitopes  
based peptide 
MOMP 
Human papilloma 
virus like particles 
(VLP) 
Mice I/m Chlamydia trachomatis Four times Th1 biased immune response 
Upregulation of cytotoxic T lymphocyte activity 
[145] 
rMOMP CpG-Montanide Mice Intravagi
nal and 
I/m 
Chlamydia muridarum Three 
times 
Significant protection against live challenges [146] 
rMOMP Cationic liposomes 
(CAF01) 
Mice s.c Chlamydia  muridarum Two times Significant protection against live challenges [147] 
nMOMP 
 
CpG-ODN-2395 and 
Montanide ISA 720 
Monkey I/m and 
s.c 
Chlamydia trachomatis Two times High serum IgA and IgG at mucosal and systemic sites [148] 
nMOMP CpG-1826 and 
Montanide ISA 720 
Mice I/m and 
s.c 
Chlamydia trachomatis 
mouse pneumonitis 
Two times Increased secretion of antibodies in plasma 
Increase lymphopoliferative response of T cells 
[149] 
rMOMP CpG-10109 and 
Cholera toxin 
Guinea 
pig 
Intranasa
l 
Chlamydia trachomatis Three 
times 
MOMP specific IgA and IgG in the vaginal wash [150] 
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Fig 5. C. trachomatis MOMP diagrammatic structure. The residues in the trans-membrane 
strands are boxed with bold border and the side chains facing the lipid bi-layer are shown 
(both NH2 and COOH terminal ends of the protein are internal). External loops (L1-L8) with 
Variable domains 1, 2, 3 and 4 (VS1-4) are labelled with cysteine residues that are shaded. 
(Figure taken from Findlay et al.[151]) 
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While MOMP has received the most attention, the construction of complete genome libraries 
and expression of specific predicted proteins have identified a range of immunogenic proteins 
as vaccine antigens [152, 153]. A few of them are described below. 
 
Sequence analysis has identified 9 and 21 surface exposed polymorphic membrane proteins 
(Pmps) in C. trachomatis [154] and C. pneumoniae [155] respectively. Pmps play  critical 
roles in chlamydial biology and virulence [156, 157], as they represent 13.6% and 17.5% of 
the coding capacity of these two genomes, It is suggested that these diversified proteins play  
vital roles in escaping from host immune surveillance [158, 159]. The pmp genes are 
predicted to encode membrane proteins to be localized in the outer membrane, due to the 
tryptophan residues in the C-terminal half and a C-terminal phenylalanine residue [160-163]. 
Genomics study revealed, the Pmp proteins are unique to the Chlamydiales family, and 
contain multiple GGAI and FXXN repeated motifs, associated with host cells adhesion [154, 
164]. Pmps stimulate CD4+ T cells and pro-inflammatory cytokine production in murine 
chlamydial infection with C. pneumoniae [165-167]. 
 
Moreover, several Pmp proteins, Chlamydial protease like activity factor (CPAF), Plasmid 
encoded Pgp3 protein, Outer membrane complex protein (OmcB), Porin B protein (PorB), 
and Inclusion membrane protein (Incs) have also become leading vaccine candidates for 
Chlamydia. OmcB, rich in cysteine [168-170], is the second most abundant outer membrane 
protein complex, encoded by a bicistronic operon [171, 172] . This protein is highly 
conserved among Chlamydia [169], and has been involved to the conversion process of RBs 
to EBs during chlamydial infection [173], inducing humoral immune response in humans and 
animals [174, 175]. Cationic adjuvant formulation (CAF01) consisting of DDA as a delivery 
vehicle and synthetic mycobacterial cordfactor as immunomodulatory. 
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(Dimethyldioctadecylammonium (DDA) bromide and a, a'-trehalose 6, 6'-dibehenate (TDB), 
facilitates a Th1 biased immune response. Furthermore the adjuvant is stated to triggers both 
arms of the immune system and had shown promising results in experimental malaria, 
tuberculosis and chlamydial  vaccines [176]. 
 
CPAF was the first established virulence factor secreted by Chlamydia in the cytosol [177], 
degrading host transcription factors RXF5 and upstream stimulation factor 1 (USF1), 
suppressing interferon-γ mediated expression of MHC I and II in infected cells, that may aid 
in chlamydial evasion of host immune system [178-180]. In addition, CPAF can cleave the 
cytoskeleton, facilitating expansion and growth of the inclusion [181]. During the 
developmental cycle, all Chlamydia multiply within a host cell derived vacuole termed an 
inclusion, which has insertions of specific bacterial proteins (Inc proteins). The major 
function of the Inc proteins is to interact with host cell components and elicit cell mediated 
immune response following chlamydial infection [182]. 
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Table 4. Summary of Chlamydia vaccine research with major antigen-adjuvant approaches. i.m: intracmuscular; i.n: intranasal; s.c: subcutaneous; i.v: intravenous [181] 
Vaccine Antigen and adjuvant Immunization 
route 
Model/Chlamydia 
infection route 
Immune response Reference
(s) 
Intact 
Chlamydia 
Plasmid-deficient Chlamydia (CM972, CM3.1)  Mouse/i.v Elevated IgG2a (Th1), low levels of IgG1(Th2) 
 
[184] 
Plasmid deficient Chlamydia (L2)  Mouse/i.v Elevated IgG2a, low IgG1, no IgA (mucosal) [185] 
Purified 
subunits 
MOMP plus cholera toxin subunit B conjugated to CpG i.m + s.c Mouse/i.n Elevated IgG2a and IgG3 (Th1), lower IgG1 level, elevated IFNγ (Th1) [143] 
MOMP-ISCOM i.n or i.m Mouse/i.n i.m route induced highest IFNγ and IL4 (Th2) levels [186] 
MOMP plus Freund’s adjuvant i.m + s.c Mouse/i.v Vortexted MOMP elicited higher IgG2a than IgG1 
Sonicated MOMP elicited higher IgG1 than IgG2a 
[187] 
MOMP plus IC31 i.m + s.c Mouse/i.n Higher IgG1 than IgG2a [188] 
MOMP plus CpG/Montanide i.m + s.c Rhesus macaque Elevated IgG, IgA, IFNγ and TNFα [189] 
Recombinants 
protein 
rMOMP plus cholera toxin/CpG or CTA1 s.1 or. T.c or i.n Mouse/i.n Elevated IFNγ and TNFα [190] 
rMOMP plus CpG/Montanide i.m + s.c Mouse/i.n Vaccination protected against fibrotic scarring in lungs [191] 
rCPAF plus Il12 i.n Mouse/i.v Increased IFNγ and minimal IL4 [192] 
rCPAF plus CpG i.n Mouse/i.v Vaccination significantly prevented infertility [193] 
rCTh1 plus CAF01 s.c Mouse/i.v T cell production of TNFα, IFNγ and Il2 [194] 
rGlgP plus CpG i.m Mouse/i.v Th1 dominat T cell response [195] 
rMIP i.m Mouse/i.v Elevated IFNγ and no IL4 [196] 
rCT043 i.m Mouse/i.n Reduces bacterial load [197] 
rCT823 plus ISCOM and CT144 plus ISCOM s.c Mouse/i.v Elevated IFNγ, TNFα and IL2 [198] 
rPmpG plus GNE and SctC plus GNE s.c Pig/i.v PmpG protected better than SctC 
PmpG vaccination did not elicit antibody production 
SctC vaccination elicited  
high antibody titers 
[199] 
DNA vaccine DNA MOMP i.m Mouse/i.v Elevated levels of IgG2a and IgG1 [200] 
Priming with MOMP and secondary boost with DNA 
MOMP-ISCOM 
i.m Mouse/i.n Elevated levels of IgG2a, IgA and IFNγ [201] 
DNA MOMP plus GM-CSF, enterotoxins (E. coli) A and 
B 
i.n + i.v Pig/i.v Vaccination induced significant protection against genital challenge 
Anti MOMP antibodies and low IL4 production 
[202] 
OmpA i.m Pig/i.m  [203] 
Bacterial ghosts MOMP and PorB DNA plasmid i.m Mouse/i.v High levels of IgG2a and IgA [204] 
PmpD and PorB DNA plasmid i.m Mouse/i.v High levels of IgG2a, IgA and IFNγ and low levels of IL5 (Th2) [205] 
Biodegradable 
polymers 
rMOMP encapsulated in PLGA s.c Mouse Elevated CD4+ and CD8+ T cells [206, 207] 
Chitosan containing rMOMP DNA i.m  Elevated IFNγ and IL12 and reduced IL4 and IL10 [208] 
Vaccine from 
transgenic 
plants 
MOMP introduced into A. thaliana and D. carota    [209] 
Gas vesicles Gene fragments coding for MOMP, OmcB and POMP 
loaded into Halobacteria –derived gas vesicles 
  Elicited Th1 cytokines in human foreskin fibroblasts [210] 
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2.13 Adjuvants 
Vaccines based exclusively on MOMP antigen alone, induce weak immune-protection 
against experimental genital chlamydial infection [211]. Therefore, the development of potent 
adjuvants is predicted to be the key to successful chlamydial vaccine development [152]. 
 
Adjuvants are substances combined with antigens to enhance the host immune response 
through the depot effect, antigen presentation or targeting, immune activation or modulation 
and cytotoxic lymphocyte infiltration. The protection may require a neutralising antibody 
response, interferon γ secretion by CD4+ T cells and cytotoxic CD8 lymphocyte response 
[212]. 
 
Toll like receptor agonists (TLR) are a group of immunopotentiators that promote maturation 
of the antigen presenting cells such as DCs (dendritic cells) [213]. TLR activation leads to 
activation and recruitment of the immune cells at the infection site, provision of adequate 
cytokines, chemokines and antimicrobial peptides, resulting in an overall adaptive immune 
response against conserved  pathogen associated molecular patterns (PAMPs ) [214] (Fig. 6). 
 
Saponin-based adjuvants possess immunomodulatory abilities, including induction of 
balanced Th1/Th2 immune response, adequate antibody production [215] and cytotoxic 
CD8+ T lymphocytes [216] at the infection site through TLR-independent and IL-18 
signalling pathways. ISCOMATRIX®, a saponin-based adjuvant, elicits rapid influx of innate 
cells to the draining lymph node [217]. This process enhances the cross and prolonged 
antigen presentation through antigen presenting cells (APCs) in the lymphatic channels [218] 
(Fig. 6). 
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Cationic adjuvant formulation (CAF01) consisting of DDA as a delivery vehicle and 
synthetic mycobacterial cordfactor as immunomodulatory. (Dimethyldioctadecylammonium 
(DDA) bromide and a, a'-trehalose 6, 6'-dibehenate (TDB), forms CAF01 [176] which has 
strong adjuvant activity through delaying release of antigen [217] with efficient memory T 
cell production [220]. It induces a Th1 biased immune response including Th17 response 
[221]. 
 
Aluminium containing adjuvants, widely used in human vaccines, can stimulate humoral 
immunity with a strong Th2 response [222]. It forms a depot effect at the injection site. The 
formation of particulate facilitated phagocytosis by antigen presenting cells [223]. The 
immunostimulatory property of aluminium salts depends on Nalp3 inflammasome activation 
[224], inducing pro-inflammatory cytokines, CD4+ T cell activation and antibody production 
[218] (Fig. 6). 
 
2.14 Mechanism of action of adjuvant 
2.14.1 TLR ligand agonist adjuvants 
Toll like receptors (TLR) family recognise a wide range of microbial specific signature 
molecules, including nucleic acids, protein and lipid components of microbial membranes. 
Activation of TLRs results in a series of reactions followed by inflammation and innate 
immune response [225, 226]. Indeed, the diversity of the cascade reaction depends on the 
distinct TLR activated (summarised in table 5). This TLRs family are promising vaccine 
adjuvants, as they mainly induce Th1 biased immune response. Unmethylated CpG 
oligodeoxynucleotides (ODNs) is a TLR9 agonist adjuvant currently using in different 
animals models [226]. This adjuvant induces the production of  pro-inflammatory cytokines 
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and overall eliciting a Th1-type immune response.TLR7 and TLR8 are single stranded RNA 
analogue, leading to type I IFN production and promoted Th1 response [225]. TLR3 is a 
double stranded RNA agonist as such poly inosinic:polycytidylic acid (poly I:C) that mimics 
viral RNA and exhibit as a potential vaccine adjuvant in different animal models [227-229]. 
In pigs, poly I: C was demonstrated to enhance the cell surface molecules which is thought to 
play the vital role for migrating the mature dendritic cells (DCs) to the lymphoid organs 
[230]. Nonetheless, poly I: C was shown to promote antigen specific CD4+ T cell response 
against malarial circumsporozoite protein [227]. 
 
2.14.2 Polyphosphazene based adjuvant 
Polyphosphazenes (PCEP) are biodegradable polymers with an inorganic backbone 
consisting of alternative nitrogen and phosphorus atoms. Several laboratory animals’ studies 
revealed that PCEP is potent immunological adjuvants that can enhance the quality, 
magnitude and duration of the immune responses against a wide range of vaccine antigens 
[231]. PCEP were shown to induce increased chemokines (CCL2, CXCL-10) and cytokines 
(IFN-γ, IL-4, IL-6, IL-8, IL-12) and antigen specific Ig (IgG1, IgG2) for a variety of bacterial 
and viral antigens [232-234]. Ideally PCEP has form micro-particles with antigen and 
enhance the stability, integrity of the vaccine during its formulation, processing and storage 
process [234]. In addition, this micro-particulate formulation effectively induces the antigen 
specific immune response in both plasma and mucosal compartment [235, 236]. PCEP was 
shown to significantly up-regulate antibody titers of IgG1 and IgG2a and induce a mixed 
Th1/Th2 immune response when co-administered with hepatitis B surface antigen (HBsAg) 
and influenza virus [232, 237]. Indeed, PCEP was shown to reduce the antigen requirement 
by 25-fold without affecting the quality and magnitude of the immune response [232]. 
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2.14.3 Cationic host defense peptides (HDPs) 
Cationic host defense peptides are small peptides that consist of positively charged and 
hydrophobic residues. The HDPs has been studied extensively in mouse models and majority 
of these studies focussed on immuno-modulation [238]. The immuno-modulatory properties 
of HDPs include (i) decrease the pro-inflammatory cytokines production induced against 
microbial signature molecules (ii) modulate the expression of chemokines (iii) induction of 
angiogenesis (iv) polymorphonuclear cells (PBMCs) activation (v) macrophage and 
leukocyte differentiation [239]. Initially the peptides bind either with surface receptors or the 
plasma membrane and then translocated inside the cellular compartment via various 
mechanisms [240]. After translocation, HDPs interact with intracellular receptors to generate 
multiple signal transduction pathways to elicit innate immune response [241]. 
 
2.14.4 Triple adjuvant combination 
Combination adjuvants as dual and triple combinations are currently being tested in different 
animal’s studies. However, the combination adjuvant can form complexes that become highly 
immunogenic and displayed a strong synergistic effect [242]. Novel combination adjuvants 
comprising HDP, PCEP and TLR ligand agonist has been assayed with a variety of vaccine 
antigens for a wide range of species including cattle, sheep, pigs, mice and cotton rats [241-
245]. This vaccine approach shifted immune response to a Th1 type or mixed Th1/Th2 type 
[246]. In mice and pig’s model, the Bordetella pertussis antigens in combination with CpG 
ODN, HDP and polyphosphazene was demonstrated to produce protective immune response. 
The longevity and magnitude of this immune response was effective following a single 
vaccination in the presence of maternal antibodies [247]. Recent vaccine trial utilising the 
chlamydial or influenza virus antigens, promoted strong innate and adaptive immune 
response in vaccinated animals [245, 248]. 
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2.15 Safety of adjuvant 
A wide variety of adjuvant have been utilised in different animals and human chlamydial 
vaccine trials (Table 5). Though a wide range of vaccine adjuvants elicit a strong immune 
response, most of them are too toxic for use in human vaccine formulations. For example, 
complete Freund’s adjuvant (CFA) is a potent inducer of strong cellular immune response in 
mice, but it causes toxic effects in humans [225]. In koalas, TiterMax Gold has toxic side 
effects as it forms abscess at the injection side, though it has immune-modulatory properties 
(Table 6) [249].  
 
2.16 Stability and cost of adjuvants 
In order to produce a large volume of vaccine for a larger group of animals, they must be 
available at low cost. In this regards, the potential vaccine adjuvants should be made with low 
cost production [250]. The ideal vaccine adjuvants can significantly reduce the amount of 
antigen required as well as it has antigen sparing properties. In addition, it is convenient to 
administer vaccine adjuvant that is stable at room temperature. Another important factor as 
simpler administers preferably the Holy Grail being single dose vaccine adjuvant [225]. 
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Table 5. Summary of different adjuvant with their mode of action and specific immune response [251] 
Adjuvant Class Mechanism of action or receptor Type of immune response 
dsRNA analogues (poly I:C) Immunomodulatory molecule TLR3 Antibody, Th1, CD8+ T cells 
Lipid A analogues (MPL, RC529,GLA, 
E6020) 
Immunomodulatory molecule TLR4 Antibody, Th1 
Flagellin Immunomodulatory molecule TLR5 Antibody, Th1, Th2 
Imidazoquinolines (Imiquimod, R848) Immunomodulatory molecule TLR7 and TLR8 Antibody, Th1 
CpG ODN Immunomodulatory molecule TLR9 Antibody, Th1, CD8+ T cells 
Saponins (QS21) Immunomodulatory molecule Unknown Antibody, Th1, Th2, CD8+ T cells 
C-type lectin ligands (TDB) Immunomodulatory molecule Mincle, Nalp3 Antibody, Th1, Th17 
CD1d ligands (α-galactosylceramide) Immunomodulatory molecule CD1d Antibody, Th1, Th2, CD8+ NKT cells 
Aluminium salts Particulate formation Nalp3, immunoreceptor tyrosine-based 
activation motif, antigen delivery 
Antibody, Th2 
Emulsions (MF59, AS03, AF03, SE) Particulate formation Immune cell recruitment, apoptosis-
associated speck-like protein containing 
caspase recruitment domain, antigen uptake 
Antibody, Th1, Th2 
Virosomes Particulate formation Antigen delivery Antibody, Th1, Th2 
AS01 (MPL, QS21, liposomes) Combination of immunomodulatory 
molecule and particulate formation 
TLR4 Antibody, Th1, CD8+ T cells 
AS02 (MPL, QS21, emulsion) Combination of immunomodulatory 
molecule and particulate formation 
TLR4 Antibody, Th1 
AS04 (MPL, aluminium salts) Combination of immunomodulatory 
molecule and particulate formation 
TLR4 Antibody, Th1 
AS15 (MPL, QS21, CpG, liposomes) Combination of immunomodulatory 
molecule and particulate formation 
TLR4 and TLR9 Antibody, Th1, CD8+ T cells 
GLA-SE (GLA, emulsion) Combination of immunomodulatory 
molecule and particulate formation 
TLR4 Antibody, Th1 
IC31 (CpG, cationic peptide) Combination of immunomodulatory 
molecule and particulate formation 
TLR9 Antibody, Th1, Th2, CD8+ T cells 
CAF01 (TDB, cationic liposomes) Combination of immunomodulatory 
molecule and particulate formation 
Mincle, Antigen delivery Antibody, Th1, CD8+ T cells 
ISCOMs (saponin, phospholipids) Combination of immunomodulatory 
molecule and particulate formation 
Unknown Antibody, Th1, Th2, CD8+ T cells 
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Fig 6. Mechanism of action of different classes of adjuvants. Some adjuvants can act through 
multiple pathways including antigen uptake, PPR signalling, inflammasome activation and 
recruitment of immune cells. (For example: Alum) [251] 
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2.17 Development of vaccine against chlamydiosis in koalas 
Chlamydial MOMP is the best studied immune-protective antigen to date [67, 252]. 
Nevertheless, vaccination with MOMP does have its limitations. The surface exposed 
variable domains of MOMP are genetically diverse. Initially in the process of vaccine design, 
our group utilized MOMP as the vaccine antigen along with NrdB and CT512 with three 
different adjuvants namely Alhydrogel, TiterMax Gold and Immune Stimulating Complex 
(ISC) in koalas [249]. Recombinant NrdB was used to prime CD4+ T cells to produce both 
anti-Chlamydia antibodies and a lymphocyte response.  This antigen has the advantage that it 
is highly conserved across many chlamydial species. CT512 is an immunogenic antigen, 
originally developed from outer membrane protein (omp85) of C. muridarum, and elicits 
partial protection against genital chlamydial infection in mouse model [253]. This 
preliminary study showed that a multi-subunit vaccine is feasible in koalas against 
chlamydial infections. The adjuvant, ISC is composed of purified saponin complex with 
cholesterol and phospho-lipid and has shown cytotoxic T-cell response in different animal 
models [201]. Vaccination of koalas with rMOMP plus ISC adjuvant induced a strong 
cellular and humoral response in several trials [249, 254-256]. These studies showed a multi-
subunit rMOMP based vaccine could provide immune-protection against chlamydial 
infection in koalas. 
 
The major issue of chlamydial infection in humans is the asymptomatic nature of the 
infection. This is also a problem in koalas with molecular studies showing high prevalence 
rates in the absence of disease (reviewed in Polkinghorne et al. [75] ). Interestingly, Wan et 
al. [257] showed that high infection loads can be found in asymptomatic animals [257]. These 
animals might be a source of infection for future transmission of Chlamydia in wild koalas. 
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Therefore, the importance of producing a vaccine that elicits immune response in healthy as 
well as in diseased koalas is significantly important. 
 
 
 
Due to the diversified nature of the MOMP protein [258], it was unexpected to have a similar 
form of immune response in koalas that have either received a single or multiple dose of 
MOMP vaccine. Surprisingly, single MOMP vaccinated koalas were able to recognize the 
homologous as well the heterologous strains of koala C. pecorum [255]. This study is very 
promising as it illustrates the feasibility of developing an effective recombinant MOMP-
based C. pecorum vaccine against a wide range of circulating strains. Nonetheless, a recent 
study utilising the Pepscan method (www.pepscan.com) was able to identify the B cell 
epitopes across the MOMP protein of four C. pecorum strains. This study revealed that 
vaccine induced epitopes were distinct from natural infection [256]. Most of the epitopes 
were in the conserved domain, suggesting the cross reactive nature of the previously 
described immune response with single rMOMP protein [258].   
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Table 6. The vaccination profile for koala’s (Literature thus far) 
 
Antigen Adjuvant Immune response Reference 
MOMP, NrdB and 
TC0512 
Alhydrogel IgG had significant response 
in genital tract up to 158 
days 
[249]  
Significant Peripheral blood 
mononuclear cell (PBMC) 
proliferation 
MOMP, NrdB and 
TC0512 
Immuno-stimulating complex 
(ISC) 
Sustained plasma IgG up to 
1 year 
 [249] 
MOMP, NrdB and 
TC0512 
TiterMax Gold Abscess in the inoculation 
site 
 [249] 
Minimal IgG response up to 
102 days 
MOMP and NrdB Immuno-stimulating complex 
(ISC) 
Sustained IgG in the plasma 
and eyes secretion up to 140 
days 
[254]  
MOMP monovalent Immuno-stimulating complex 
(ISC) 
Sustained plasma IgG  for 
MOMP A up to 21 wks 
[255] 
Sustained plasma IgG for 
MOMP F up to 21 wks 
Plasma IgG response up to 
10 wks for MOMP G 
MOMP polyvalent Immuno-stimulating complex 
(ISC) 
Significant IgG up to 10 wks 
and moderately up to 21 wks 
[255] 
 
 
While a chlamydial vaccine development in koalas looks promising, we still lack species 
specific immunological reagents due to our lack of understanding of the koala immune 
response against infection or vaccination. Recently Mathew et al. [259] provided some 
knowledge in koala immunology by optimising and developing the koala specific quantitative 
real time PCR assays for measuring the important Th1 cytokine, IFN-γ .In addition, they 
identified IL-17A gene expression in diseased animals as a key immune marker for 
chlamydial disease severity and pathogenesis [260]. Furthermore, they characterised the 
expression of anti-inflammatory (TNF-α and IL-10) cytokine in a cohort of diseased koalas 
[261]. 
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2.18 Concluding remarks 
A Chlamydia vaccine is the most appropriate and realistic approach against the widespread 
infections that continue to be present in koalas. Early human trachoma vaccine trials utilising 
whole inactivated Chlamydia, resulted in adverse disease pathology in recipients [127]. Since 
then, immune-protective subunit antigens have been the focus of anti-chlamydial vaccine 
designs. While MOMP of Chlamydia is the best studied antigen to date, identification of 
novel and immune effective antigens combined with appropriate adjuvants that could replace 
the multi-dose strategy through a simpler single vaccine dose would certainly be beneficial to 
the welfare of koalas. 
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3.2 Abstract 
Chlamydial infections are wide spread in koalas across their range and a solution to this 
debilitating disease has been sought for over a decade. Antibiotics are the currently accepted 
therapeutic measure, but are not an effective treatment due to the asymptomatic nature of 
some infections and a low efficacy rate.  Thus, a vaccine would be an ideal way to address 
this infectious disease threat in the wild. Previous vaccine trials have used a three-dose 
regimen; however this is very difficult to apply in the field as it would require multiple 
capture events, which are stressful and invasive processes for the koala.  In addition, it 
requires skilled koala handlers and a significant monetary investment. To overcome these 
challenges, in this study we utilised a polyphosphazine based poly I: C and a host defense 
peptide adjuvant combined with recombinant chlamydial major outer membrane protein 
(rMOMP) antigen to induce long lasting (54 weeks) cellular and humoral immunity in female 
koalas with a novel single immunising dose. Immunized koalas produced a strong IgG 
response in plasma, as well as at mucosal sites. Moreover, they showed high levels of C. 
pecorum specific neutralizing antibodies in the plasma as well as vaginal and conjunctival 
secretions. Lastly, Chlamydia-specific lymphocyte proliferation responses were produced 
against both whole chlamydial elementary bodies and rMOMP protein, over the 12-month 
period. The results of this study suggest that a single dose rMOMP vaccine incorporating a 
poly I:C, host defense peptide and polyphosphazine adjuvant is able to stimulate both arms of  
the immune system in koalas, thereby providing an alternative to antibiotic treatment and/or a 
three-dose vaccine regime. 
 
Key words: Chlamydia, Koala, Single dose, Vaccine, Adjuvant
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3.3 Introduction 
Koala populations along the eastern coast of Australia face localized extinction due to 
anthropogenic pressures such as habitat destruction [1], motor vehicle trauma [2], bush fire, 
dog attacks [3] and disease [4]. Control measures targeting disease may reduce mortalities 
and as such could have the potential to stabilize declining koala populations [5]. Based on 
data collected from wild hospital admissions, Chlamydia is the most common cause of 
disease in koalas [6]. Chlamydia is an intracellular bacterium that causes disease, not only in 
koalas, but also in a wide range of wild and domestic animals and humans [7]. In koalas, 
Chlamydia pecorum is the most pathogenic species and is associated with urogenital and 
ocular infections. Clinical signs include cystitis, sterility, infertility, conjunctivitis, kerato-
conjunctivitis and rhinitis [8]. Antibiotics are the currently accepted therapy, however, they 
can have a deleterious effect on the animal’s gastrointestinal microenvironment [9], as well as 
having quite low efficacy rates for chronic infections [10].  Further, many wild koalas have 
asymptomatic infections [11], challenging efforts to effectively treat and control disease in 
affected populations.  
 
An effective vaccine would be an ideal disease management tool for koalas as in other host 
species infected with this bacterial pathogen. Across the broader chlamydial research field, 
the design of a successful vaccine has proven challenging, however, as researchers have had 
to consider both the selection of a suitable vaccine candidate capable of inducing immune-
protection, and the development of an effective delivery system and adjuvant capable of 
boosting immune responses against the candidate antigens [12]. 
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The most promising candidate for a chlamydial vaccine antigen is the chlamydial major outer 
membrane protein (MOMP), accounting for 60% of the chlamydial outer membrane [13]. A 
koala C. pecorum vaccine has been under development for the past four years using a 
recombinant MOMP (rMOMP)-based antigen [14, 15]. The first koala vaccine trial 
demonstrated the induction of both cellular (>1 year) and humoral immunity (>35 wks) in 
female koalas with a rMOMP-based vaccine combined with three different adjuvants, and 
identified the best adjuvant candidate as immunostimulating complex (ISC) [16]. The second 
trial elucidated the feasibility and safety of a C. pecorum specific rMOMP antigen combined 
with ISC as a vaccine in healthy as well as diseased female koalas [15]. The third trial 
identified the cross reactive nature of the monovalent rMOMP proteins in female koalas, 
which is useful as there are a significant number of genetically distinct C. pecorum strains 
circulating in wild populations [14].  
 
While these results are promising, a limitation of the koala Chlamydia vaccine that is 
presently under development is that the adjuvant currently used requires a three (or two) dose 
regime [14]. This three dose regime would be logistically challenging to deliver to wild 
koalas while also potentially causing unnecessary stress to animals associated with repeated 
capture and handling. A single dose adjuvant that would deliver a similar level of immune 
recognition and response would be advantageous to plans to deploy this vaccine to koala 
populations across Australia.  
 
This current study evaluated a novel one-dose vaccine in koalas. The adjuvant chosen 
consisted of three components, polyinosinic polycytidylic acid (poly I: C), a host defense 
peptide [17] and polyphosphazine (PCEP). Poly I: C is a TLR3 ligand that mimics viral 
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double stranded RNA (dsRNA), the natural ligand of TLR3. From studies in other animals, 
Poly I:C is known to induce a predominantly Th1 immune response [18] due to the strong 
induction of type 1 interferon production and proinflammatory cytokines. Host defense 
peptides (HDP) are cationic peptides that function as antimicrobials, have multiple 
immunostimulatory activities and are highly conserved across plants, insects and mammals 
[19]. Polyphosphazines such as PCEP are synthetic water-soluble and biodegradable 
polymers that have demonstrated strong adjuvant affects. PCEP induces the recruitment of 
myeloid and lymphoid cells to the injection site and draining lymph nodes [20], activates the 
NLRP3 inflammasome resulting in the production of pro-inflammatory cytokines such as IL-
1β and IL-18 [21] and also induces potent mucosal IgA responses when delivered by multiple 
immunization routes [22]. 
 
Because it is widely believed that a protective chlamydial vaccine needs to elicit both a 
strong Th1 immune response at the infection site [18],  as well as the production of 
neutralizing antibodies at the mucosal surfaces of the genital tract and eyes [23], we reasoned 
that this combination adjuvant should elicit such a balanced response. The present study 
therefore evaluated this three-component adjuvant, mixed with C. pecorum rMOMP and 
given as either a single or double dose immunisation for induction of anti-chlamydial 
immunity in the koala.  
 
3.4 Materials and methods 
Production of rMOMP 
Previously, Kollipara et al.[24] developed a typing scheme for C. pecorum strains infecting 
koalas. In our study, we used three koala C. pecorum genotypes (A, F and G) as they 
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represent genotypes that are common in South-East Queensland (SEQ) koala populations. 
The purified C. pecorum MOMPs (A, F and G) were used as antigens in the current vaccine 
trial. Details for preparation of the recombinant MOMPs were as described by Kollipara et al.  
[14] but briefly, Escherichia coli (strains JM109; BL21 (DE3 pLysS) were used for 
molecular cloning, protein expression and purification. The respective expression constructs 
were transformed into the E. coli and grown in Luria-Bertani broth with constant shaking at 
37° C. The cell growth was assessed by measuring OD600. The complete ompA genes for each 
C. pecorum strain were amplified using primers ompAXhol (5′-
AAAAACTCGAGTTGCCTGTAGGGAACCC-3′) and OmpAKpnIn (5′-
AAAAAGGTACCTTAGAATCTGCATTGAGCAG-3′). The PCR product was amplified to 
generate products consisting 5′-Xhol and 3′-Kpnl restrictions and were ligated into a N-
terminal polyhistidine (His) pRSET expression vector. His-tag expression constructs were 
then transformed into BL21 (DE3) pLysS bacterial cells and grown in Luria-Bertani broth 
medium. The cells (expressing rMOMP) were harvested by centrifugation and resuspended in 
lysis buffer I. Lysed cells were incubated with TALON metal affinity resin at 4° C for 1 hr 
with gentle mixing. The resin then washed with buffer I and the protein was eluted. The 
recombinant protein yields were estimated by the bicinchoninic acid method. 
 
Adjuvant 
The combination adjuvant consists of polyposphazine (PCEP), the host defense peptide HH2 
(VQLRIRVAVIRA-NH2) [17] and poly I:C (Vaccine and Infectious Disease Organization, 
Saskatchewan, Canada), which was combined with our rMOMP antigens. Each 500 μl dose 
of the vaccine was prepared using sterile PBS to contain approximately 50 µg of each 
rMOMP (A, F and G), with 250 µg each of PCEP, Poly I:C and 500 µg of HH2.  
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Animals 
Six healthy female koalas, which were seronegative for previous chlamydial infections, and 
aged 1-3 years, were used for this study and were housed at Lone Pine Koala Sanctuary, 
Brisbane, Queensland. There was no history of chlamydiosis in this facility for at least 10 
years.  All work was conducted under permissions from the Queensland University of 
Technology Animal Ethics Committee (permit # 0900000285). 
 
Immunization schedule and sample collection 
Koalas were randomly assigned into two cohorts. One group (n = 3) received a single dose of 
vaccine and the second group (n = 3) received two doses, with a one month interval between 
the doses. All the animals were immunized via the subcutaneous route by a registered 
veterinarian. Samples included 5 mL whole blood collected in EDTA blood collection tubes 
(Interpath Services), stored at 4°C and processed within 24 h. The swabs were collected at the 
urogenital (UGT) and ocular sinuses (Aluminium rayon dry swabs; Copan) and were stored 
at -80°C in 0.5 ml phosphate buffer solution (PBS) containing 1 mM 
phenylmethysulphonylfluride (PMSF). Blood samples were collected at 0 weeks (pre-
immunized), 6, 10, 14, 21, 41 and 54 weeks. UGT and ocular swabs were collected at 0 
weeks (pre-immunized), 6, 10, 21, 41 and 54 weeks time points. 
 
Measurement of anti-MOMP lymphocyte proliferation response 
 
Lymphocyte proliferation responses were assayed as per Carey et al.[16] except that UV-
irradiated C. pecorum G elementary bodies (EBs) were used for in vitro stimulation of 
PBMCs. PBMCs were collected from blood samples at 0 (pre-immunized), 6, 21 and 54 
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weeks after the first immunization. PBMCs were isolated on Ficoll gradients, labelled with 
Carboxyfluorescein succinimidyl ester (CFSE) then stimulated with rMOMP, UV-inactivated 
C. pecorum EBs or Concanavalin A (ConA) as a positive stimulator, and no antigen as a 
negative control.  Proliferation of PBMCs was determined using a Beckman Coulter flow 
cytometer (FC500, Gladesville, NSW, Australia). Proliferation was expressed as the % of 
PBMCs that had undergone > 3 cell divisions. The mean fluorescent intensity of individual 
CFSE peaks, representing cycles of cell division, was analysed using ModFit software as 
described in Lyons and Doherty [25]. 
 
Enzyme linked immunosorbent assay (ELISA) 
 
Enzyme-linked immunosorbent assay (ELISAs) were performed as per Kollipara et al.[15] at 
0 (pre-immunized), 6,10, 14, 21, 41 and 54 weeks for plasma and 0 (pre-immunized), 6, 10, 
21, 41 and 54 weeks for swab samples. To obtain material from the swabs, the swabs were 
were collected into the protease inhibitor, PMSF plus buffer, vortexed vigorously, centrifuged 
and the supernatant analysed for antibodies by ELISA. 
 
In vitro Chlamydia neutralization assay 
 
In vitro neutralisation assays were performed using koala plasma and mucosal secretions 
(UGT and ocular) collected at 0, 6, 10, 21 and 54 weeks post immunization according to 
Kollipara et al. [15]. All samples were diluted 1:10 prior to testing.  For each assay, C. 
pecorum genotype G purified EBs (50,000 IFU) were mixed with the diluted plasma or 
secretions and incubated at 37C for 30 min prior to inoculation onto cell monolayers for 
assay of residual infectivity. Pre-immunisation plasma, ocular and UGT secretions were 
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collected from each individual animal pre-vaccination and were used to establish the 
background levels for each koala.  The individual background level was then subtracted from 
post-vaccination neutralization levels for each individual to get the actual neutralization 
effect.    
 
 
Statistics 
 
All statistical analyses were performed using Graph-Pad Prism version 6 (Graph pad 
Software, LaJolla, CA, USA). Data are presented as mean ± SD from triplicate assays. Data 
between cohorts was analysed using one –way ANOVA Kruskal-Wallis (non-parametric) 
tests. The P value for significance was set at ≤ 0.05. 
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3.5 Results 
Vaccine safety 
There were no adverse effects following administration of the vaccine in any of the six koalas 
(such as swelling or abscess formation around the injection site) immediately after 
immunization, or for the entire study period.  There was no evidence of clinical illness from 
the vaccine for the 54 weeks of the trial (data not shown).   
 
Cellular immunity 
CFSE dye-dilution assays demonstrated significant PBMC proliferation following in vitro 
stimulation with rMOMP (Fig.1) and UV-inactivated EBs (Fig. 2) at the 6, 21 and 54 weeks 
post-immunization time-points, compared to pre-immunization levels. Recombinant MOMP 
induced the highest proliferation rates (20.3% in single dose; 20.8% in double dose) (p value 
0.842)(Fig. 1) compared to UV inactivated EBs (9.5% in single dose; 13.4% in double dose) 
(Fig. 2) at the six week time point. At 21 weeks post-immunization, PBMCs had slightly 
reduced proliferation in both vaccine cohorts compared to the six-week time point for both 
rMOMP (10.4% in single dose; 14.1% in double dose) and EBs (9.3% in single dose; 11.4% 
in double dose). At 54 weeks post immunization, PBMCs were still proliferating in response 
to both rMOMP (9.7% in single dose; 9.8% in double dose) (Fig. 1) and EBs (6.04% in single 
dose; 5.9% in double dose) (Fig. 2). No statistically significant differences were observed in 
PBMC proliferation levels between the single and double vaccine groups at any time point.  
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Humoral immunity at systemic and mucosal sites 
MOMP-specific IgG antibody in plasma (Fig. 3) and mucosal secretions (Fig. 4) were 
determined by ELISA. All pre-immunizations samples were negative for MOMP IgG.  
Plasma IgG levels peaked at 41 weeks for both groups of koalas (EPT: End Point Titer; 2-3 
x106), before beginning to plateau or decrease slightly by week 54.  No significant 
differences in plasma EPT were observed between koalas in the single and double dose 
vaccine groups at the end period (54 weeks). In UGT secretions (Fig. 4 A), the IgG EPT in 
both groups peaked at 10 weeks post-immunization (EPT 1.5-3.2x102). Ocular antibody EPT 
(Fig. 4 B and C) were similar for both eyes and reached a peak by week 21 (EPT 1.0-2.2x102) 
and then declined by week 41. There were no significant differences in IgG levels in UGT 
and ocular secretions between the single and double dose vaccine groups.  
 
Neutralizing antibodies in plasma, vaginal and ocular secretions 
Fig. 5 A, B and C demonstrate the percent neutralization in plasma, UGT and ocular 
secretions compared to pre-immunization samples. All samples were tested at a 1:10 dilution. 
The increase in plasma neutralising antibody (Fig. 5A) peaked at 21 weeks (69% in single 
dose; 70% in double dose) and had declined by week 54 (57% in single dose; 62% in double 
dose). Neutralizing antibodies in the UGT secretions increased (17% in single dose; 25% in 
double dose) (Fig. 5 B) in both groups, peaking at 21 weeks then declining out to 54 weeks. 
Neutralizing antibodies in ocular secretions (Fig. 5C) ranged from 4-25%, peaking at 21 
weeks post immunization in both cohorts.  
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3.6 Discussion 
This study evaluated a novel vaccine consisting of a chlamydial rMOMP combined with a 
poly I:C, polyphosphazine (PCEP) and a synthetic host defense peptide adjuvant, given 
subcutaneously as either a single or double dose, to healthy female koalas. We have recently 
developed a rMOMP-based vaccine that induces strong cell-mediated and humoral immune 
responses following two or three vaccinations. This vaccine was effective in naturally 
infected and diseased koalas, as well as in healthy individuals [15] and elicited cross 
neutralizing antibodies that were able to neutralize multiple MOMP genotypes of C. pecorum 
in vitro [14]. While these results are very promising, the deployment of this vaccine to wild 
koalas in care or in the field will be problematic as the use of injectable vaccines in wild 
koala populations requires capture and restraint of wild animals, or a prolonged stay in a 
koala hospital or wildlife carer facility. Beyond the logistical and economic considerations 
associated with the vaccine delivery schedule, capture of a wild koala is a stressful and 
traumatic process for each animal and hence alternative single dose regimes would be ideally 
suited for vaccination of wild animals. 
 
The adjuvant components used in this single-dose vaccine experiment were chosen based on 
the immunomodulatory effects of each of the individual components, which in combination, 
should induce the type of immune response required to provide protection against Chlamydia, 
namely a strong cell-mediated response as well as a humoral response [26]. Poly I:C is a 
synthetic dsRNA and a TLR3 ligand. TLR3 is found in the endosomal compartment of a wide 
variety of cell types including monocytes, macrophages, Langerhans cells, myeloid dendritic 
cells, as well some fibroblasts and epithelial cells. Binding of poly I:C by TLR3 results in the 
production of type 1 interferons (IFNα and IFNβ) as well as pro-inflammatory cytokines 
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such as IL-12 and IL-6. TLR3 ligation by poly I:C also induces maturation of dendritic cells 
and the transcription of many interferon-regulated genes (IRG).  Poly I:C can also trigger 
innate anti-viral immunity by binding to the retinoic acid inducible gene 1 (RIG-1) receptor, 
which also elicits production of type 1 interferons and pro-inflammatory cytokines. Poly I: C 
has been used as an adjuvant in a wide range of animal species (monkey, mice, pigs) to target 
diseases as such papilloma virus, foot and mouth disease, influenza and tuberculosis [27-29].  
 
Polyphosphazenes are high molecular weight, water soluble polymers consisting of a 
backbone of alternating phosphorous and nitrogen atoms with organic side chains attached to 
each phosphorous that have been shown to possess strong adjuvant activity. The best-studied 
polyphosphazene adjuvant is PCEP.  Following intramuscular injection PCEP induces the 
expression of many innate immune genes (“adjuvant core response genes”)[31] including 
chemokines, inflammatory cytokines, pattern recognition receptors (PRR), interferon-
regulated genes, adhesion molecules and antigen presentation-associated genes. Importantly, 
PCEP activated the NLRP3 inflammasome, resulting in production of caspase-1 dependent 
cytokines IL-1β and IL-18. Thus PCEP creates a strong immune-stimulatory environment at 
the injection site, which likely contributes to its adjuvant activity together with the formation 
of water-soluble protein polymer complexes with antigen, which facilitates antigen 
processing and may provide a depot effect. In mouse studies, PCEP induces recruitment of 
neutrophils, macrophages and dendritic cells to the injection site [20], is a potent inducer of 
mixed Th1/Th2 responses when administered with influenza antigen [30] and elicits a strong 
mucosal IgA response when delivered by nasal, vaginal and pulmonary routes [22]. 
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Cationic host defense peptides (HDP) are small peptides that contain mainly positively 
charged and hydrophobic residues. They are abundant in eukaryotes as well as being found in 
bacteria and appear to be highly conserved across species. They were originally isolated 
because of their antimicrobial activity, having varying direct toxic effects against bacteria, 
viruses, fungi and parasites. With regard to potential adjuvant activity, HDP have multiple 
immunostimulatory properties including leukocyte recruitment and activation, enhanced pro-
inflammatory cytokine production, increased co-stimulatory molecule expression on APCs 
and increased phagocytic activity. When administered together with CpG the HH2 HDP 
elicited strong mixed Th1/Th17 responses that protected against chlamydial infection in a 
mouse model [31].  
 
The combination of poly I:C, PCEP and HDP (HH2) has proven to be an extremely potent 
adjuvant in mouse and porcine infection models, where a single immunization resulted in 
high titers of circulating antibodies (>106) that were extremely long lasting. This combination 
adjuvant was effective even in neonates and was unaffected by circulating maternal antibody.  
 
Using this novel adjuvant mix, the results of the current study suggest that vaccinated koalas 
developed strong lymphoproliferative responses to our vaccine. MOMP-specific PBMC 
proliferation was detectable for over a year in animals immunized with both single and 
double doses of the vaccine. Importantly, vaccinated koalas responded to both the vaccinating 
antigen (rMOMP), as well as the native whole chlamydial EB. A strong Th1 response has 
been shown to be essential for protection against Chlamydia in a murine model [32]. While 
we do not yet have the reagents to identify CD4 cells in the koala, the induction of long-lived 
cell-mediated responses are promising. Furthermore, the ability of this combination adjuvant 
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to induce strong Th1/Th17 responses and mixed Th1/Th2 responses in mice and pigs [30,33] 
makes it highly likely that vaccinated koalas will mount a strong and successful anti-
Chlamydia Th1 response, although this needs to be confirmed. 
 
When comparing the results of this work to our previous multi-dose trials, the present single 
dose combination adjuvant appears to produce similar immune responses to those previously 
described in koalas receiving multiple doses of our rMOMP-based vaccine [14, 15]. The 
adjuvant component, PCEP, may be partially responsible for the antibody in mucosal 
secretions since it has been shown to enhance mucosal antibody (IgA and IgG) responses [34] 
in mouse models. Though we have no koala IgA reagent to measure this antibody at mucosal 
surfaces, currently, the presence of IgG responses in mucosal secretions is a positive sign. 
The degree of neutralization achieved in this study (60-70% for plasma) was similar to that 
obtained in a previous study using rMOMP and ISC adjuvant (50-90%) [15, 16]. 
 
In summary, the current study has shown that the novel single dose vaccine using a poly I:C, 
PCEP, HDP combination adjuvant is capable of inducing significant cellular and humoral 
immune responses in koalas for an extended time period (54 weeks). Although the animal 
numbers were small, the results are promising and suggest that a single shot vaccine may 
represent an effective approach for protecting wild koalas against chlamydial infection while 
minimising potential capture-related stress associated with booster immunizations.  Future 
work will evaluate this single dose antigen: adjuvant vaccine in animals under field 
conditions. 
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Fig. 1. Lymphocyte proliferation assay (LPA):  PBMCs were isolated from koalas at 6, 21 
and 54 weeks post-immunization, labelled with CFSE and stimulated with rMOMP. Results 
are presented as the percentage of cells that have undergone three or more cell divisions and 
are expressed as the mean + SD (n = 3 animals) 
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Fig. 2. Lymphocyte proliferation assay (LPA):  PBMCs were isolated from koalas at 6, 21 
and 54 weeks post-immunization, labelled with CFSE and stimulated with UV-inactivated C. 
pecorum EBs. Results are presented as the percentage of cells that have undergone three or 
more cell divisions and are expressed as the mean + SD (n = 3 animals) 
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Fig. 3. rMOMP-specific IgG in koala plasma: rMOMP-specific IgG in plasma of immunized 
koalas was assayed by ELISA at 0, 6, 10, 14, 21, 41 and 54 weeks post immunization. IgG 
levels are expressed as end-point titers and represent the mean + SD of three animals per 
group. EPT at 54 weeks did not differ significantly between koalas immunized once or twice.  
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Fig. 4. rMOMP-specific IgG in koala mucosal secretions: rMOMP-specific IgG in urogenital 
secretions (A), left eye swabs (B) and right eye swabs (C) of immunized koalas were assayed 
by ELISA at 0, 6, 10, 21, 41 and 54 weeks post immunization. IgG levels are expressed as 
end-point titers and represent the mean + SD of three animals per group. There were no 
statistically significant differences in EPT in samples collected from koalas that had been 
immunized once or twice.  
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Fig. 5. Percentage of vaccine induced C. pecorum neutralizing antibodies in plasma (A), 
UGT secretions (B) and ocular secretions (C). All samples were diluted 1:10 and C. pecorum 
EBs (50,000 IFU) were added to samples and results are expressed as the percentage in 
neutralization of immune samples compared to that of the pre-immune samples. Results are 
expressed as the mean + SD of three animals per group. There were no significant differences 
between samples collected from animals immunized once or twice. 
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Chapter 4: Humoral immune responses in koalas 
(Phascolarctos cinereus) either naturally infected 
with Chlamydia pecorum or following administration 
of a recombinant chlamydial major outer membrane 
protein vaccine 
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4.2 Abstract 
The development of a vaccine is a key strategy to combat the widespread and debilitating 
effects of chlamydial infection in koalas. One such vaccine in development uses recombinant 
chlamydial major outer membrane protein (rMOMP) as an antigen and has shown promising 
results in several koala trials. Previous chlamydial vaccine studies, primarily in the mouse 
model, suggest that both cell mediated and antibody responses will be required for adequate 
protection. Recently, the important protective role of antibodies has been highlighted. In our 
current study, we conducted a detailed analysis of the antibody mediated immune response in 
koalas that are either (a) naturally infected, and/or (b) had received an rMOMP vaccine. 
Firstly, we observed that naturally infected koalas had very low levels of C. pecorum specific 
neutralising antibodies.  A strong correlation between low IgG total titers/neutralising 
antibody levels, and higher C. pecorum infection load was also observed in these naturally 
infected animals. In vaccinated koalas, we showed that the vaccine was able to boost the 
humoral immune response by inducing strong levels of C. pecorum specific neutralising 
antibodies. A detailed characterisation of the MOMP epitope response was also performed in 
naturally infected and vaccinated koalas using a PepScan epitope approach. This analysis 
identified unique sets of MOMP epitope antibodies between naturally infected non-protected 
and diseased koalas, versus vaccinated koalas, with the latter group of animals producing a 
unique set of specific epitope-directed antibodies that we demonstrated were responsible for 
the in vitro neutralisation activity. Together, these results show the importance of antibodies 
in chlamydial infection and immunity following vaccination in the koala. 
Key words: Koala, Chlamydia, Humoral immunity, Vaccine 
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4.3 Introduction 
While the koala is facing a number of threats to its long-term survival (habitat destruction, 
road accidents, dog attacks, bush fire)[1-3], disease caused by the obligate intracellular 
bacterial pathogen, Chlamydia is considered to be one of the more serious issues and one that 
is amenable to intervention [4]. For this reason, the development of a chlamydial vaccine is a 
major priority.  Chlamydial vaccine research in animal models indicates that a combination of 
cell-mediated and antibody responses are required for effective protection [5]. Antibodies, 
particularly against surface antigens, are thought to have a key neutralising role, but they are 
also considered to play a role in inflammatory disease processes [6]. Antigen-antibody 
complexes have a direct effect in the inflammatory pathway and initiate the cellular immune 
response via complement activation and cross-linking of Fc receptors (FcR) to promote 
phagocytosis [7]. The presence of mucosal antibodies has been found to be linked with 
decreased chlamydial shedding in women with genital tract C.trachomatis infections [8]. 
Moreover, B cell-deficient mice were prone to infection with secondary chlamydial 
infections. Interestingly, B cells promote antigen-specific T cell responses and bacterial 
dissemination in genital Chlamydia muridarum infection [9].  In addition, B cells play a key 
role in the initiation of T cell responses for C. trachomatis infections in the murine model 
[10]. 
 
Over the last five years our group has been developing a Chlamydia pecorum vaccine for 
koalas [11-14].  We have mainly focused on the chlamydial major outer membrane protein 
(MOMP) as the target antigen, including three MOMP variants in our most recent trials. 
Immunisation with recombinant MOMP (rMOMP) protein can lead to a strong antibody, as 
well as a specific lymphocyte response, up to at least one year post-vaccination [11-13].  
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While this work has shown encouraging signs in terms of our ability to induce specific and 
functional antibody responses in vaccinated animals, relatively little is still known about the 
role of antibodies in naturally-infected animals. Specifically, it is currently unknown, (a) 
whether naturally-infected koalas produce antibodies of sufficient quantity and specificity to 
control current infections and protect against future infections, and (b) whether vaccination 
can induce antibodies of comparable or higher titers and specificity than a natural infection. 
In the current study, we aimed to address these questions by studying the immune responses 
of a wild population of koalas, including both infected and uninfected individuals. Subgroups 
of either also received the prototype rMOMP vaccine. We characterised (a) total anti-
Chlamydia IgG response against rMOMP protein as well as whole chlamydial elementary 
bodies (EBs), (b) in vitro neutralisation activity, and (c) the epitope specificity of the 
antibody response using a Pepscan approach. 
 
4.4 Materials and Methods 
Animals 
The animals analysed for this study were part of a population of koalas inhabiting the 
Moreton Bay Region (MBR) of South-East Queensland, Australia. A sub-sample of this 
population (n = 30) had also been vaccinated with our rMOMP vaccine (described below) as 
part of a larger ongoing vaccine study.  For the purposes of the current study, a total of 20 
wild koalas were monitored from this MBR population over a 6-month period. The koalas 
were divided into four cohorts (each consisting of five koalas) on the basis of C. pecorum 
infection load by qPCR at the initial stage of enrolment. The groups were, (a) infected with 
Chlamydia/no vaccination (Bubbles, Cougar, Karen, Coco, and Mango), (b) infected with 
Chlamydia/vaccinated (Tash, Bev, Old Bean, Fiona, Poppy), (c) No Chlamydia infection/no 
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vaccination (Kev, Teena, Phill, Red Queen, Gauthier), (d) No Chlamydia 
infection/vaccinated (Robyn, Pepper, Maya, Hunky Harry, Randall). All work was conducted 
under permission from Queensland University of Technology’s Animal Ethics Committee 
(Permit # 1200000122). 
 
Vaccine 
Koalas recruited into the vaccine cohorts received three doses of a vaccine via the 
subcutaneous route [15]. Koala C. pecorum- specific MOMP proteins were expressed and 
purified as per Kollipara et al.[11]. The purified products were used for vaccination and 
ELISA assays. 
 
Sample collection 
The koalas were captured on 0, 2 and 6-month time points for sampling (blood from the 
cephalic vein and ocular and urogenital tract swabs) and a full health assessment. Swab 
samples were also collected from the conjunctival and urogenital (UGT) mucosa [14] and 
stored immediately at -20° C until analysis. 
 
Screening of C. pecorum infections 
Ocular and urogenital tract (UGT) swab samples from all koalas were screened for the 
presence of C. pecorum infection by a species-specific 16S rRNA quantitative PCR (qPCR) 
as per Marsh et al. [16]. 
 
Koala C. pecorum-specific IgG ELISA 
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Enzyme-linked immunosorbent assays were performed using either (a) rMOMP protein or (b) 
UV-inactivated whole EBs as per Kollipara et al. [11] on the plasma samples at the 0, 2 and 
6-month time points. 
 
C. pecorum in vitro neutralisation assay 
In vitro neutralisation assays were performed on all plasma samples as per Kollipara et al. 
[12]. All plasma samples were diluted at 1:10 prior to assay.  The background neutralisation 
was determined by using koala plasma that had no infection. Actual neutralisation was then 
determined by subtracting this background from each individual to determine the final 
neutralisation. The results were expressed as fold-change neutralisation.  
 
MOMP epitope mapping by Pepscan ELISA 
The Biotinylated peptide ELISA was performed using plasma samples as per Kollipara et 
al.[17] to identify the specific MOMP peptide recognised by (a) vaccinated koalas and (b) 
naturally-infected koalas. Briefly, we designed 88, 15-mer peptides (overlapping by 9 amino 
acids) that spanned the full length of koala C. pecorum MOMP. The wells of 96 (previously 
coated with streptavidin) were coated with each individual peptide at a concentration of 
2μg/well in PBST (Phosphate buffer solution-Tween20) and incubated for 2 hrs at room 
temperature. Post incubation, the wells were washed 3x with PBST and coated with 
individual plasma samples at 1:1000 dilution for overnight incubation at 4° C followed by 
4xPBST wash. The plates were then incubated with the secondary and tertiary antibody with 
sheep anti-koala IgG (1:4000 dilution) and HRP-labelled rabbit anti-sheep IgG (1:1000 
dilution) (Southern Biotech/In vitro Technologies, Cleveland, Australia)  respectively. After 
1 hr incubation, the plates were washed with PBS (Phosphate buffer solution) and ABTS [2, 
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2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid), Southern Biotech, Alabama, USA] 
solution was added and incubated for 10 mins to observe the greenish color development.  
The optical density was measured at 405nm wavelength (Bio-Rad, North Ryde, Australia).  
In subsequent experiments, we utilised just the positive peptides to coat the streptavidin plate 
at a concentration of 2μg/well and performed the standard ELISA as described.  
 
Characterisation of the specific anti-epitope antibodies responsible for Chlamydia in vitro 
neutralisation 
Once we had identified the epitope specificity of plasma from the post-vaccinated koalas, we 
wanted to determine if the in vitro neutralisation capacity of the plasma was explained by the 
antibodies to these epitopes. We coated the plates just with the specific peptides (4, 28, 41, 
and 42) at a concentration of 2μg/well and incubated at room temperature for 2 hrs. Post-
incubation, the plates were washed with 3x PBST and incubated with the positive plasma 
samples at 4° C overnight. This step resulted in removal of the antibodies to the selected key 
peptides. Post-incubation plasma was collected and used in the biotinylated peptide ELISA as 
described above. We then measured the C. pecorum-specific neutralising antibodies for the 
pre- and post-adsorption plasma, as described above. 
 
Statistics 
Statistical analyses were performed using Graph-Pad Prism version 6 (Graph Pad Software, 
La Jolla, CA, USA) and SPSS.22 version for Mann-Whitney U test. Correlation analysis was 
performed by Spearman’s rank correlation test using Software STATA/IC-11 (StataCorp, 
4905, Lakeway Drive, College station, TX 77845, USA). The P value for significance was set 
at ≤ 0.05. 
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4.5 Results 
Antibody responses in non-vaccinated but naturally-infected koalas, as well as in vaccinated 
koalas  
Wild koalas sampled from the MBR population were divided into C. pecorum PCR-negative 
and PCR-positive sub-groups following screening of conjunctival and urogenital swabs by 
our species-specific qPCR. To quantify the presence of C. pecorum MOMP and C. pecorum 
EB-specific systemic antibody responses, plasma samples from the naturally-infected and/or 
vaccinated koalas screened in this study were subjected to C. pecorum MOMP and C. 
pecorum EB-specific ELISAs. All five C. pecorum PCR-negative animals (not vaccinated) 
did not have any antibodies to either C. pecorum recombinant MOMP protein or to whole 
chlamydial EBs (Fig. 1; A and B respectively). By comparison, all five C. pecorum PCR-
positive unvaccinated animals had antibodies that recognised both recombinant MOMP 
protein (titers ranging from 0.5x106 to 2x106 EPT) as well as whole chlamydial EBs (titers 
ranging from 0.5x103 to 1x103 EPT; Fig. 1 C and D). Given that we did not know when each 
animal was initially infected (potentially months to years previously), not surprisingly, the 
titers remained relatively constant across the 6-month study period. 
 
Following vaccination, all 10 koalas produced antibodies to both rMOMP protein as well as 
whole C. pecorum EBs (Fig. 2. A-D). Interestingly, animals that were PCR-positive at the 
time of vaccination produced stronger antibody responses than those that were PCR-negative 
(although there was animal to animal variation). This was particularly evident with the anti-
MOMP responses, where four out of five PCR positive animals produced titers of around 3-
4x106 (Fig . 2 C), compared to peak titers for the C. pecorum PCR-negative vaccinated 
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animals of around 1x106, with a single animal at 2x106 (Fig. 2 A). These differences were not 
observed for the antibody level measured against whole chlamydial EBs (Fig. 2 B) 
 
In vitro neutralisation levels were boosted significantly following vaccination 
To assess the function of the antibodies induced in response to natural infection and/or 
vaccination, in vitro neutralisation assays were performed on C. pecorum-infected cell culture 
monolayers. Naturally-infected koalas (C. pecorum PCR-positive at time of analysis) were 
found to have relatively low levels of in vitro neutralisation titers ranging from 0.5 to 2.0 fold 
change with a mean of 1.0 fold change (Fig. 3 C; 1.0 fold represents no change compared to 
baseline). When these PCR-positive animals received the vaccine, their in vitro neutralisation 
levels were boosted significantly (Mann-Whitney U test was performed to measure the level 
of significance; though the p value is not statistically significant: p < 0.056), increasing to 
levels of 2.5 to 8.0 fold change, with a mean of 4.8 fold change (Fig. 3 D). In the cohorts that 
were C. pecorum PCR negative and received the vaccine, they also developed in vitro 
neutralising antibodies (1.5 to 3.0 fold change with a mean of 2.7 fold change; Fig. 3 B), 
although their levels were slightly lower than the C. pecorum PCR-positive animals. 
 
Lower plasma antibody titers correlate with higher infectious burden in naturally-infected 
koalas 
In the naturally-infected cohort (which we increased to a total of 14 animals for this aspect), 
we compared the chlamydial infection level of the animal (as measured by qPCR at the UGT 
site) with the plasma antibody titers (measured against rMOMP protein). We found a strong 
and statistically significant correlation (p < 0.01) between higher infection load and lower 
antibody titer (Fig. 4). 
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Naturally-diseased animals, as well as vaccine cohorts, show unique but distinct peptide 
antibody response profiles 
We used Pepscan methodology to examine the epitope specificity of the antibodies produced 
in (a) C. pecorum PCR-positive animals with and without chlamydial disease, and (b) C. 
pecorum PCR-negative/positive animals following vaccination. We found that diseased 
koalas (Cougar, Karen and Mango had developed disease at the 6-month time point) (Fig. 5 
B1) had plasma antibodies that specifically recognised a unique set of MOMP epitopes 5, 33, 
79 and 85.  These epitopes were not recognised by plasma from healthy koalas (Fig. 5 A). By 
comparison, vaccinated koalas produced antibodies that recognised a different unique set of 
epitopes; 4, 28 and 41 (80% to 90% of koalas tested had responses to these epitopes) and to a 
lesser level, epitope 42 (40% to 60% of koalas) (Fig. 5 B2). 
 
In vitro neutralisation of post-vaccination plasma is associated with antibodies against 
specific MOMP epitopes 
We observed that the in vitro neutralisation titers were highest in animals that were 
previously infected and then vaccinated (Fig. 3 D). We therefore wanted to know if it was the 
antibodies to specific epitopes that were responsible for this in vitro neutralisation effect. 
Peptides 4, 28, 41 and 42, shown in the previous experiment to be recognised by vaccinated 
koalas, were used to adsorb plasma from the infected and/or non-infected plus vaccinated 
cohort. We then tested the post-adsorption plasma to confirm that we had indeed removed the 
antibodies specific for these epitopes (Fig. 6 B) and then tested this post-adsorption plasma in 
an in vitro neutralisation assay (Fig. 6 C). The data show that we were successful in removing 
antibodies against epitopes 4, 28, 41 and 42. Compared to the pre-adsorption plasma which 
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had an in vitro neutralisation fold effect of 4.8 times (Fig. 6 C), the post-adsorption plasma 
had virtually no in vitro neutralising ability (fold change of 1.0) (Fig. 6 C) ( p < 0.001). This 
confirms that all, or at least the majority, of the in vitro neutralisation was due to antibodies 
against these specific epitopes.  
 
4.6 Discussion 
While our efforts to develop an effective koala chlamydial vaccine are progressing well [11-
15, 17], we still do not fully understand which aspects of the koala’s immune system are 
required for an optimal vaccine response. In this project, we analysed the role of antibodies in 
naturally-infected koalas, as well as koalas that received our prototype vaccine. Vaccine 
research in the mouse model in particular, has shown that an interferon-gamma T cell 
response is important [5], but also suggests that neutralising antibodies have a role in 
protection [18, 19]. In our current study, this analysis revealed a number of new and 
significant observations that are not only relevant to chlamydial infections in koalas, but also 
show how the “C. pecorum-koala model” might be able to inform human C. trachomatis 
vaccine development. In terms of the latter, a unique aspect of our study was that we 
vaccinated C. pecorum-positive (by PCR) koalas as well as C. pecorum-negative koalas. It is 
not possible to do this in humans, as protocol requires that any Chlamydia-positive 
individuals be immediately treated with antibiotics. Perhaps not surprisingly, in our test 
koalas, we found higher antibody responses in vaccinated koalas which had a current 
chlamydial infection. We also observed a different kinetic response, reminiscent of a 
secondary response, in these animals. While there have been limited studies in human C. 
trachomatis infections, antibodies produced against natural infections generally do not appear 
to be protective for most individuals [18, 20].  
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We then examined the functionality of these antibodies by assaying their ability to neutralise 
C. pecorum infections in an in vitro neutralisation assay. We first examined the in vitro 
neutralisation ability of antibodies from naturally-infected animals and found that they have 
very low, to nil antibodies that are capable of neutralisation. This suggests that the antibody 
response to whole live chlamydiae in a natural infection somehow results in antibodies of 
specificity that do not negate the infection. By comparison, plasma from vaccinated animals 
(both animals with current infection but also Chlamydia-negative animals) did neutralise C. 
pecorum infections in vitro. Somewhat unexpectedly, the plasma from animals which were 
previously naturally infected (and not protected) but then vaccinated, produced a higher in 
vitro neutralisation effect. We observed two types of antibody responses: for some of the 
epitopes against which there was a response following natural infection, we observed a 
boosting of the response to these epitopes following vaccination (eg. epitopes 54 and 87), 
however, the majority of antibodies produced following vaccination were to new epitopes 
(eg. epitopes 4, 28, 41, 42). 
 
The concept of “original antigen sin” suggests that a prior exposure to an antigen leads to a 
sub-optimal second immune response if the strains are too closely related [21]. In the case of 
Chlamydia infections, several previous reports have suggested that original antigen sin may 
occur when closely related C. trachomatis serovars are involved in the priming and challenge 
infections [21, 22].  In our case of C. pecorum infections in koalas, if original antigen sin was 
occurring, we might have expected that in animals previously infected naturally, our vaccine 
response may have been limited to boosting only the previously induced antibody types.  By 
comparison, we found that the vaccine induced a new set of novel epitope antibodies (located 
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elsewhere along the MOMP protein), suggesting that original antigen sin is not of concern in 
this case. This may have been linked to the fact that most of our epitope responses were to 
conserved regions of the MOMP protein, although it has also been reported that the use of an 
adjuvanted vaccine can overcome original antigen sin [23]. Another possible explanation is 
that the adjuvant Iscomatrix® induced epitope spreading as has been demonstrated in 
human’s immunised with influenza VLPs with Iscomatrix® [24]. 
  
Given the promising antibody response that we observed following C. pecorum vaccination 
in our koalas, we wanted to characterize the type of antibodies being produced. We used 
Pepscan methodology and found that there were two unique epitope profiles. One profile was 
found in naturally-infected animals, a proportion of which progressed to disease (ie. they 
were not protected). Recently, we (Waugh et al.-submitted) evaluated the protection provided 
by vaccinating wild koalas against Chlamydia, as measured primarily by the reduction in 
Chlamydia infection load at the ocular and urogenital sites. This study showed that animals 
with high levels of neutralising antibodies were less likely to progress to disease, which 
supports a protective role of antibodies. By comparison, vaccinated koalas produced a 
different, unique profile, against 3-5 key MOMP epitopes. All of these epitopes were in the 
conserved domain, suggesting that the response should have broad neutralizing ability across 
multiple C. pecorum strains. While it has previously been assumed that antibodies must bind 
to externally presented epitopes to enable neutralisation [25], recent reports have shown that 
antibodies, via FcRn mediation, can internalize and neutralise virus [26] and intracellular 
bacteria such as Chlamydia, within the cytoplasm of epithelial cells [27]. Antibodies to 
internal proteins such as NrdB have also been shown previously to facilitate the neutralisation 
process [28]. To confirm the specificity of these epitope responses, we used the individual 
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peptides to adsorb the specific antibodies out of these groups and then re-tested their in vitro 
neutralising ability. This clearly demonstrated that the in vitro neutralisation ability was due 
to the novel peptide responses following vaccination. 
 
While MOMP is known to be highly antigenic, [29] it is also highly variable across koala C. 
pecorum strains [30]. This means that for a vaccine to be broadly protective under field 
conditions, it may need to contain a range of MOMP variants (we used three full length 
MOMP proteins in our vaccine cohort). A defined epitope vaccine would be an ideal 
approach to overcoming this problem and could also avoid any deleterious epitopes. Recent 
studies found that systemic and mucosal immune responses could be generated with the 
induction of a peptide-based vaccine for C. trachomatis infection [31], which highlights the 
promising aspect of these investigations for the koala. In addition to antibodies, a strong and 
specific T cell response is also necessary for an effective vaccine [32].  It will therefore be 
necessary in future to identify the key T cell epitopes in koala C. pecorum MOMP.  
 
Our findings provide novel information in relation to the antibody responses in naturally-
infected koalas as well as koalas following vaccination, which should significantly inform 
future vaccine development. Firstly, even though naturally-infected koalas produce an 
antibody response, it is of relatively low total titer, does not neutralise, and is apparently non-
protective against disease progression. Secondly, the response is to epitopes in the constant 
domains of MOMP, although why the host/parasite has “directed” the response to these 
epitopes (non-protective) is not clear. Finally, additional antibodies to epitopes not present in 
naturally-infected koalas can be induced following vaccination, and these additional epitopes 
are able to neutralise whole EBs in a live assay. 
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Fig. 1. The circulatory antibody titers (IgG) against rMOMP (A and C) and EBs (B and D) in 
Chlamydia-negative (Group A and B) and naturally-infected animals (Group C and D) at the 
initial time point. Five animals were included in each cohort.   
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Fig. 2. Antibody titers (IgG) against rMOMP (A and C) and EBs (B and D) in plasma from 
Chlamydia-negative animals (Groups A and B) or naturally-infected animals (Group C and 
D) at the initial time point. Both groups were vaccinated three times at 1-month intervals. 
Five animals were included in each cohort. Arrows indicate the vaccination time points. 
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Fig. 3. Fold change in neutralising antibodies in different cohorts of koalas. Chlamydia-
negative animals without (3A) or following vaccination (3B) and Chlamydia-infected koalas 
without (3C) and with vaccination (3D) are shown. Arrows indicate the vaccination time 
points. All samples were diluted 1:10 in media and results are expressed as fold change 
neutralisation of immune samples compared to those pre-immune samples. The level of 
 
Humoral immune responses in koalas (Phascolarctos cinereus) either naturally infected with Chlamydia 
pecorum or following administration of a recombinant chlamydial major outer membrane protein vaccine Page 107  
significance was measured as *p - 0.01-0.05, **p - 0.001-0.01, ***p<0.001. Mann-Whitney 
U test was performed to measure the level of significance (p <0.056). 
 
 
 
 
Fig. 4. The correlation of bacterial burden measured by C. pecorum-specific qPCR and 
antibody titers in koalas with current infection (n =14) at the initial enrolment. The infection 
loads were measured at the UGT. The Spearman’s correlation coefficients were performed to 
measure the relationship between IgG and infection load. The level of significance was 
measured as *p - 0.01-0.05, **p - 0.001-0.01, ***p<0.001 
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Fig. 5. Specific epitopes detected in koalas with current C. pecorum infection and/or 
following vaccination. The antibody-specific epitopes detected in infected and non-infected 
animals is shown at 0 months (5A).  At the 6-month time point, antibody-specific epitopes (5 
B) were measured in animals with and without vaccination. (B1= Animals naturally infected: 
Bubbles, Coco and progressing to disease: Cougar, Karen and Mango; B2= naturally infected 
following vaccination for Tash, Bev, Old Bean, Poppy and Fiona and non-infected animals 
following vaccination for Robyn, Pepper, Maya, Hunky Harry and Randall; B3= Chlamydia-
negative animals without vaccination).  
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Fig. 6.  Epitopes detected antibodies and C. pecorum-specific neutralisation in vaccinated 
cohort. The grey boxes indicate the vaccine induced unique epitopes response. The epitope 
response in plasma before (Fig 6 A) and after (Fig 6 B) adsorption out of the positive 
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epitopes (4, 28, 41 and 42) is shown. All samples were diluted 1:10 and results are expressed 
as fold change neutralisation of immune samples compared to those pre-immune samples. 
The fold change neutralisation as pre and post-adsorption (Fig 6 C) cohorts. The level of 
significance was measured as *p - 0.01-0.05, **p - 0.001-0.01, ***p<0.001. Significant 
reduction of neutralising antibodies in post-adsorption plasma (p < 001). Results are 
expressed as the mean ± SD of 10 animals per group. Error bars represent SD.  
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Epitopes mapping for C. pecorum infected koalas following vaccination 
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Epitopes mapping for koalas having no chlamydial infection following vaccination 
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Epitopes mapping in koalas with C. pecorum infection 
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Epitopes mapping in koalas with clinical C. pecorum infection 
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chlamydial burden and less clinical disease in free-
ranging koalas (Phascolarctos cinereus) 
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5.2 Abstract 
Diseases associated with Chlamydia pecorum infection are a major cause of decline in koala 
populations in Australia. While koalas in care can generally be treated, a vaccine is 
considered the only option to effectively reduce the threat of infection and disease at the 
population level.  In the current study, we vaccinated 30 free-ranging koalas with a prototype 
Chlamydia pecorum vaccine consisting of a recombinant chlamydial MOMP adjuvanted with 
an immune stimulating complex. An additional cohort of 30 animals did not receive any 
vaccine and acted as comparison controls. Animals accepted into this study were either 
uninfected (Chlamydia PCR negative) at time of initial vaccination, or infected (C. pecorum 
positive) at either urogenital (UGT) and/or ocular sites (Oc), but with no clinical signs of 
chlamydial disease.  All koalas were vaccinated / sampled and then re-released into their 
natural habitat before re-capturing and re-sampling at 6 and 12 months. All vaccinated koalas 
produced a strong immune response to the vaccine, as indicated by high titres of specific 
plasma antibodies.  The incidence of new infections in vaccinated koalas over the 12-month 
period post-vaccination was slightly less than koalas in the control group, however, this was 
not statistically significant.  Importantly though, the vaccine was able to significantly reduce 
the infectious load in animals that were Chlamydia positive at the time of vaccination. This 
effect was evident at both the Oc and UGT sites and was stronger at 6 months than at 12 
months post-vaccination. Finally, the vaccine was also able to reduce the number of animals 
that progressed to disease during the 12-month period. While the sample sizes were small 
(statistically speaking), results were nonetheless striking. This study highlights the potential 
for successful development of a Chlamydia vaccine for koalas in a wild setting.  
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5.3 Introduction 
Infections by the intracellular bacterium Chlamydia pecorum contribute to significant 
morbidity and mortality in the koala (Phascolarctos cinereus).  Disease progression can 
include kerato-conjunctivitis, cystitis, reproductive disease/sterility and blindness; the 
progression of which, in severe cases, can cause death.  An antibiotic treatment regime is 
currently recommended for mild infections [1], however for koalas affected by severe 
chlamydial disease, antibiotics alone are not sufficient to cure the clinical signs [1].   
 
In recognition that a reduction in disease may have a positive effect in the conservation of 
koalas [2, 3], our group has been leading the development of a prototype C. pecorum vaccine 
[4-9]. Based on studies which have shown efficacy in animal models (reviewed in Farris and 
Morrison [10]), the primary component of the C. pecorum vaccine has been the recombinant 
proteins derived from the chlamydial Major Outer Membrane Protein (rMOMP).  rMOMP is 
highly immunogenic in humans and animals and has been studied in detail as a vaccine 
candidate. In the initial studies utilizing this vaccine antigen adjuvanted with an immune 
stimulating complex, we have shown that this prototype chlamydial vaccine (i) induces long-
lasting specific humoral and cell-mediated immune responses in vaccinated koalas [9]; (ii) 
induces an immune response that can recognize genetically distinct C. pecorum strains, a 
capability that natural infection does not appear to have [6]; (iii) induces the production of 
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specific antibodies that are effective in neutralizing C. pecorum in vitro [9]; and (iv) does not 
have any apparent deleterious effects on the health of Chlamydia-free koalas or koalas with 
current chlamydial infection and/or disease [8, 11].  
 
In the absence of an established infection challenge model for the koala, further 
understanding of the efficacy of the vaccine for reducing the risk and impact of chlamydial 
infection at both the individual and population level is limited.   In the current study, we 
assessed the health outcomes of a cohort of 60 koalas, including 30 animals vaccinated with 
the prototype Chlamydia vaccine within one free-ranging population in South-East 
Queensland (SEQ), Australia. Vaccinated and control cohorts of animals were then released, 
monitored for a period of 12 months, and recaptured periodically to compare a range of 
health parameters between the two groups.  
 
5.4 Materials and Methods 
Chlamydia pecorum MOMP recombinant preparation 
Purified C. pecorum MOMP from three koala C. pecorum genotypes (A, F and G) were used 
as previously described by Kollipara et al. [7].   
Animals and Immunizations 
Animals included in the study (n = 60) were part of a larger population-wide study by the 
Queensland Government Department of Transport and Main Roads (as part of the Moreton 
Bay Rail Link project), conducted between 2012 and 2015 in the Moreton Bay Region, 
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Queensland, Australia. Criteria for inclusion into the study were animals of breeding age (>1 
year) of either sex, with no clinical signs of chlamydial disease, as assessed during the initial 
capture event by qualified wildlife veterinarians.  Animals were randomly assigned to either 
the vaccinated or control (non-vaccinated) group at initial capture.  The vaccinated group (n = 
30) received a three-dose regime of the vaccine via the sub-cutaneous route, given at one-
month intervals, consisting of the three rMOMP proteins as the antigens (50µg each of 
MOMP-G, MOMP-A, and MOMP-F) and an Immunostimulating complex adjuvant (50µg , 
ISC, Zoetis Australia [4]). Following a detailed veterinary health assessment, animals were 
released with a radio collar or anklet for tracking (Sirtrack). Animals were re-captured at 1 
month, 2 months, 6 months, and 12 months for the purpose of (i) additional vaccinations for 
the vaccine cohort animals only (1 month and 2 months) or (ii) detailed health checks and 
sampling (2, 6 and 12 months). While 30 animals were originally recruited into each group, 
unfortunately, only 23 vaccinated and 27 control koalas could be resampled at the six month 
time point due to animal losses associated with misadventure (e.g. predation, trauma, koala 
movements outside of study area, or disease).  At 12 months, again, further losses had 
occurred and numbers were considerably reduced in each cohort to 15 vaccinated and 14 
control koalas.  
All procedures were approved by the University of the Sunshine Coast (USC) Animal Ethics 
Committee (Animal ethics number AN/A/13/80) and by the Queensland Government 
(Scientific Purposes Permit, WISP11532912).  The trial was performed under the Australian 
Pesticides and Veterinary Medicines Authority Permit PER 7250. 
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Health assessments and sampling 
Veterinary assessments and sampling, while under a short period of anesthesia, were 
conducted on each animal at 0, 2, 6, and 12 month time-points following their initial capture 
and veterinary examination.  Ultrasound examination of the kidneys, ureters, urinary bladder 
and the reproductive tract allowed for identification of urogenital tract diseases including 
cystitis and reproductive-tract cysts in female koalas.  Urinalysis was utilized to detect 
possible kidney or urinary tract disorders, such as cystitis, which is also associated with 
Chlamydia. Chlamydial disease scores were assessed according to the disease scoring criteria 
outlined in detail in Wan et al. [12].   For the purposes of this study, one set of 
conjunctival/ocular (Oc) and urogenital (UGT) swabs were collected for Chlamydia load 
determination and a blood sample of up to 5mL was collected from the cephalic vein. This 
was used for preparation of haematology smears and separation of plasma and serum by 
centrifugation.  
Chlamydia-specific IgG plasma response 
IgG response was analysed via enzyme-linked immunosorbent assays (ELISAs). ELISAs 
were performed on plasma samples at 0 and 6 months as per Khan et al. [5], and served as a 
control to demonstrate that vaccinated koalas produced a specific immune response to the 
vaccine antigens as previously shown [5 
C. pecorum quantification  
Swab samples were stored at -20°C until the DNA was extracted as described by Devereaux 
et al. [13].  The extracted samples were screened for the presence of C. pecorum using a 
diagnostic quantitative real-time PCR (RT-PCR) targeting a 204 bp fragment of the 
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chlamydial 16S rRNA gene.  Assays were as described in Marsh et al. [14] except for the 
PCR mixture containing  1× QuantiTect SYBR Green PCR Master Mix (Qiagen) and 10 μM 
primers [14] made up to a final volume of 15 μl with PCR-grade water, as well as an 
increased initial denaturation to 15 mins at 94°C.  All reactions were carried out on a Rotor-
Gene Q 5-plex HRM platform (Qiagen).   
Statistical analysis 
Significant differences between 0 and 6 month IgG antibody titres were evaluated with a 
Wilcoxon signed-rank test.  To evaluate how C. pecorum infection prevalence and loads 
differed among vaccinated versus control koalas, Chi-square contingency table analyses were 
used to compare the changes in C. pecorum load over time (0 vs. 6 and 0 vs. 12 months), with 
changes categorized into bands as either, decreasing, stable or increasing (ΔqPCR ≤ -100, -99 
– 99, and ≥ 100 copies/µL respectively). These categories were chosen because small 
variations of up to 100 copies/µL in qPCR can occur across assays. We conducted this 
analysis on the raw numbers of koalas within each group (which we considered a 
conservative analysis, given our sample size), and on the percentage of koalas in each group 
(which we considered a more sensitive approach, given our sample size). We chose these 
conservative and sensitive approaches because, though our results are striking, the numerical 
effect of koala mortalities in the field inflated the Type-II statistical error, limiting detection 
of statistical significance based on raw data alone. Where appropriate we used Markov chain 
Monte Carlo simulations to overcome Chi-square statistical issues associated with expected 
values < 5. Analyses were conducted on both Oc and UGT infections (see Results).  All 
analyses were conducted using Rv3.0.2 (www.r-project.org). 
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5.5 Results 
Vaccine safety data 
All vaccinated animals were monitored for up to 24 hours post-vaccination and given a 
thorough veterinary health check at 2 months and thereafter at their regular 6-monthly 
capture and sampling events. There were no short or longer-term adverse events reported due 
to administration of the vaccine in any of the animals. 
Immune response to vaccination 
We used our Chlamydia ELISA to determine plasma IgG antibody levels both (i) at 0 months 
and (ii) 6 months post vaccination in the vaccine group (n = 23).  We found that the average 
antibody titre at 6 months post-vaccination in PCR negative and PCR positive animals was 
significantly greater than at 0 months (Figure 1; PCR negative p = 0.002; PCR positive p < 
0.001; Supp Info 1) indicating that we had successfully induced a vaccination-specific 
immune response.   
Chlamydia prevalence 
Overall, the 60 animals initially included in our study had a C. pecorum prevalence of 54% at 
time of capture (as defined by C. pecorum species-specific PCR).  After recruitment into the 
trial, the koalas were assigned into groups consisting of: (i) animals with a current infection, 
as defined by being C. pecorum PCR positive, at the Oc site (Vaccinated: n = 10; Control: n 
= 6); (ii) C. pecorum PCR positive animals at the UGT site (Vaccinated: n = 8; Control: n = 
13); and (iii) animals that were C. pecorum PCR negative at either site (Vaccinated: n = 
16; Control n = 21). Some animals (Vaccinated: n = 7; Control n = 6) were necessarily 
included in both groups due to the occurrence of C. pecorum positivity at both sites.  At 12 
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months, the number of animals remaining in each group decreased (mortality among wild 
koalas) to: (i) C. pecorum PCR positive animals at the Oc site (Vaccinated: n = 7; Control: n 
= 4); (ii) C. pecorum PCR positive animals at the UGT site (Vaccinated: n = 5; Control: n = 
6; and (iii) C. pecorum PCR negative animals (Vaccinated: n = 11; Control n = 10).    
 
Rate of new C. pecorum infections in vaccinated koalas compared to unvaccinated controls  
For this analysis we utilized the animals that were C. pecorum negative at 0 months and able 
to be recaptured at 12 months.  In the control group, the 12 month incidence rate at the UGT 
site was 25% (two new infections in the 8 animals in this group), and 20% (2/10) at the Oc 
site.  By comparison, the vaccinated animals had a slightly lower 12 month incidence rate of 
20% (2/10) and 12% (1/8) at the UGT and Oc sites respectively.  While the incidence rate in 
the vaccinated group was lower, the group size was small and hence the difference was not 
statistically significant (raw data X2 = 0.392, p > 0.999; percentage differences X2 = 2.381, p 
= 0.176). 
Changes in Chlamydia load following vaccination 
For animals that were infected (PCR positive) at the time of recruitment, we measured their 
Chlamydia load by quantitative-PCR (qPCR) at 0, 6, and 12 months to evaluate the effect the 
vaccine had on the level of chlamydial shedding (Table 1). For the purposes of analysis, we 
grouped the animals into three categories, based on their PCR load change, whether the load 
decreased, stayed stable, or increased (ΔqPCR ≤ -100, -99 – 99, and ≥ 100 copies/µL 
respectively).  
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At 6 months post-vaccination, animals in the vaccine group were significantly more likely to 
decrease or stabilize their chlamydial load, whereas animals in the control group were 
significantly more likely to increase their load (Table 1).  This effect was observed as a near 
significant trend (p > 0.01) using the conservative (raw) data and a significant effect based on 
the more sensitive (%) data. For example, at the ocular site 90% (9/10) of vaccinated animals 
decreased or stabilized their load, compared to the control group where only 33% (2/6) had 
decreasing or stabilizing loads (Table 1).  Similarly, at the UGT site, 100% (8/8) of animals 
in the vaccinated group had decreasing or stabilizing loads compared to 69% (9/13) in the 
control group (Table 1).   
At 12 months, the positive vaccine effect was maintained at the UGT site with 100% (5/5) of 
vaccinated animals showing a decrease in chlamydial load compared to 83% (5/6) in the 
control group (Table 1). We are cautious about drawing conclusions on the statistical 
significance of this owing to the difference of only a single individual. However importantly, 
throughout the entire study, not one animal in the vaccine group showed an increase at the 
UGT site.  At the Oc site at 12 months, 100% (7/7) of vaccinated animals also decreased or 
stabilized their chlamydial load; although a similar trend (100% [4/4] decrease) was seen in 
the control group (Table 1). Again, we are highly cautious about interpreting the statistical 
significance of this based on the sample size. Overall, smaller sample sizes of koalas, owing 
to field mortalities, cause us to be cautious about statistical interpretation of results at 12 
months.   
Progression to chlamydial disease  
To investigate the impact that vaccination had on the progression of chlamydial disease, we 
compared the presence and absence of disease in vaccinated and control animals.  Over the 
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12 months of the study, only 1 of 23 (4% of koalas) vaccinated animals developed clinical 
signs of chlamydial disease, whereas 4 of 27 (14.8%) control animals developed clinical 
disease over the same time period. Based on percentage differences, the control and 
vaccinated groups were significantly dissimilar (X2 = 7.037, p = 0.013), but the same result 
could not be observed in the raw data (X2 = 1.512, p = 0.363) owing to the sample size.  The 
one vaccinated animal developed mild, sub-acute, chronic cystitis, was treated in care with 
the standard chloramphenicol dosage and released as healthy. Three of the four animals that 
developed disease in the control group developed cystitis and were treated; the final animal 
developed severe and extensive reproductive disease as well as severe chronic cystitis, and 
was euthanized. 
5.6 Discussion 
We have, for the first time, examined the effect of a rMOMP based anti-chlamydial vaccine 
on chlamydial infection risk and outcome in free-ranging koalas.  The vaccine induced a 
significant immune response in wild-caught koalas. The incidence of new C. pecorum 
infections was lower at both anatomical sites in vaccinated animals, despite not being 
statistically significant. Importantly, we also found that vaccinated koalas were more likely to 
have stable or decreasing C. pecorum PCR loads, and were also less likely to increase their 
chlamydial burdens at 6 months post-vaccination at both anatomical sites. At 12 months, this 
positive effect could still be observed in the vaccinated cohort, with no animals increasing 
their chlamydial loads at either anatomical site. However, we caution the low number of 
koalas at this time point made statistical inference unreliable.  Lastly, we showed a positive 
effect for protecting against progression to disease in vaccinated animals.  
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Therapeutic vaccines are a promising new approach to enhance immunogenicity, and reduce 
viral and bacterial load in infected humans and animals [15].  Due to the difficulties 
associated with antibiotic treatment in the koala, a therapeutic vaccine may provide an 
important alternative to reduce infection. While antibiotics are curative in many cases of 
chlamydial disease, the therapeutic course is relatively long and labour intensive, often 
precluding its efficacy for the treatment of koala outside of the clinic. Therefore, a therapeutic 
vaccine provides a more practical solution for disease management at a non-captive 
population level, particularly if a single-dose vaccine were to be developed. In our current 
study, the positive therapeutic effect seen at both anatomical sites in the koala is a promising 
result for the development of a therapeutic chlamydial vaccine for this species. The loss of 
meaningful statistical inference at 12 months due to severe field mortalities is disappointing, 
masking our ability to confidently detect an effect at this time interval.  This effect seems 
largely skewed by the four animals in the control group reducing their chlamydial ocular 
burden.  When followed longitudinally up to two years, two of these four animals developed 
clinical signs of disease, whereas none of the vaccinated animals in that cohort developed any 
clinical signs (unpublished data). 
While we did not observe a significant improvement in the risk of new infections in the 
vaccinated koalas, it was interesting to note nevertheless that asymptomatically infected 
control animals were more likely to advance to disease than asymptomatically infected 
vaccinated animals. Promisingly, over 12 months, only one vaccinated animal developed new 
disease symptoms (cystitis), whereas 4 animals in the non-vaccinated cohort succumbed to 
disease (cystitis n = 3 and reproductive disease n = 1).  While beyond the scope of this 
manuscript, it is also promising to observe that available longitudinal data for the remaining 
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animals at 18-24 months suggests that two (of 7; 28.6%) additional control animals 
contracted cystitis, whereas none of the vaccinated animals has yet succumbed to disease 
(0/6; 0%).   
To conclude, the first field trial to date of this prototype koala chlamydial vaccine suggests 
that vaccinated Chlamydia-infected koalas have an improved infection outcome – an outcome 
that highlights the potential for the development of a therapeutic vaccination schedule for this 
species.  This is especially promising given the small sample sizes, and the natural variability 
of an outbred population.  In the koala, the main goal for population management from an 
ecological standpoint is maintaining health and young animal recruitment.  Therefore, if a 
vaccine is able to lower or prevent increases of infection load, as well as to decrease the 
progression to disease, than this will have positive effects on population health and fecundity 
and may be an important tool in the management and conservation of the koala.   
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Fig. 1. Antibody (IgG) titre response in vaccinated animals at 0 months (pre-vaccination) and 
6 months post-vaccination (n = 23): Mean and standard error of IgG titre levels. P < 0.05 *; P 
< 0.001 **. 
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Table 1. Change in Chlamydia PCR load following vaccination : Percentage (and raw 
number calculations) of koalas that were C. pecorum positive at time point 0 (i.e. at initial 
vaccination time), and then exhibited changes in their C. percorum load between either 0 and 
6 months, or between 0 and 12 months, post vaccination. Statistically significant effects are 
shown in bold. Trending (P < 0.1) results indicated with *.  Grey shading represents groups 
with more than expected (based on Pearson residuals) for significant results. The changes are 
categorized as decreasing, stable or increasing (ΔqPCR ≤ -100, -99 – 99, and ≥ 100 copies/µL 
respectively). 
  Eye (0 vs. 6 months)   Eye (0 vs. 12 months)   UGT (0 vs. 6 months)        
  Decrease Stable Increase   Decrease Stable Increase   Decrease Stable Increase      
Control 33% (2) 0% (0) 67% (4)  100% (4) 0% (0) 0% (0)  69% (9) 0% (0) 31% (4)        
Vaccinated 50% (5) 40% (4) 10% (1)  71% (5) 29% (2) 0% (0)  88% (7) 12% (1) 0% (0)        
X2 85.677   31.619   45.299     
P  < 0.001 (0.052 *)     < 0.001 (0.496)     < 0.001 (0.099*)          
a analysis based on 2 x 2 contingency table Chi-square owing to no individuals with decreasing loads for both 
control and vaccinated koala 
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Chapter 6: Antibody and cytokine responses of 
koalas (Phascolarctos cinereus) vaccinated with 
recombinant chlamydial major outer membrane 
protein (MOMP) with two different adjuvants
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6.2 Abstract 
Developing a vaccine against Chlamydia is key to combating widespread mortalities and 
morbidities associated with this infection in koalas (Phascolarctos cinereus). In previous 
studies, we have shown that two or three doses of a Recombinant Major Outer Membrane 
Protein (rMOMP) antigen-based vaccine, combined with Immune Stimulating Complex 
(ISC) adjuvant, results in strong cellular and humoral immune responses in koalas. We have 
also separately evaluated a single dose vaccine, utilising a tri-adjuvant formula that comprises 
polyphosphazine based poly I: C and host defense peptides, with the same antigen. This 
formulation also produced strong cellular and humoral immune responses in captive koalas. 
In this current study, we directly compared the host immune responses of two sub-groups of 
wild Chlamydia negative koalas in one population vaccinated with the rMOMP protein 
antigen and adjuvanted with either the ISC or tri-adjuvant formula.  Overall, both adjuvants 
produced strong Chlamydia-specific cellular (IFN-γ and IL-17A) responses in circulating 
PBMCs as well as MOMP-specific and functional, in vitro neutralising antibodies. While the 
immune responses were similar, there were fine detailed differences between the adjuvants, 
particularly in relation to the specificity of the MOMP epitope antibody responses. 
 
Key words: Chlamydia, Vaccine, rMOMP, Adjuvants, Koala 
 
6.3 Introduction 
Chlamydial infections are responsible for significant mortality and morbidity of mainland 
koalas (Phascolarctos cinereus) and are one major factor threatening the long term future of 
this iconic species [1-4]. The main species of Chlamydia that infects koalas is C. pecorum, 
and virtually all koala populations are infected, with rates ranging from 10% to as high as 
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90% in some regions [1]. Despite the significant advances in chlamydial research, a 
prophylactic vaccine to stabilize the population decline caused by chlamydial infections [5] 
has yet to be fully developed.   
 
Chlamydia is an intracellular bacterium with a unique biphasic developmental cycle, 
consisting of two developmental forms, the non-dividing, but infectious, elementary bodies 
(EBs) and the replicative, but non-infectious reticulate bodies (RBs) [6]. It is usually accepted 
that a host requires the development of a balanced Th1 and Th2 protective immune response 
to adequately control chlamydial infections [7]. Several small animal studies have confirmed 
the protective role of IFN-γ secreting CD4+T cells in chlamydial infection [8]. Recently, 
there is also re-emerging evidence supporting the prominent role of B cells to elicit protective 
anti-Chlamydia antibodies [9]. The primary role of the neutralizing antibodies is to reduce the 
initial infectious burden and further prevent secondary bacterial infections [10]. Once the 
bacterium parasitises the host’s cells, the cell mediated immune response pathway contributes 
significantly to protective immunity through IFN-γ secretion [11]. Whilst IL-17A is a strong 
recruiter of neutrophils which secrete antimicrobial peptides and promote a Th1 immune 
response against intracellular pathogens [12], other animal studies suggest that IL-17 plays a 
role in both immune pathology and  protection [13].  
 
The chlamydial major outer membrane protein (MOMP) is the leading vaccine candidate in 
chlamydial vaccine research, and our group has been developing a prototype vaccine utilizing 
recombinant chlamydial MOMP (rMOMP) as a vaccine antigen for koalas. Although the 
choice of immunogenic antigen is of prime importance, selecting the right adjuvant to 
appropriately trigger the immune response is also essential. In this context, we have used two 
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different adjuvant formulations with differing properties, combined with rMOMP, to 
vaccinate groups of koalas: ISC (Immune stimulating complex) adjuvant [14-17] or Tri-
adjuvant which is a mixture of the three components  (Polyphosphazine based poly I: C and 
host defense peptides)  [18].  
 
In our previous koala vaccine trials, the ISC adjuvant was able to induce strong cellular and 
humoral immune responses [14-17]. However, the ISC adjuvant requires two or three 
injections to promote a significant immune response. This is logistically problematic for wild 
koalas, which would need to be tracked and re-captured, or kept in captivity for extended 
periods of time, increasing the cost of the process as well as the stress experienced by the 
animal itself.  A trivalent adjuvant (Tri-Adj) containing polyphosphazine, poly I: C and host 
defense peptides, has been developed to be effective with just a single dose [18]. In other 
species, this adjuvant promoted a Th1 and Th2 balanced immune responses following a 
single injection [19-23]. In a small preliminary trial in captive koalas (n = 6), we have shown 
that this adjuvant was safe to use and elicited promising immune responses [18]. 
 
In the current study, we evaluated, in detail, both the cellular and humoral immune responses 
of wild koalas vaccinated with rMOMP, combined either with (a) the single-dose Tri-Adj or 
(b) three doses of ISC. Firstly, we evaluated the cellular response for each adjuvant by 
measuring cytokine expression elicited by the peripheral blood mononuclear cells (PBMCs) 
at defined post-vaccination time points. Secondly, we measured the neutralising antibodies 
produced by vaccination and mapped the corresponding MOMP epitopes recognized for both 
cohorts.  
 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial 
major outer membrane protein (MOMP) with two different adjuvants 
 Page 141  
6.4 Materials and Methods 
Koalas  
The koalas used in our study were sourced from a wild population of around 400 animals 
located in South East Queensland. Prior to vaccination, all animals were examined and those 
animals that (i) had no clinical evidence of chlamydiosis; and (ii) were negative at 
conjunctival and genital sites following Chlamydia pecorum-species-specific qPCR screening  
[24] were selected. Two sub-sets of these animals have been vaccinated with an anti-
C.pecorum vaccine and we analysed a further sub-set of these vaccinated animals in the 
current study. The first group of 10 koalas (Cindy, Greg, Cherry, Maxwell, Kylie, Paige, 
Janke, Squeek, Linky and Kelly) (Group A) were vaccinated with chlamydial rMOMP 
protein (see below for details) mixed with the Tri-Adj. A second group of 5 koalas (Robyn, 
Pepper, Maya, Hunky Harry and Winnic) (Group B) were vaccinated with rMOMP protein 
mixed with ISC [17]. At the end of the trial, all koalas were successfully returned to their 
habitat in accordance with current legislation and the detailed Koala Action Plan for the 
Moreton Bay Rail Link project. All work was conducted under permission from Queensland 
University of Technology’s Animal Ethics Committee (AEC; Permit # 1200000122), the 
University of the Sunshine Coast AEC (ANA1380) and Scientific Purposes Permit 
(WISP11532912). 
 
Vaccines 
Both vaccines consisted of C. pecorum rMOMP combined with either adjuvant (Tri-Adj or 
ISC). We combined three rMOMP proteins (A, F and G types) for the vaccine, as described 
previously [14, 17, 18]. Koala-specific C. pecorum MOMP proteins were expressed and 
purified as per Kollipara et al. [14]. The purified products were used for vaccination and 
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ELISA assays. After vaccination, the animals were released back into the wild and tracked 
with a wildlife telemetry system (K-Tracker, LX Solutions Pty Ltd). The ISC vaccinated 
koalas were re-captured at 1 monthly interval to receive the 2nd and 3rd dose of the vaccine 
and a veterinary health examination. 
 
Samples  
Aluminium shafted cotton-tipped swabs (Copan, Interpath Services, Melbourne) were used to 
collect samples from the conjunctiva of the left and right eye,  as well as the urogenital sinus 
( prostatic urethra in males), as previously described [18]. These swabs were used for 
measuring the C. pecorum infection load using a C. pecorum-species-specific qPCR targeting 
the 16S rRNA gene  [24]. Blood samples were obtained from the cephalic vein into EDTA-
containing tubes and stored at 4° C for processing within 24 h of collection, to obtain 
PBMCs. After centrifugation at 1000 rpm for 5 mins, plasma was separated and used for 
ELISAs and C. pecorum in vitro neutralisation assays. The samples were collected at 0 (pre-
vaccinated), 2 and 6 months post vaccination. 
 
 Cytokine assays 
The blood samples were centrifuged within 4-8 h of collection to separate the plasma. The 
PBMC were isolated by centrifugation on Ficoll-paque gradients (GE Healthcare, Rydalmere, 
Australia) washed and suspended in 1ml RPMI 1640 T cell media supplemented with 5% 
foetal calf serum, antibiotics and β-mercaptoethanol (0.001M) (Sigma) at a concentration of 
2x106 cells/ml. A 500 μl aliquot of cell suspension was used as the pre-stimulation sample. 
The remaining cells were then stimulated with either mitogens (Ionomycin and PMA 
combination)[25] or UV-inactivated C. pecorum EBs. After stimulation and incubation at 37° 
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C with 5% CO2, the cells were collected at 12 and 24 h post-stimulation time points. RNA 
extraction and cDNA synthesis were completed for all these pre- and post-stimulation 
samples according to our previously published protocol (21).  The end products were utilized 
in qPCR assays to determine the mRNA expression level as fold change for interferon 
gamma (IFN-γ), interleukin 17A (IL-17A), interleukin 10 (IL-10), tumour necrosis factor 
alpha (TNF-α) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [25-27]. GAPDH 
was used as reference to normalise IFN-γ, IL-17A, IL-10 and TNF-α using the  2-∆∆CT method 
(∆∆CT = (Ct of target gene - Ct of GAPDH) at 12 or 24 h time point – (Ct of target gene – Ct 
of GAPDH) at 0 time point [28]. 
 
C. pecorum specific ELISA 
Enzyme linked immunosorbent assays were performed using purified rMOMP as per 
Kollipara et al. [14] and Khan et al.[18] on the plasma samples collected at 0, 2 and 6 month 
time points post-vaccination. 
 
C. pecorum MOMP peptide ELISA 
We initially screened the plasma to identify the reacting epitopes for individual animals, 
using the methods described previously [9]. Then we measured the individual peptide 
concentrations as determined using our previously described ELISA methods [18]. Instead of 
using the whole rMOMP protein, we used selected peptides for coating the ELISA plates at a 
concentration of 2μg/well in PBST. Post-incubation, the wells were washed 3x with PBST 
and the plasma sample was serially diluted two fold at 1:200 dilution initially, and incubated 
at 4° C overnight. Plates were then washed 3x in PBST and a sheep anti-koala IgG (1:8000 in 
PBST;[16]) was added. At this point, plates were incubated for a further one hour at room 
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temperature. After a further three washes (PBS-T), HRP-conjugated rabbit anti-sheep IgG 
(1:1000, Southern Biotech ⁄ Millipore, North Ryde, Australia) was added to wells and 
incubated at room temperature for 1 hr. Post incubation, plates were washed 4x with PBS and 
50 μl ABTS [2, 2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid), Southern Biotech, 
Alabama, USA] solution was added and incubated for 10 mins to observe the greenish color 
development. The reaction was stopped with 1M sulphuric acid following color observation. 
The optical density was measured at 405 nm wavelength and the data was transformed into 
excel sheet for later analysis. 
 
Koala-specific C. pecorum neutralising antibodies 
We conducted in vitro neutralisation assays using the methodology of Kollipara et al. [14] 
either on whole plasma or on plasma collected at 0, 2 and 6 month time points which had 
been pre-adsorbed with one or more individual peptides [14]. All plasma samples were 
diluted at 1:10 prior to assay. The background neutralisation was determined by using koala 
plasma that was Chlamydia negative. Percentage neutralization was then determined by 
subtracting this background from each individual to determine the final neutralisation. The 
results were expressed as fold change neutralisation.  
 
C. pecorum MOMP peptide mapping 
Biotinylated Pepscan ELISA was performed as previously described [9] to identify the 
specific rMOMP epitopes produced by each vaccine in animals receiving either the ISC or 
Tri-Adj adjuvants.  Briefly, we designed 88 peptides with 15-mer peptides that spanned the 
full length of koala C. pecorum MOMP F protein and used these individually in ELISA 
assays (or grouped) as described above. The background for each plasma sample was 
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calculated from the mean plus twice the standard deviation of the negative wells (no plasma 
added). We scored samples with an absorbance value greater than 0.5 as a positive response. 
In subsequent experiments, we utilised only the positive peptides to coat the streptavidin plate 
at a concentration of 2μg/well and performed the standard ELISA as described.  
 
C. pecorum MOMP-peptide specific neutralising antibodies 
We performed three types of neutralising assays by using the (a) whole plasma at 1/10 
dilution for either Tri-Adj or ISC cohort, (b) whole plasma at post-adsorption against either 
peptide 58 and 77 for tri-adjuvant or at post-adsorption against epitope 4 for ISC cohort and 
finally (c) whole plasma at post-adsorption against either epitopes 4, 28, 41, 42, 58, 59 and 77 
for Tri-Adj cohort or 4, 28, 41, 42 for ISC cohort. We utilised the previously described novel 
protocol for peptide adsorption [9].  
 
Statistical analysis 
Statistical analyses were performed using Graph-Pad Prism version 6 (Graph Pad Software, 
La Jolla, CA, USA) and the P value for significance was set at ≤ 0.05. 
 
6.5 Results 
There was a non-significant trend towards stronger IFN-γ and IL-17A responses in animals 
immunised with the Tri-Adj compared to ISC immunised animals  
 
To evaluate differences in the immune response of koalas vaccinated with a C. pecorum 
rMOMP-vaccine adjuvanted with either Tri-Adj or ISC, we vaccinated a cohort of koalas that 
were clinically healthy at the time of vaccination and were Chlamydia PCR negative at both 
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urogenital and ocular sites (data not shown). Immune profiling of these vaccinated animals 
revealed that 60% of the animals in both groups produced IFN-γ at 2 or 6 months post 
vaccination in response to stimulation of PBMCs with UV-inactivated EBs (elementary 
bodies) (6 out of 10 for Tri-Adj and 3 out of 5 for ISC adjuvant).  For those animals who’s 
PBMCS expressed IFN- γ in response to stimulation, the level of IFN-γ expression varied 
from 2.73 to 17.89 for Tri-Adj and from 2.08 to 12.67 for ISC (Fig. 1). We also observed 
differences among the responders between the 2 month and 6 month time points. For the Tri-
Adj responders the highest expression was observed at 2 months, whereas, for ISC 
responders the highest IFN-γ responses were at the 6-month time point.  Overall, the IL-17A 
responses were lower than IFN-γ, and only 40% of animals (4/10 Tri-Adj; 2/5 ISC) produced 
IL-17A responses to stimulation above 1.0 fold. We did not observe any measurable 
expression for the anti-inflammatory cytokine, IL-10 and TNF-α following stimulation of 
collected PBMCS from animals in either cohort (Fig. 2 A-D). 
 
The kinetics of the total antibody (IgG) titres was similar in both cohorts, though there was an 
increased trend towards higher plasma IgG titres in ISC cohorts 
 
Both vaccine formulations elicited strong anti-MOMP antibody levels following vaccination. 
The Tri-Adj cohort produced titres of around 5x105 at 2 months post-vaccination, which 
persisted up to 6 months. The ISC cohort produced a similar average titre at 2 months (7x105) 
which increased  (to 9x105) by the 6 months time point (p value 0.302) (Fig. 3A). We also 
measured the antibody responses to individual peptides (selected ones) by ELISA (Fig 5). 
The titres for the individual epitopes varied from 0.3x103 to 2.8x103 EPT. Interestingly, there 
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was very little difference in titres for the individual epitopes, except for epitope 77 in a single 
koala (Kelly) (Fig. 5). 
 
Similar C. pecorum specific neutralising antibody potential was produced by both adjuvants 
 
To compare the function of antibody responses induced by either vaccine formulation, in 
vitro neutralisation assays were performed with plasma from the Tri-Adj and ISC cohorts at 2 
and 6 months post-vaccination. All samples were diluted 1:10 prior to testing their 
neutralising ability on C. pecorum infected cell culture mono-layers. Both adjuvant cohorts 
produced almost identical in vitro neutralisation levels, with both groups having increased 
neutralisation levels at 6 months compared to 2 months post vaccination (Fig. 3B).  
 
Epitope mapping identified two distinct anti- C. pecorum MOMP peptide antibody profiles 
for the two adjuvant groups. 
 
We used the Pepscan approach [9] to examine the epitope specificity of the plasma antibody 
response to vaccination in our Tri-Adj versus ISC adjuvant groups. In total, four C. pecorum 
MOMP peptides (4, 28, 41, and 42) were recognized in our C. pecorum peptide ELISA from 
animals in each cohort with an additional three peptides recognised by koalas receiving the 
Tri-Adj formulation only (58, 59 and 77). There was variability in the responses to these 
individual peptides with peptide 4 recognised by 80% (4 out of 5) of the ISC cohort but only 
by 10% (1 out of 10) of the tri-adjuvant cohort. For the other epitopes, none were recognised 
by 100% of the animals in any cohort, although the most-broad recognition by the animals 
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was with epitopes 77 (8/10 of tri-adjuvant animals), 58/59 (5/10 tri-adjuvant animals), 41/42 
(5/10 tri-adjuvant cohort) and 28 (4/5 ISC animals) (Fig. 4).  
 
The vaccine induced anti-epitope antibodies had neutralising ability, either individually or in 
synergy with other epitopes 
 
We examined the contribution of antibodies against individual epitopes or groups of epitopes, 
to the observed in vitro neutralisation effect. We compared (a) whole plasma versus (b) 
plasma pre-adsorbed against the most recognized peptides 58, 77 for Tri-Adj, and peptide 4 
for ISC versus (c) plasma pre-absorbed against epitopes 4, 28, 41, 42, 58, 59, 77 for Tri-Adj 
and 4, 28, 41, 42 for ISC. We evaluated the neutralising ability of each of these pre- and post-
absorption samples and compared the relative reduction of neutralisation ability in each case 
(Fig. 6 B, E). We found that most (if not all) of the individual anti-epitope antibodies 
contributed to in vitro neutralisation. In the case of the Tri-Adj vaccinated animals, anti-58 
and anti-77 epitope antibodies made a major contribution to the in vitro neutralisation effect 
(white bars in Fig 6B). The effect of these antibodies was confirmed with animal “Cherry” 
(did not produce any anti-58 antibodies) and animal “Squeek” (did not produce any anti-77 
antibodies) as the in vitro neutralisation level for these animals was not reduced following 
absorption against 58 or 77 peptides. We also observed significant in vitro neutralisation by 
antibodies against peptides 4, 41/42 and 28, with anti-peptide 4 antibodies (especially in the 
ISC cohort), having a major effect (Fig 6E).   
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6.6 Discussion 
Our previous work suggested that the koala’s immune system is able to mount both effective 
cellular and humoral immune responses against a rMOMP vaccine, when administered in 
combination with two different adjuvant systems  [14-18]. While both adjuvant vaccines look 
promising, one requires two or three doses (ISC) while the other is a single administration 
vaccine (Tri-Adj). We therefore decided to directly compare the immune responses of the two 
vaccine formulations using the same rMOMP antigens to vaccinate koalas from the same 
wild population.  
 
Studies with the mouse model of C.muridarum show that an IFN-γ response is required for 
adequate protection against chlamydial infections. While there is no direct evidence yet for 
protection against C. pecorum infections in koalas, vaccine development should aim for a 
strong IFN-γ response. We found that both vaccine formulations induced good IFN-γ 
responses in 60% of animals that lasted for up to 6 months. No significant difference could be 
seen in the specific IFN-γ response induced by the single dose Tri-Adj formulation or the ISC 
formulation. IFN-γ activity is the hallmark of the Th1 immune response against chlamydial 
infection and IFN-γ gene knockout mice are indeed unable to resolve the infection [29]. 
Despite the promising IFN-γ response in some animals (60%), not all koalas produced a 
detectable IFN-γ response. The animals in this trial are outbred animals and this highlights 
key Major Histocompatibility Complex (MHC) considerations for future vaccine 
development. Genetic differentiation and structure analysis has revealed that the koala’s 
MHC-II gene is more diverse in koalas in the northern states of Queensland and New South 
Wales, compared to the southern states of Victoria [30, 31]. The higher MHC-II diversity 
could be the potential cause of the variable immune response within this group of koalas. 
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In addition to IFN-γ, IL-17A has been suggested as an important cytokine for chlamydial 
infection, both for protection, but potentially also in disease pathology [13, 32]. We observed 
Chlamydia-specific IL-17A responses for 40% of koalas with both vaccine formulations. 
Whilst, recent studies in koalas [27] and women [33] reported that strong expression of IL-
17A has been associated with clinical chlamydiosis and chlamydial cervicitis, the IL-17-/- 
mice had shown less pathological lesions compared to BALB/c [13]. Moreover, an elevated 
IL-17A response has been observed in clinical chlamydial infection in mouse model [34]. 
Though the mechanism of IL-17A in pathogenesis is unclear, this study confirms both 
vaccines can induce expression of this cytokine. 
 
While we did not observe any measurable anti-inflammatory cytokines response in either 
group, still their role in chlamydial immunity and pathogenesis is controversial. In general, 
IL-10 suppresses the secretion of various pro-inflammatory cytokines involved in chlamydial 
pathogenesis [35]. Furthermore, in the mouse model, the IL-10 dominated response has been 
attributed with susceptibility to chronic infection [36]. A similar observation has been seen in 
trachoma infected populations [37]. The higher expression of the IL-10 gene promoter has 
been associated with increased chlamydial infection and disease severity [38]. Similarly, a 
higher level of IL-10 has been linked to C. trachomatis infertility [39, 40] and tubal damage 
in women [41]. However, koalas with clinical chlamydiosis, expressed IL-10 in variable 
levels, with some animals showing higher level of expression similar to IFN-γ [25, 27]. In a 
similar fashion, the role played by TNF-α in chlamydial infection has provided disparate 
results. However, TNF-α has been linked to an initial clearance of primary infection but 
challenge infection elicited immune-pathology in the mouse [42] and guinea pig model [43]. 
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In the mouse model studies showed TNF-α produced by CD8+ T cells, promote inflammation 
in the oviduct following C. muridarum infection [44] but CD4+ T cells producing IFN-γ and 
TNFα are generally immune-protective. In contrast, reduced chlamydial shedding following 
challenge infection in vaccinated mice, has been attributed to the co-expression of TNF-α and 
IFN-γ [45].  
 
While cytokines are considered to be the major immune mechanism for protection against 
chlamydial infections, antibodies continue to be considered just as important.  In fact, recent 
data confirmed the protective roles of antibodies in chlamydial infection in koalas and other 
animal studies [46, 47]. If antibodies do play a role in protection, then it will be via their 
neutralisation role. We therefore measured the in vitro neutralisation ability of plasma 
antibodies from animals immunised with the two adjuvants. We evaluated both their total 
neutralisation ability but we also determined which peptides within the MOMP protein the 
antibodies were directed against and which of these were the most important for the 
neutralisation effect.  This produced very interesting and promising results for the 
neutralisation ability of plasma from vaccinated koalas. 
 
Firstly, both adjuvants produced antibodies that were equally neutralising. This confirms that 
MOMP has B cell epitopes that can be neutralising, validating it as a good vaccine target. 
Interestingly, the adjuvants resulted in a different, but overlapping, set of vaccine-induced 
epitopes.  Three peptides were recognised by both adjuvants (4, 28, and 41/42), but two 
additional epitopes (58/59 and 77) were solely recognised by Tri-Adj-immunised animals. 
The adsorption experiments nicely confirmed that several anti-epitope antibodies contributed 
to the in vitro neutralisation effect. Studies in the non-human primate model utilising native 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial 
major outer membrane protein (MOMP) with two different adjuvants 
 Page 152  
MOMP formulations had previously shown serovar- specific immune response either to 
homologous serovars [48] or cross-reacting to the closely related heterologous serovars [49]. 
Interestingly, in this study, the vaccine-induced epitopes recognised are all located in the 
conserved domains suggesting their role in cross-reactive recognition against diversified 
MOMP genotypes. Several vaccine studies have used the native form of MOMP, arguing that 
MOMP in its native should elicit a more robust immune response [48]. However, this study 
suggests that rMOMP is capable of generating neutralising epitopes in koalas. Nonetheless, 
80% of the animals responded to epitope 77 in the variable region, but did not result in extra 
neutralising capacity. 
 
In summary, both the adjuvants induce Th1-biased immune responses with neutralising 
antibodies. It is promising that the single dose Tri-Adj is able to produce a comparable 
immune response to the two or three-shot ISC up to 6 months time point.  Tri-Adj has proven 
to be an effective adjuvant system for koala-Chlamydia vaccine design, and a practicable 
solution to eliminate multiple vaccination events. All of the surviving animals in our original 
study [16] that were immunised with the ISC adjuvant have high plasma antibody levels and 
memory CD4+ T cells 8 years after vaccination, while we don’t yet have similar data for the 
Tri-Adj.  The identification of key epitopes (for the development of neutralising antibodies) 
enables future studies to focus on including these, or to develop specific assays to evaluate 
vaccine effectiveness. 
 
6.7 Acknowledgements 
This project was financially supported by an Australian Research Council (ARC) Linkage 
grant (LP1202000051) awarded to PT, AP and KB. This work was significantly supported by 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial 
major outer membrane protein (MOMP) with two different adjuvants 
 Page 153  
the Moreton Bay Rail Link project team and the Department of Transport and Main Roads, 
Queensland Government. Special thanks to our other collaborators including Queensland 
Department of Environment and Heritage Protection, Moreton Bay Regional Council, 
Endeavour Veterinary Ecology Pty Ltd, Australia Zoo Wildlife Hospital, Friends of the 
Koala, Lone Pine Koala Sanctuary and VIDO, Canada for their continued support. 
Conflict of interest 
The authors declare that they have no conflict of interest. 
6.8 References 
[1] Polkinghorne A, Hanger J, Timms P. Recent advances in understanding the biology, 
epidemiology and control of chlamydial infections in koalas. Veterinary microbiology. 2013. 
[2] Dique DS, Thompson J, Preece HJ, Penfold GC, de Villiers DL, Leslie RS. Koala 
mortality on roads in south-east Queensland: the koala speed-zone trial. Wildlife research. 
2003;30:419-26. 
[3] Lunney D, Gresser S, O'Neill LE, Matthews A, Rhodes J. The impact of fire and dogs on 
Koalas at Port Stephens, New South Wales, using population viability analysis. Pacific 
conservation biology. 2007;13:189. 
[4] Wilmer JW, Melzer A, Carrick F, Moritz C. Low genetic diversity and inbreeding 
depression in Queensland Koalas. Wildlife research. 1993;20:177-87. 
[5] Rhodes JR, Ng CF, de Villiers DL, Preece HJ, McAlpine CA, Possingham HP. Using 
integrated population modelling to quantify the implications of multiple threatening processes 
for a rapidly declining population. Biological conservation. 2011;144:1081-8. 
[6] Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. Journal of 
infectious diseases. 2010;201:S88-S95. 
[7] Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. 
Journal of infectious diseases. 2010;201:S114-S25. 
[8] Loomis WP, Starnbach MN. T cell responses to Chlamydia trachomatis. Current opinion 
in microbiology. 2002;5:87-91. 
[9] Khan SA, Polkinghorne A, Waugh C, Hanger J, Loader J, Beagley K, et al. Humoral 
immune responses in koalas (Phascolarctos cinereus) either naturally infected with 
Chlamydia pecorum or following administration of a recombinant chlamydial major outer 
membrane protein vaccine. Vaccine. 
[10] Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia 
trachomatis genital infection: evidence from human studies. The Journal of infectious 
diseases. 2010;201 Suppl 2:S178-89. 
[11] Yang X, Brunham R. T lymphocyte immunity in host defence against Chlamydia 
trachomatis and its implication for vaccine development. The Canadian journal of infectious 
diseases. 1998;9:99-108. 
[12] Scurlock AM, Frazer LC, Andrews CW, O'Connell CM, Foote IP, Bailey SL, et al. 
Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial 
major outer membrane protein (MOMP) with two different adjuvants 
 Page 154  
Chlamydia muridarum genital tract infection but is not required for macrophage influx or 
normal resolution of infection. Infection and immunity. 2011;79:1349-62. 
[13] Andrew DW, Cochrane M, Schripsema JH, Ramsey KH, Dando SJ, O'Meara CP, et al. 
The duration of Chlamydia muridarum genital tract infection and associated chronic 
pathological changes are reduced in IL-17 knockout mice but protection is not increased 
further by immunization. PloS one. 2013;8:e76664. 
[14] Kollipara A, George C, Hanger J, Loader J, Polkinghorne A, Beagley K, et al. 
Vaccination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia 
pecorum multi-subunit vaccine: evaluation of immunity and pathology. Vaccine. 
2012;30:1875-85. 
[15] Kollipara A, Wan C, Rawlinson G, Brumm J, Nilsson K, Polkinghorne A, et al. 
Antigenic specificity of a monovalent versus polyvalent MOMP based Chlamydia pecorum 
vaccine in koalas (Phascolarctos cinereus). Vaccine. 2013;31:1217-23. 
[16] Carey AJ, Timms P, Rawlinson G, Brumm J, Nilsson K, Harris JM, et al. A multi-
subunit chlamydial vaccine induces antibody and cell-mediated immunity in immunized 
koalas (Phascolarctos cinereus): comparison of three different adjuvants. American journal 
of reproductive immunology (New York, NY : 1989). 2010;63:161-72. 
[17] Waugh CA, Timms P, Andrew D, Rawlinson G, Brumm J, Nilsson K, et al. Comparison 
of subcutaneous versus intranasal immunization of male koalas (Phascolarctos cinereus) for 
induction of mucosal and systemic immunity against Chlamydia pecorum. Vaccine. 2015. 
[18] Khan SA, Waugh C, Rawlinson G, Brumm J, Nilsson K, Gerdts V, et al. Vaccination of 
koalas (Phascolarctos cinereus) with a recombinant chlamydial major outer membrane 
protein adjuvanted with poly I:C, a host defense peptide and polyphosphazine, elicits strong 
and long lasting cellular and humoral immune responses. Vaccine. 
[19] Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, et al. Poly [di 
(sodium carboxylatoethylphenoxy) phosphazene](PCEP) is a potent enhancer of mixed 
Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine. 
2007;25:1204-13. 
[20] Brown TH, David J, Acosta-Ramirez E, Moore JM, Lee S, Zhong G, et al. Comparison 
of immune responses and protective efficacy of intranasal prime-boost immunization 
regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital 
Chlamydia muridarum infection. Vaccine. 2012;30:350-60. 
[21] Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S-i, et al. Synthetic 
double-stranded RNA poly (I: C) combined with mucosal vaccine protects against influenza 
virus infection. Journal of virology. 2005;79:2910-9. 
[22] Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, et 
al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and 
humoral immune responses to human papillomavirus in rhesus macaques. PLoS pathogens. 
2009;5:e1000373. 
[23] Dar A, Lai K, Dent D, Potter A, Gerdts V, Babiuk LA, et al. Administration of poly [di 
(sodium carboxylatoethylphenoxy)] phosphazene (PCEP) as adjuvant activated mixed 
Th1/Th2 immune responses in pigs. Veterinary immunology and immunopathology. 
2012;146:289-95. 
[24] Waugh C, Khan SA, Carver S, Hanger J, Loader J, Polkinghorne A, et al. A Prototype 
Recombinant-Protein Based Chlamydia pecorum Vaccine Results in Reduced Chlamydial 
Burden and Less Clinical Disease in Free-Ranging Koalas (Phascolarctos cinereus). PloS 
one. 2016;11:e0146934. 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial 
major outer membrane protein (MOMP) with two different adjuvants 
 Page 155  
[25] Mathew M, Beagley KW, Timms P, Polkinghorne A. Preliminary Characterisation of 
Tumor Necrosis Factor Alpha and Interleukin-10 Responses to Chlamydia pecorum Infection 
in the Koala (Phascolarctos cinereus). PloS one. 2013;8:e59958. 
[26] Mathew M, Pavasovic A, Prentis PJ, Beagley KW, Timms P, Polkinghorne A. 
Molecular characterisation and expression analysis of Interferon gamma in response to 
natural Chlamydia infection in the koala, Phascolarctos cinereus. Gene. 2013;527:570-7. 
[27] Mathew M, Waugh C, Beagley KW, Timms P, Polkinghorne A. Interleukin 17A is an 
immune marker for chlamydial disease severity and pathogenesis in the koala (Phascolarctos 
cinereus). Developmental and comparative immunology. 2014;46:423-9. 
[28] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2− ΔΔCT method. methods. 2001;25:402-8. 
[29] Johansson M, Schön K, Ward M, Lycke N. Genital tract infection with Chlamydia 
trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice 
despite a strong local immunoglobulin A response. Infection and immunity. 1997;65:1032-
44. 
[30] Jobbins SE, Sanderson CE, Griffith JE, Krockenberger MB, Belov K, Higgins DP. 
Diversity of MHC class II DAB1 in the koala (Phascolarctos cinereus). Australian Journal of 
zoology. 2012;60:1-9. 
[31] Lau Q, Jaratlerdsiri W, Griffith J, Gongora J, Higgins D. MHC class II diversity of koala 
(Phascolarctos cinereus) populations across their range. Heredity. 2014;113:287-96. 
[32] Bai H, Cheng J, Gao X, Joyee AG, Fan Y, Wang S, et al. IL-17/Th17 promotes type 1 T 
cell immunity against pulmonary intracellular bacterial infection through modulating 
dendritic cell function. The Journal of immunology. 2009;183:5886-95. 
[33] Jha R, Srivastava P, Salhan S, Finckh A, Gabay C, Mittal A, et al. Spontaneous secretion 
of interleukin-17 and-22 by human cervical cells in Chlamydia trachomatis infection. 
Microbes and infection. 2011;13:167-78. 
[34] O'Meara CP, Armitage CW, Harvie MC, Andrew DW, Timms P, Lycke NY, et al. 
Immunity against a Chlamydia infection and disease may be determined by a balance of IL-
17 signaling. Immunology and cell biology. 2014;92:287-97. 
[35] Igietseme JU, Ananaba GA, Bolier J, Bowers S, Moore T, Belay T, et al. Suppression of 
endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for 
specific Th1 induction: potential for cellular vaccine development. The Journal of 
immunology. 2000;164:4212-9. 
[36] Yang X, Gartner J, Zhu L, Wang S, Brunham RC. IL-10 gene knockout mice show 
enhanced Th1-like protective immunity and absent granuloma formation following 
Chlamydia trachomatis lung infection. The Journal of immunology. 1999;162:1010-7. 
[37] Mozzato-Chamay N, Mahdi OS, Jallow O, Mabey DC, Bailey RL, Conway DJ. 
Polymorphisms in candidate genes and risk of scarring trachoma in a Chlamydia 
trachomatis—endemic population. Journal of Infectious Diseases. 2000;182:1545-8. 
[38] Holland MJ, Bailey RL, Hayes LJ, Whittle HC, Mabey DC. Conjunctival scarring in 
trachoma is associated with depressed cell-mediated immune responses to chlamydial 
antigens. Journal of infectious diseases. 1993;168:1528-31. 
[39] Agrawal T, Gupta R, Dutta R, Srivastava P, Bhengraj A, Salhan S, et al. Protective or 
pathogenic immune response to genital chlamydial infection in women—a possible role of 
cytokine secretion profile of cervical mucosal cells. Clinical immunology. 2009;130:347-54. 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial 
major outer membrane protein (MOMP) with two different adjuvants 
 Page 156  
[40] Gupta R, Srivastava P, Vardhan H, Salhan S, Mittal A. Host immune responses to 
chlamydial inclusion membrane proteins B and C in Chlamydia trachomatis infected women 
with or without fertility disorders. Reproductive Biology and Endocrinology. 2009;7:38. 
[41] Öhman H, Tiitinen A, Halttunen M, Lehtinen M, Paavonen J, Surcel H-M. Cytokine 
polymorphisms and severity of tubal damage in women with Chlamydia-associated 
infertility. Journal of infectious diseases. 2009;199:1353-9. 
[42] Darville T, Andrews C, Laffoon KK, Shymasani W, Kishen L, Rank R. Mouse strain-
dependent variation in the course and outcome of chlamydial genital tract infection is 
associated with differences in host response. Infection and immunity. 1997;65:3065-73. 
[43] Darville T, Laffoon KK, Kishen LR, Rank RG. Tumor necrosis factor alpha activity in 
genital tract secretions of guinea pigs infected with chlamydiae. Infection and immunity. 
1995;63:4675-81. 
[44] Murthy AK, Li W, Chaganty BK, Kamalakaran S, Guentzel MN, Seshu J, et al. Tumor 
necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae 
following primary genital Chlamydia muridarum infection. Infection and immunity. 
2011;79:2928-35. 
[45] Yu H, Karunakaran KP, Kelly I, Shen C, Jiang X, Foster LJ, et al. Immunization with 
live and dead Chlamydia muridarum induces different levels of protective immunity in a 
murine genital tract model: correlation with MHC class II peptide presentation and 
multifunctional Th1 cells. The Journal of immunology. 2011;186:3615-21. 
[46] Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Protection Against 
Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-
Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane 
Protein. The Journal of infectious diseases. 2015. 
[47] Li LX, McSorley SJ. B cells enhance antigen-specific CD4 T cell priming and prevent 
bacteria dissemination following Chlamydia muridarum genital tract infection. PLoS 
pathogens. 2013;9:e1003707. 
[48] Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM, et al. 
Chlamydia trachomatis native major outer membrane protein induces partial protection in 
nonhuman primates: implication for a trachoma transmission-blocking vaccine. The Journal 
of immunology. 2009;182:8063-70. 
[49] Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. Immunogenicity of a 
vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane 
protein in a nonhuman primate model. Vaccine. 2011;29:3456-64. 
 
 
 
 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial major outer membrane protein (MOMP) with two different 
adjuvants 
 Page 157  
 
 
 
Antibody and cytokine responses of koalas (Phascolarctos cinereus) vaccinated with recombinant chlamydial major outer membrane protein (MOMP) with two different 
adjuvants 
 Page 158  
Fig. 1 IFN-γ (A, C) and IL17A (B, D) gene expression in koala PBMCs stimulated with UV inactivated C. pecorum at 0, 2 and 6 months post 
vaccination. The Tri-Adj (A, B) and ISC (C, D) cohort’s response are presented together (Fig. 1 A-D). Results are expressed as fold increase 
compared to internal control gene GAPDH
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Fig. 2 IL-10 (A, C) and TNFα (B, D) gene expression in koala PBMCs stimulated with UV inactivated C. pecorum at 0, 2 and 6 months post 
vaccination. The Tri-Adj (A, B) and ISC (C, D) cohorts are presented together (Fig. 2 A-D). Results are expressed as fold increase compared to 
internal control gene GAPDH
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Fig. 3 rMOMP specific IgG in plasma of vaccinated koalas was assayed by ELISA at 0, 2 and 
6 months post vaccination. IgG levels are expressed as end-point titers (EPT) and represent 
the mean ± SD of 10 and 5 koalas in the Tri-Adj and ISC cohort respectively (Fig. 3A). 
Vaccine induced C. pecorum percent neutralisation in plasma is presented (Fig. 3B) 
compared to pre-immunisation samples. All samples were assayed at 1:10 dilution and C. 
pecorum EBs (50,000 IFU) were added to samples. The results are expressed as the 
percentage neutralisation of post-immunized samples compared to that of the pre-immunized 
and non-infected samples. Results are expressed as the mean ± SD of 10 and 5 koalas in the 
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tri adjuvant and ISC cohort respectively. There was no significant difference between the two 
cohorts.
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Fig. 4 Epitope mapping of antibodies in plasma samples at 6 months post vaccination as determined by Pepscan assay. CD: MOMP Conserved 
domain; VD F1: Variable domain 1 for MOMP F; VD F2: Variable domain 2 for MOMP F; VD F3: Variable domain 3 for MOMP F; VD F4: 
Variable domain 4 for MOMP F; VD A: Variable domain 1, 2, 3, 4 for MOMP A; VD G: Variable domain 1, 2, 3, 4 for MOMP G; VD H: 
Variable domain 1, 2, 3, 4 for MOMP H. 
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Fig. 5 ELISA titers against individual peptide. Panel A (10 animals) for the tri-adjuvanted 
vaccinated animals and panel B (5 animals) for the ISC cohorts. We did not consider epitope 
86 as this epitope was detected in naturally infected koalas in our previous study.
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Fig. 6 In vitro neutralisation levels of plasma from vaccinated koalas (A) whole plasma at 1/10 dilution for Tri-Adj cohort, (B) whole plasma 
after absorption against peptides 58 and 77, or (C) whole plasma after adsorption against peptides, 4, 28, 41,58, 59, and 77. Separately, the in 
vitro neutralisation of plasma from ISC cohort (D) whole plasma at 1/10 dilution, (E) whole plasma after adsorption against peptide, 4, (F) whole 
plasma after adsorption against peptides, 4, 28, 41 and 42. The neutralising antibodies were presented against individual animals and all samples 
were diluted at 1:10 dilution and C. pecorum EBs (50,000 IFU) were added to samples. The results are expressed as the percentage in 
neutralisation of immune samples compared to that of the pre-immune and non-infected samples. The reductions of neutralising antibodies are 
presented as empty spaces in the bar. 
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General discussion 
The koala (Phascolarctos cinereus) is an iconic Australian tree-dwelling marsupial and the 
only surviving member of the Family Phascolarctidae. This animal has a unique position in 
the rich biodiversity of Australia as well as its valued contribution to the tourism industry. 
However, in the early 1800s, during the European settlement in Australia, its survival was 
threatened by a number anthropogenic risk factors [1]. The Australian Federal Government 
has recently recognised koalas as a threatened species across two-thirds of their range, in 
New South Wales (NSW) and Queensland (QLD) populations which have shown the largest 
decline [2]. A recent study showed that QLD, NSW and the Australian Capital Territory 
(ACT) koala populations have been declining in numbers, with high mortality rates being 
attributed to domestic dog attacks [3], vehicle strikes [4], pronounced urbanisation [2] and 
chlamydial disease [5]. Chlamydia is continuing to drive the overall koala population decline 
through increased mortality and reduced fecundity [2]. Disease modelling suggests that 
halting chlamydial infection would be a significant management strategy that could 
potentially help reverse the population’s declining trends [6]. 
 
Chlamydiosis is unfortunately a very common reason for the admission of wild koalas to 
koala hospitals and koala care centres, being the second most frequent reason for such 
admissions [7]. Koala chlamydial infection is widespread in most wild koala populations, and 
has been associated with ocular and reproductive tract diseases, including kerato-
conjunctivities, rhinitis, inflammation and fibrosis of the urinary bladder and the upper 
genital tract. There are different grades of infection at both anatomical sites [8]. The chronic 
active form of chlamydiosis results in the shedding of the highest number of infectious 
particles, posing serious threat to future transmission [9]. However, the asymptomatic nature 
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of infection, as also seen in humans, makes it difficult to treat with systemic antimicrobial 
drugs [10]. Therefore, a vaccine would be an ideal option to effectively control this infection 
and potentially increase the lifespan of koalas [11]. 
 
In the process of vaccine development, the QUT research group identified several key 
priorities, including; (a) the safety and immunogenicity of rMOMP protein in koala-
Chlamydia vaccine design [12], (b) matching of the natural diversity seen in C. pecorum 
strains among naturally infected koalas, and how this might relate to vaccine development 
[13], (c) the suitability of a recombinant MOMP vaccine for use in healthy as well as in 
naturally infected and diseased koalas [14], (d) the cross-reactive recognition of the single 
MOMP based vaccine against multiple strains of C. pecorum infection [15] and finally, (e) 
MOMP epitope specificity of the antibody response following infection and vaccination [16]. 
While vaccine research in koalas is promising, effort is still needed to address issues such as; 
(a) developing a simpler-to-administer, preferably single dose, vaccination strategy, (b) 
understanding the detailed mechanisms that underpin both humoral (epitopes mapping and 
neutralisation) and cellular immunity (cytokines response specifically IFN-γ) in both 
naturally infected and more importantly, vaccinated koalas, including the role of the adjuvant, 
(c) evaluating the protective effect of a prototype rMOMP vaccine against the course of 
infection in wild koalas. This thesis has addressed all of these key research areas. 
 
Initially, this thesis investigated the feasibility of a single dose tri-adjuvant to elicit strong and 
long lasting cellular and humoral immune responses (Chapter Three). The rMOMP of C. 
pecorum is a promising vaccine candidate that has been evaluated in several koala vaccine 
trials [12, 14-17]. The immunogenic nature of MOMP has been studied in detail as both 
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recombinant and native forms, in different animal and human studies [18-24]. Chlamydial 
MOMP, with it’s highly disulphide cross-linked structure, comprises 60% of the outer 
membrane surface of chlamydial elementary bodies (EBs). However, MOMP has been 
suggested to have multiple key roles in chlamydial infection and transmission through 
protection against the host environment, defense against the host’s immune response and 
attachment to the host’s target cells.  It contains multiple B cell and T cell epitopes, inducing 
both neutralising antibodies as well as a strong T cell response [25, 26]. Even though MOMP 
is an immune-dominant component in vaccine design, it has been reported that native MOMP 
is more suitable for vaccine development [18, 24]. Some of the potential limitations of using 
rMOMP protein for vaccine development, include, (a) inability to elicit cross-serovar 
protection and (b) the requirement of adequate tertiary structure to restore the required level 
of immunogenicity [25].  
 
While MOMP is the leading subunit vaccine antigen and has shown good promise, the 
adjuvant component is equally important and further effort is still needed. Adjuvants are an 
important component of vaccine formulations and have major functions for enhancement of 
antigen uptake and presentation to the secondary lymphoid tissues. These immunomodulatory 
substances have multiple activities, including depot effects, antigen delivery, recruitment of 
the specific immune cells to the site of immunisation and maturation of antigen presenting 
cells [27].To increase the effectiveness of koala chlamydial rMOMP, several adjuvants have 
previously been evaluated, including, Alhydrogel, Titermax Gold, and Immune Stimulating 
Complex (ISC) in the design of a chlamydial vaccine for koalas [12]. Several immunisation 
studies have used ISC adjuvant and these have provided the best immune protection obtained 
to date.  One disadvantage of ISC is that it requires multiple immunisations [14,15, 17]. This 
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requirement can cause unnecessary stress to the koalas through repeated capture and 
handling. The koalas also must be held for a longer period of time in captivity, wildlife 
hospital or wildlife care centre which would be logistically and financially challenging. 
Therefore, to overcome the limitations of multiple vaccination schedules, we evaluated a tri-
component adjuvant containing polyphosphazine, poly I: C and host defence peptide, to 
generate long lasting cellular and humoral immunity in koalas following a single vaccination 
 
This is the first study in koalas that utilised these novel adjuvant components. Therefore, to 
evaluate the safety of this tri-adjuvant vaccine formulation, we monitored the koala’s health 
following the administration of the vaccine and throughout the study period. There was no 
evidence of side effects at the injection site and also no evidence of adverse pathology during 
the 54 weeks trial period. For evaluating the specific chlamydial cellular immune response, 
we measured the proliferative response of the PBMC’s (peripheral blood mononuclear cells) 
stained with CFSE (carboxyfluoresceion succinimidyl ester) expressed as the percentage 
proliferation rate (%). The PBMC’s responses were measured against rMOMP and UV-
inactivated chlamydial C. pecorum EBs. There were no observed differences for proliferation 
percentage between single and double dose vaccine regimes utilising the tri-adjuvant 
combined with rMOMP. We also evaluated the humoral immune responses by measuring the 
IgG antibody titers in plasma and mucosal secretions and again were no significant 
differences for IgG titers EPT value between two cohorts of animals, irrespective of the 
anatomical sites (urogenital and conjunctival secretions) analysed. We also measured the 
C.pecorum EB-specific neutralising antibodies in the systemic circulation, ocular and vaginal 
mucosal secretions. While there were no statistically significant differences between single 
dose and two dose vaccine cohorts, it was interesting and a promising aspect of this particular 
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study, that the tri-adjuvant was able to stimulate the neutralising IgG secretions at both the 
ocular and urogenital tract sites.  
 
The tri-adjuvant that we used in our koala vaccine trial contained 3 immune-stimulating 
components. The adjuvant mix or individual components have previously been evaluated in 
different animal models [28, 29]. Synthetic analogue double stranded RNA components such 
as poly I: C, have been previously tested as an effective immune inducer in several animal 
species [28, 29]. Poly I: C promotes an immune response via two distinct pathways 
involving, TLR3 activation and RIG-I/MDA-5, triggering the production of IL-12, type I 
IFNs production, improved MHC class II and antigen presentation enhancing T and B cell 
immunity [30]. The presence of type I interferons can enhance antibody titers, increase IFN-γ 
secretion levels and elicit the generation of long lived memory immune responses [31]. A 
recent study in humans suggested that IFN-γ can directly induce Th1 cell differentiation, 
which is critically important for developing cellular immunity against intracellular pathogens 
[32]. Indeed, IFN-γ contributes to the induction of cytotoxic T cells, activating the antigen 
presenting cells and thereby promoting the development of Th1 type cellular and humoral 
immune responses [33, 34]. 
 
The tri-adjuvant component PCEP (Polyphosphazine) is a biodegradable polymer and has 
been shown to enhance mucosal antibody responses (IgG and IgA) in mouse models to a 
number vaccines when administered parenterally, including influenza, hepatitis B surface 
antigen, herpes simplex virus type 2 glycoprotein D and cholera toxin [35-37]. PCEP, in 
combination with influenza antigen, elicits a strong mucosal IgA response when 
administrated through either the respiratory, nasal or vaginal routes [38]. In addition, PCEP 
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was shown to induce a mixed Th/Th2 immune response with long lasting and high titers of 
antibodies in a mouse model [39]. Studies in mice showed the role of PCEP to enhance Th1 
type humoral and cellular immune responses for bovine respiratory virus [40]. These mice 
developed mucosal immune responses, as was the evident from increased production of 
vaccine antigen specific IgG and IgA in lung tissue culture. Indeed, the increases in systemic 
and mucosal IgG, and in particular the neutralising IgA, were the most critical aspect of this 
adjuvant effect. The reason behind this immune response is the production of IL-12 and IFN-
γ cytokine responses [41, 42]. Additionally, this Th-1 biased immune response elicited IgG2 
antibodies. In a pig model, this PCEP induced IFN-γ based cellular immunity associated with 
an overall balanced immune response [43]. Similar enhancement of a balanced immune 
response has been reported with co-administration of PCEP and CpG ODN in a bovine 
herpes virus vaccine in ruminants (cattle and sheep) [44]. 
 
The peptide components of this tri-adjuvant are positively charged with hydrophobic residues 
that exhibit immune modulatory properties in different animal studies [27, 45]. The adjuvant 
activities of these HDP (host defense peptides) include PBMC recruitment and activation, 
increased production of pro-inflammatory cytokines and co-stimulatory molecules on antigen 
presenting cells which promote phagocytic activities [46]. Previous studies demonstrated that 
CpG and HDP complexes have potent adjuvant activities in stimulating B cell proliferation 
and antigen specific antibody production [47, 48]. A recombinant chlamydial protease like 
activity factor (CPAF) vaccine formulated with CpG and HDP stimulated strong humoral and 
cellular immune responses with the characteristics of a Th1-biased immune profile [45]. 
Detoxified pertussis toxin (PTd) in combination with HDP-CpG leads to a 100-fold increase 
in total IgG levels. Indeed, PTd co-administered with PCEP, HDP and CpG resulted in 
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increased levels of both IgG2a and IgG1 antibodies in mice and pigs, after just a single dose 
of vaccination [49]. These studies suggest that HDP in combination with PCEP and TLR3 
ligand agonist complex, bridges innate and adaptive immune response to provide a balanced 
Th1 and Th2 response [46]. The immune responses that we observed in koalas to rMOMP 
combined with the tri-adjuvant were similar to the previously described study and look very 
promising. 
 
While a koala-specific IgA reagent to measure this secretory antibody at mucosal surfaces 
was not available for this particular project, the presence of an IgG response in the UGT and 
ocular sites is a promising sign. However, the mucosal priming immune sites are generally 
thought to be mainly located in the Peyer’s patches of the intestinal tract for an ocular 
response, whereas, they are generally thought to be located at distant sites (spleen and iliac 
lymph node) for a genital tract response [50]. The dominant Ig- subclass in the genital tract is 
IgG and it is thought that, at least in volume, IgG predominates over IgA [51].  IgG does 
however play a significant role at genital mucosal surfaces through exudation or translocation 
from plasma and also by being produced in the local B cells [52]. These unique 
characteristics of the immune system within the genital tract, and with Chlamydia itself 
targeting the mucosal epithelium, highlight the importance of producing both systemic and 
mucosal immune responses from the administration of a Chlamydia vaccine. In this current 
study, we demonstrated that the tri-adjuvant elicited systemic and mucosal humoral immune 
responses against C. pecorum MOMP vaccine antigen. The tri-adjuvant components are 
thought to act synergistically through different immune mechanisms [53]. The adjuvant and 
immune stimulating properties of poly I: C, polyphosphazine and HDP have been shown to 
have a synergistic effect in mouse and porcine models [43, 54]. The adjuvant combination of 
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CpG ODN, cationic host defense peptide (HDP) and PCEP resulted in the induction of a 
robust and long-lived immune response. Nonetheless, the combination of different adjuvants 
into a single formulation is an evolving approach to enhance the immunogenicity of the 
antigen, both in human and animal vaccine trials [53]. 
 
The protective immune response against the intracellular bacterium, Chlamydia, requires 
interferon gamma secreting CD4+ T cells [55] and neutralising antibodies in mucosal 
secretions [56]. Although the Th1 immune response is critical in chlamydial infections, the 
role of antibodies has been described in a considerable number of published articles in mouse 
and guinea pig models, and these support the role of antibodies in protective immunity [56-
61]. One suggestion is that antibodies, in conjunction with T cell mediated adaptive changes, 
promotes an anti-chlamydial response through FcR mediated phagocytosis, complement 
activation and neutralisation [62]. Mucosal antibodies have been found to be associated with 
decreased shedding of C. trachomatis infections in women with genital tract diseases, such as 
cervicitis and uterine infections [63]. Mouse infection model studies, using B cell and Fc 
receptor deficient mice, also support the role of B cells in immune-protection [64]. Other 
studies in mice also suggest the immune-protective role of  antibodies against secondary 
chlamydial infections [65]. However, antibody function ultimately depends on the cellular 
responses that regulate the adaptive changes at mucosal surfaces for genital tract [61].  
 
Nonetheless, much of the information that has informed chlamydial vaccine development and 
disease progression is obtained from laboratory animal studies, particularly the mouse model. 
While there are significant differences between mice and koalas, the former is still considered 
to be the best experimental animal to elucidate the complex host-pathogen interactions [66]. 
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Nevertheless, infection is usually self-limiting following a single challenge in mice, whereas 
in other animal models, including humans and koalas,  chronic infections develop following 
undiagnosed and untreated conditions [55]. Moreover, mice are often treated with hormone 
injections (particularly progesterone), to synchronise the reproductive tract physiology and 
thus increase their susceptibility to infection [67]. Therefore, there are clearly significant host 
differences in immune response, including to immunisation, and these differences need to be 
taken in to account for vaccine development [68-70]. Prior to the work in this thesis, there 
was a relatively limited analysis of the humoral immune response to vaccine in koalas, except 
for the reports by Carey et al. [12] and Kollipara et al. [16] . The results presented in this 
thesis with koalas, identified the novel role of B cells specifically to elicit immune response 
through neutralisation, and might potentially contribute to the C. trachomatis human 
chlamydial vaccine design.   
  
The surface exposed protein, MOMP, is a major immunodominant antigen on the surface of 
the chlamydial infectious elementary body. This protein consists of four variable domains 
interspersed with five constant domains. The high rate of substitution at the variable domains 
and the immunological pressure to mutate, promotes host immune evasion. Kollipara et al. 
previously reported that koala C. pecorum genotypes have high levels of diversity [13]. 
Despite the antigenic diversity of MOMP, our rMOMP vaccine was able to induce an antigen 
specific neutralising antibody mediated immune response. In addition, we were able to 
demonstrate specific antibodies titers against not only rMOMP, but also against native whole 
EBs, and this is an important characteristic for an effective vaccine.  
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The major aspect in analysing the protective humoral immune response induced by an 
effective vaccine is to demonstrate the functionality of the antibody response through 
neutralisation. Therefore, we performed a PepScan approach to better understand the epitope 
profile of the two different cohorts of koalas, namely diseased and vaccinated. The 
vaccinated animals showed a unique MOMP epitope profile, with 4 key epitope responses 
associated with neutralising ability against in vitro C. pecorum infection. A C. trachomatis 
vaccine study, which used a primate model, demonstrated that the neutralising antibodies 
produced following vaccination with native MOMP from either ocular or genital serovars, 
were highly serovar specific, even though there was only two amino acid differences between 
homologous and heterologous strains [18, 24]. In the mouse model, C. trachomatis serovar 
L1 vaccination through different routes, and subsequent C. trachomatis serovar F infection 
through the bursal route, induced limited protection  against vaginal shedding, but no 
protection against infertility [71]. Interestingly, in our current study, the vaccine induced 
epitopes are all located in the conserved domains, perhaps explaining their role in cross-
reactive neutralisation against diverse MOMP genotypes. While it has previously been 
assumed that antibodies must bind to externally presented epitopes to enable neutralisation 
[64], recent reports have shown that antibodies, via FcRn mediation, can internalize and 
neutralise virus [72] and intracellular bacteria such as Chlamydia, within the cytoplasm of 
epithelial cells [73]. Antibodies to internal proteins, such as the chlamydial NrdB, have also 
been shown previously to facilitate the neutralisation process [74]. In addition, during the 
infection process, the host immune system might contribute by releasing the previously 
inaccessible or unexposed protein from disintegrated cell walls, and thereby become exposed 
to B cell antigen receptors. Nonetheless, upon unfolding the native MOMP structure through 
limited proteolysis, the unexposed or conserved linear motifs can be exposed to the anti-
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MOMP epitope B cell antibody [75]. The identification of common and hidden epitopes that 
induce cross-serovar protection poses a major challenge in several human pathogens, 
including hepatitis C virus, Neisseria meningitides and influenza virus [76-79]. The findings 
of our current study suggest that conserved and hidden B cell epitopes are poorly exposed to 
the immune systems in natural chlamydial infections, but that the rMOMP vaccine we 
evaluated, which presumably had only linear MOMP, has the ability to stimulate the immune 
system successfully and to elicit cross-reactive antibodies that can neutralise multiple 
serovars of C. pecorum. However, several vaccine studies have used the native form of 
MOMP, arguing that this could ideally represent and restore the EB’s MOMP conformation 
into its original 3-D form, to elicit a more robust immune response [18]. However, this 
current koala vaccine study suggests that immunisation with recombinant linear MOMP is 
able to generate neutralising antibodies against epitopes in the conserved domain and might 
be capable of protecting against a wide range of C. pecorum infections in koalas. The 
previous koala vaccine study  [15] demonstrated the cross-reactive properties of the immune 
plasma in either diseased or healthy animals, following vaccination. For example, koalas with 
C. pecorum strain F infection and subsequently vaccinated with heterologous rMOMP of C. 
pecorum were still able to neutralise C. pecorum infection [15]. The results of our current 
study confirm that  koalas vaccinated with non-conformational rMOMP of C. pecorum, can 
develop an antibody response that can effectively neutralise homologous as well as 
heterologous infection [15]. A recent study in a mouse model of C. trachomatis infection, 
showed that a multivalent peptide vaccine was able to induce neutralising antibodies directed 
to the variable domain of the MOMP protein [57]. Furthermore, their study suggests that a 
small fragment of the MOMP protein was able to induce specific and neutralising C. 
trachomatis-specific antibodies. This study further confirms the immune protective role of 
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antibodies in challenge infection. Nonetheless, vaccine induced antibodies were able to 
reduce the bacterial burden and prevent the upper reproductive tract pathology in subsequent 
challenge infection [57]. Similarly, a recombinant epitope based vaccine strategy has been 
successfully demonstrated by Murtada et al.[80]. They showed that this vaccine can stimulate 
antigen specific systemic and mucosal antibody responses [80]. In a recent mouse study, 
these authors reported that rMOMP adjuvanted with ISC can reduce the infection burden and 
prevent subsequent oviduct pathology [81]. This study indicated that the vaccinated animals 
produced different cytokines and chemokines, specially, IFN-γ, TNF-α, at the genital 
mucosa. There was an increased accumulation of macrophages and neutrophils at this site. 
One of the major findings of this study was that antibodies generated following vaccination 
might contribute towards immune protection through enhancing innate and adaptive 
responses [81]. 
 
In addition to the testing of rMOMP protein vaccine in captive koalas at the Lone Pine Koala 
Sanctuary, this thesis work also examined chlamydial vaccination of wild koalas in a 
population in South East Queensland, termed the MBRL population. This larger population 
contained around 300 koalas and 60 koalas in this population were used for chlamydial 
vaccination studies. Of these 60 koalas, half of the animals were assigned to an unvaccinated 
control group, to evaluate the prophylactic and therapeutic effect of the current version of the 
koala-Chlamydia vaccine. While systemic antimicrobial drugs are used for treating 
chlamydial infections, several studies have shown the ineffectiveness of the current antibiotic 
regimes for controlling severe chlamydiosis in koalas [10, 82]. As koala chlamydial infection 
is widespread and often asymptomatic in free ranging animals, a prophylactic vaccine is of 
paramount importance. Recent studies showed that women with C. trachomatis infection 
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without clinical disease, and treated with antibiotic, had a significant level of subsequent re-
infections within a 1 year time period [83]. This clearly suggests that some individuals 
receiving antibiotic treatment did not develop protective immunity [84]. Similarly, molecular 
studies have suggested similar observations with wild koalas without signs of clinical 
chlamydiosis [5]. Therefore, we evaluated the vaccine induced immune response within this 
cohort of naturally infected koalas. Perhaps not surprisingly, we found higher antibody 
responses in vaccinated koalas which had a current chlamydial infection. Notably, the level 
of neutralising antibodies was significantly higher in the vaccinated group compared to 
control koalas. However, we found a strong and statistically significant correlation between 
higher infection load and lower antibody titre. This might be an interesting finding as koalas 
with a high infectious loads at genital and ocular mucosal sites were most likely to have 
infection with clinical chlamydiosis [85].  
 
A part of the thesis work utilised this wild koala population to study, (a) immune response 
(antibodies) to natural infections as well as the (b) immune response following vaccination. 
An important finding in this study was that a different and unique set of antibodies (to 
different epitopes on MOMP) were induced by vaccination, compared to those seen in 
natural, live infections. All vaccinated koalas produced neutralising antibodies to 4 key 
epitopes that were located in the conserved regions of MOMP. This is promising for vaccine 
development because these epitopes would be conserved across the multiple MOMP 
genotypes. Not only were the vaccine induced antibodies unique, but they were neutralising 
in our in vitro assay. By comparison, the antibodies present in sera of naturally infected 
koalas with clinical disease, were found not to have any neutralisation ability. Although it has 
previously been thought that antibodies predominantly bind to the surface exposed epitopes 
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to enable the neutralisation [86], we found that antibodies targeting apparently internal 
epitopes, such as those in the conserved/membrane anchored regions of MOMP, could also 
effectively neutralise infectivity. One possible explanation for this is that, recent studies have 
shown that antibodies can be taken up inside the  epithelial cells through FcRn mediated 
transport and thereby neutralise virus [72] and intracellular bacteria, like Chlamydia  [73].  
 
The final aspect of this thesis work was to compare the responses of two MOMP vaccines, 
containing the same recombinant MOMP proteins, but mixed with two different adjuvants 
(Chapter Six). Overall, both adjuvants induced a strong cell mediated immune response 
through IFN-γ mRNA expression in circulating PBMCs. The animals in both cohorts given 
these two vaccines showed a very specific and distinct neutralising antibody profile, though 
the neutralisation level was generally similar. It is generally thought, IFN-γ secreting CD4+ T 
cells and neutralising antibodies at the infection site provided immune protection against 
chlamydial infection [63].  
 
In several koala Chlamydia vaccine trials, our group measured the proliferative response of 
the PBMCs against rMOMP protein or UV-inactivated EBs of C. pecorum [14, 15, 87]. 
These studies were unable to measure the cytokines profile following vaccination because 
koala specific cytokine assays were not available at the time of these earlier studies. 
Cytokines are the immune system’s molecules that modulate the immune response against 
chlamydial infection or vaccination. In this current study we first measured the koala specific 
mRNA expression of a selected Th1 cytokine, namely IFN-γ, in circulating PBMC following 
vaccination. For an intracellular organism like Chlamydia, the host immune system requires a 
CD4+ T cell response for the production of a protective immune response, as shown in 
 
General discussion 
 Page 183  
several animal models [88, 89]. CD4+ T cells are classified into two cohorts based on their 
type of cytokine production, T helper 1 (Th1) and T helper 2 (Th2) cells. Th1 cells produce 
IFN-γ and IL-12 cytokines to regulate immunity against intracellular infections, whereas, IL-
4, IL-5 and IL-13 are the dominant cytokines for the mediation of humoral immunity against 
parasite infections [90]. The IFN-γ response has been shown to be critical for protection 
against chlamydial infection in the mouse model [91, 92]. However, our current study only 
involved clinically healthy koalas that presented with no sign of chlamydial infection. While 
we found significant IL-17A gene expression in some koalas from both cohorts, the role of 
IL-17A in protection versus disease is still unclear [93]. It is interesting that both IL-17A and 
IFN-γ have been implicated in pathological damage in the mouse model [94]. Recent studies 
have shown a strong correlation between higher expression of IL-17A with clinical 
chlamydiosis and cervicitis in koalas [93] and women [95]. Even though the role of IL-17A 
in chlamydial pathogenesis has yet to be fully understood, our study demonstrated that 
vaccination induced expression of this cytokine at variable levels in koalas. IL-17A is a 
strong recruiter of neutrophils [96] which secrete anti-microbial peptides namely defensins 
and cathelicidins, at the infective sites [97] and which play a critical role in host defense 
against infection [98]. These neutrophil-derived defensins have significant immuno adjuvant 
properties, promoting an antigen specific Ig response in mouse model. In addition, defensins 
induced an increased production of IFN-γ, a Th1 cytokine [99]. Recent studies identified that 
human defensins as a potent ligand for the chemokine receptor (CCR6), which is present on 
dendritic as well as T cells, thereby, promoting a link between the innate and adaptive 
immune responses [100]. Tuberculosis vaccination in a mouse model elicited IL-17 
producing CD4+ T cells which promoted the production of chemokines that recruit the CD4+ 
T cell producing IFN-γ, eventually limiting the bacterial growth [101]. Moreover, both these 
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cytokines have shown immune protection via the up regulation of the inducible nitric oxide 
synthase (iNOS) and nitric oxide (NO) production against Chlamydia muridarum [102]. We 
did not find any measurable expression for the IL-10 and TNF-α mRNA in our koala vaccine 
study, and their role in chlamydial infection and immunity remains controversial. Generally, 
IL-10 suppresses the secretion of pro-inflammatory cytokines [103] and has been linked to 
chronic infection in the mouse model [104]. Similarly, higher expression of this cytokine has 
been attributed to tubal pathology [105] and infertility [106, 107] in women.  While several 
of the koalas analysed in our study, that had an ongoing chlamydial infection, had variable 
IL-10 and TNF-α expression [93, 108], the latter cytokine has been associated with decreased 
chlamydial shedding with co-expression with IFN-γ in vaccinated mice [109]. In these mouse 
model studies, it was shown that TNF-α produced by CD8+ T cells, could promote 
inflammation in the oviduct following C. muridarum infection [110] but that CD4+ T cells 
producing IFN-γ and TNF-α are generally immune-protective. A recent study by Mathew et 
al. [111] using koalas with natural infection and disease showed significantly higher IFN-γ 
expression compared to clinically healthy individuals [93] and this over amplified cytokine 
level might hinder the role of T cell response in preventing future infections [55] and 
dissemination of the pathogen [68, 112]. Our results therefore are very promising for the 
ability of both vaccines to elicited relevant immune response in koalas against chlamydiosis. 
 
While there were many similarities between the two groups of koalas vaccinated with the 
different adjuvants, there were also some key and very interesting differences. The animals 
showed comparatively similar immune responses regardless of the two different adjuvant 
regimes. The total antibody titers were marginally higher in the ISC animals, but showed no 
difference in terms of neutralisation percentage. Both ISC and single dose tri-adjuvant 
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formulations induced high antibody titers with good in vitro neutralisation levels. This 
strongly suggests the feasibility of the single dose vaccine to elicit functional antibody 
response to neutralise the infectious EBs in free ranging koalas. Furthermore, vaccinated 
koala PBMCs expressed promising levels of IFN-γ and IL-17A in response to stimulation 
with UV-inactivated C. pecorum infection. Vaccine studies in non-human primates for HPV 
and malaria infection have shown that this tri-adjuvant component is able to induce antigen 
specific antibodies and is a potent inducer of IFN-γ from the PBMCs [30, 113]. In addition, 
we are using koalas which are out-bred animals, with diverse MHC-II molecules across their 
range especially in the northern state of Queensland and New South Wales [114, 115]. This 
genetic variation may have an effect on infections and disease severity across the koala’s 
range, but importantly, it could also impact on the vaccine response.  
 
The results of this thesis have demonstrated that a recombinant C.pecorum protein, in 
combination with a novel tri-adjuvant, can produce a strong antibody and CMI response 
following a single immunisation in koalas. The resultant antibody response was not only high 
titer but was also directed against several conserved MOMP epitopes. This characteristic is 
potentially promising for protection against a wide range of koala C. pecorum strains.  A 
vaccine formulated with multiple MOMP types elicited neutralising and antigen specific 
antibody. Perhaps, even more promising was the IFN-γ (C. pecorum specific) response 
induced by vaccination. 
 
The current rMOMP vaccine has shown promising immune response either in combination 
with ISC or Tri-Adj. We did not observe any distinct variation in these two adjuvant regimes, 
apart from epitopes specificity. Considering the multiple doses ISC, Tri-Adj looks very 
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promising. Furthermore, the Tri-Adj induces extra epitope specificity though its neutralising 
ability was not increased. It will be interesting to measure the actual concentration of the 
specific epitopes in the systemic circulation following vaccination or natural infection. 
Nonetheless, we evaluate the Tri-Adj in a koala population that shown the evidence of the 
therapeutic effect and looks quite promising (manuscript in prep). We currently able to 
measure the IgA antibody response in secretions. Therefore this immune markers will 
enhance the detection of specific immune response following vaccination. The most 
important aspect of this vaccine trial was that the rMOMP vaccine was not aggravate any 
pathological response. We evaluate this vaccine in naturally infected koalas as well as the 
non-infected animals. 
 
In summary, our data from this project has demonstrated several key findings including, (a) 
the single dose tri-adjuvant, combined with rec MOMP protein, can elicit a long lasting (54 
weeks) cellular and humoral immune response in koalas, (b) recombinant MOMP based 
vaccines elicit a specific and distinct humoral immune response with neutralising antibodies 
(c) the prototype rMOMP protein vaccine is able to induce a Th1 biased immune response 
and has the potential to be used as therapeutic and prophylactic treatment of wild koalas. 
 
Future directions 
The study provides the first experiment that utilised tri-adjuvant components in koalas and 
we evaluated the rMOMP based protein vaccine in the natural host in its wildlife setting. 
While the progress looks promising, there are still several issues that need to be addressed 
before any koala Chlamydia vaccine can be widely used. 
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The studies presented in this thesis have successfully evaluated a rMOMP based protein 
vaccine in captive koalas as well as in wild koalas. In addition, it would be ideal to test the 
protective efficacy of the vaccine in several wild koala populations. Though, we measured 
the prophylactic effect of the vaccine, the number of organism recovered at fixed time points 
following infection could be used to define the severity of the infection or vaccine response. 
This is significantly important to measure the vaccine efficacy to determine whether a 
vaccine administered can protect against either infection or disease. 
 
The diverse immunological pathways that regulate the development of the immune responses 
are mediated through distinct immuno-regulatory cytokines produced by two types of 
regulatory T cells (CD8+ and CD4+ T cells). In the process of koala Chlamydia vaccine 
development, it is critical to identify the relevant immunological pathways in naturally 
infected animals as well as in vaccinated animals. Recent identification of the CD4+ T cell in 
koala [116] is a promising aspect to measure this T cell subset in immunised animals. In this 
thesis, we looked at the systemic cytokine response patterns of vaccinated animals. However, 
cytokines generally have a localised immune response during an infection or following 
vaccination. Nevertheless, the pathology produced by C.pecorum is also localised mainly in 
the reproductive site. However, looking at the cytokine profile at the urogenital and ocular 
site could provide a more complete picture of the disease pathogenesis and better inform 
vaccine design. The cytokine profiles measured during this thesis measured mRNA 
expressions, not actual protein. However, the majority of the cytokines are regulated through 
post-transcriptional modifications and might not truly reflect the mRNA expression within 
the biologically active protein molecule. This post-transcriptional control mechanism that 
affects the final expression of the protein might be an issue to address in future study. 
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The two immunoglobulin’s subclasses, IgG and IgA, presumably play a critical role in the 
koala immune process. Both these antibodies are transported via FcRn and PlgR receptors 
respectively and the expression of receptors has been shown to vary among different cell 
types and anatomical location in animal and human studies [117, 118]. It has been reported 
that IgA provides protection in the infection site at the very initial stage of the infection 
[119]. While the role of IgA against primary or secondary chlamydial infections appears to be 
negligible [120], the role of this antibody subclass is strongly correlated with a reduction of 
chlamydial burden in the male prostate gland [121].Therefore, it is important to measure this 
immunoglobulin subclass in the mucosal secretions during the infection process or following 
vaccination. More importantly, it will be critical to measure the neutralisation ability of this 
antibody along with IgG. 
 
Investigations in relation to the genetic diversity on the koala’s immune systems are yet to be 
done. Studies have shown that a minimum level of genetic diversity exists among certain 
island koala population (French and Kangaroo populations) [122]. Indeed, these koala 
populations have been reported as Chlamydia free isolated populations, though low genetic 
diversity might suggest a link to enhanced disease susceptibility [123]. However, large scale 
studies utilising the highly variable coding genes such as MHC class II molecules [124] need 
to be done to better understand the contribution of genetic diversity to disease biology. 
Another important confounding factor which might affect the koala’s immune system 
response to chlamydial infection is the presence of KoRV infection [125]. Studies have 
shown a higher prevalence of KoRV infection in the southern koalas. This study however 
failed to establish a link between KoRV RNA expression levels and chlamydiosis [126]. 
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Therefore, this aspect on the immune systems might be an important issue to investigate in 
future studies. 
 
While the vaccine research to date looks promising, a live challenge infection in a Chlamydia 
koala model is essential in the future. However, from the ethical point of view, this seems to 
be a challenge to implement. In addition, determining the age of vaccination would be a 
major issue in koala-Chlamydia vaccine design. We have observed high level of variation for 
animal-to-animal immune responses following vaccination. Future studies should aim to 
minimise these variations, either by the use of age, sex match cohorts or to better understand 
the MHC restriction of the MOMP epitopes. A recent study with mathematical simulation 
suggests that, female koalas at 1-2 years of age would be the preferred target population 
cohort for achieving optimum results following vaccination [127]. This period is very critical 
for the female koalas, as they attained sexual maturity at this stage. The development of 
immunity at this time point would potentially reduce the transmission of chlamydial 
infection. Recent studies in a mouse model suggests the significant role of immunised male 
or female animals in subsequent disease transmission [81]. Additionally, few studies have 
focussed on the significant role of male koalas in disease transmission pose to critically 
address this gender issue in vaccine formulations. 
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